

**TCI CO., LTD. AND SUBSIDIARIES**  
**CONSOLIDATED FINANCIAL STATEMENTS AND**  
**INDEPENDENT AUDITORS' REPORT**  
**DECEMBER 31, 2025 AND 2024**

---

For the convenience of readers and for information purpose only, the auditors' report and the accompanying financial statements have been translated into English from the original Chinese version prepared and used in the Republic of China. In the event of any discrepancy between the English version and the original Chinese version or any differences in the interpretation of the two versions, the Chinese-language auditors' report and financial statements shall prevail.

## INDEPENDENT AUDITORS' REPORT TRANSLATED FROM CHINESE

To the Board of Directors and Shareholders of TCI CO., LTD.

### ***Introduction***

We have audited the accompanying consolidated balance sheets of TCI Co., Ltd. and subsidiaries (the “ Group”) as at December 31, 2025 and 2024, and the related consolidated statements of comprehensive income, of changes in equity and of cash flows for the years then ended, and notes to the consolidated financial statements, including a summary of material accounting policies.

In our opinion, the accompanying consolidated financial statements present fairly, in all material respects, the consolidated financial position of the Group as at December 31, 2025 and 2024, and its consolidated financial performance and its consolidated cash flows for the years then ended in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and the International Financial Reporting Standards, International Accounting Standards, IFRIC Interpretations, and SIC Interpretations that came into effect as endorsed by the Financial Supervisory Commission.

### ***Basic for opinion***

We conducted our audits in accordance with the Regulations Governing Financial Statement Audit and Attestation Engagements of Certified Public Accountants and Standards on Auditing of the Republic of China. Our responsibilities under those standards are further described in the *Auditors' responsibilities for the audit of the consolidated financial statements* section of our report. We are independent of the Group in accordance with the Norm of Professional Ethics for Certified Public Accountant of the Republic of China, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

### ***Key audit matters***

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the Group's 2025 consolidated financial statements. These matters were addressed in the context of our audit of the consolidated financial statements as a whole and, in forming our opinion thereon, we do not provide a separate opinion on these matters.

Key audit matters for the Group's 2025 consolidated financial statements are stated as follows:

#### **Existence and occurrence of top ten customers**

##### Description

The Group's sales revenue arises mainly from manufacturing and sales of health foods and cosmetics. Customers are mostly direct marketing companies in America, Europe and Asia and cosmetic companies.

With the expansion of direct marketing companies in America, Europe and Asia, the sales revenue arising from such transactions has become a major operating item of the Group. And the sales revenue from top ten customers represents a significant portion of operating income to the consolidated financial statements. Because of the rapid development in the internet sales market, more time and resources were required in performing the audit procedures. Thus, we consider the existence and occurrence of top ten customers as a key audit matter.

Please refer to Note 4(31) for accounting policies on revenue recognition and Note 6(23) for details of sales revenue.

#### How our audit addressed the matter

Our audit procedures in respect of the above key audit matter included:

1. Understanding and testing the internal control procedures of the top ten customers and testing the effectiveness of internal control related to sales revenue.
2. Selecting samples from sales transactions of the top ten customers and comparing against orders and delivery bills to confirm whether the sales transactions did occur.
3. Examining sales returns and discounts from the top ten customers after the balance sheet date to confirm the existence of sales revenue.

#### ***Other matter - Parent company only financial reports***

We have audited and expressed an unmodified opinion on the parent company only financial statements of TCI Co., Ltd. as at and for the years ended December 31, 2025 and 2024.

#### ***Responsibilities of management and those charged with governance for the consolidated financial statements***

Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and the International Financial Reporting Standards, International Accounting Standards, IFRIC Interpretations, and SIC Interpretations that came into effect as endorsed by the Financial Supervisory Commission, and for such internal control as management determines is necessary to enable the preparation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, management is responsible for assessing the Group's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Group or to cease operations, or has no realistic

alternative but to do so.

Those charged with governance, including the audit committee, are responsible for overseeing the Group's financial reporting process.

### ***Auditors' responsibilities for the audit of the consolidated financial statements***

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with the Standards on Auditing of the Republic of China will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial statements.

As part of an audit in accordance with the Standards on Auditing of the Republic of China, we exercise professional judgment and professional skepticism throughout the audit. We also:

1. Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
2. Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Group's internal control.

3. Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
4. Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Group's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditors' report to the related disclosures in the consolidated financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditors' report. However, future events or conditions may cause the Group to cease to continue as a going concern.
5. Evaluate the overall presentation, structure and content of the consolidated financial statements, including the disclosures, and whether the consolidated financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
6. Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the Group to express an opinion on the consolidated financial statements. We are responsible for the direction, supervision and performance of the group audit. We remain solely responsible for our audit opinion.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the consolidated financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditors' report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Chih, Ping-Chiun

Tu, Chan-Yuan

For and on behalf of PricewaterhouseCoopers, Taiwan

March 11, 2026

---

The accompanying consolidated financial statements are not intended to present the financial position and results of operations and cash flows in accordance with accounting principles generally accepted in countries and jurisdictions other than the Republic of China. The standards, procedures and practices in the Republic of China governing the audit of such financial statements may differ from those generally accepted in countries and jurisdictions other than the Republic of China. Accordingly, the accompanying consolidated financial statements and independent auditors' report are not intended for use by those who are not informed about the accounting principles or auditing standards generally accepted in the Republic of China, and their applications in practice.

As the financial statements are the responsibility of the management, PricewaterhouseCoopers cannot accept any liability for the use of, or reliance on, the English translation or for any errors or misunderstandings that may derive from the translation.

TCI CO., LTD. AND SUBSIDIARIES  
CONSOLIDATED BALANCE SHEETS  
DECEMBER 31, 2025 AND 2024  
(Expressed in thousands of New Taiwan dollars)

| Assets             |                                                                               | Notes      | December 31, 2025 |     | December 31, 2024 |     |
|--------------------|-------------------------------------------------------------------------------|------------|-------------------|-----|-------------------|-----|
|                    |                                                                               |            | AMOUNT            | %   | AMOUNT            | %   |
| Current assets     |                                                                               |            |                   |     |                   |     |
| 1100               | Cash and cash equivalents                                                     | 6(1)       | \$ 5,470,732      | 37  | \$ 4,767,212      | 35  |
| 1110               | Financial assets at fair value through profit or loss - current               | 6(2)       | 19,760            | -   | 31,014            | -   |
| 1120               | Current financial assets at fair value through other comprehensive income     | 6(3)       | 13,675            | -   | -                 | -   |
| 1136               | Current financial assets at amortized cost                                    | 6(4) and 8 | 388,726           | 3   | 865,166           | 6   |
| 1150               | Notes receivable, net                                                         | 6(5)       | 23,803            | -   | 81,031            | 1   |
| 1170               | Accounts receivable, net                                                      | 6(5)       | 968,812           | 7   | 776,416           | 6   |
| 1180               | Accounts receivable - related parties                                         | 7          | 25,244            | -   | 48,828            | -   |
| 1200               | Other receivables                                                             |            | 43,967            | -   | 39,308            | -   |
| 1210               | Other receivables - related parties                                           | 7          | 59                | -   | 104               | -   |
| 130X               | Inventories                                                                   | 6(6)       | 736,222           | 5   | 855,908           | 6   |
| 1410               | Prepayments                                                                   |            | 420,494           | 3   | 168,115           | 1   |
| 1470               | Other current assets                                                          |            | 50,552            | -   | 48,834            | 1   |
| 11XX               | Total current assets                                                          |            | 8,162,046         | 55  | 7,681,936         | 56  |
| Non-current assets |                                                                               |            |                   |     |                   |     |
| 1517               | Non-current financial assets at fair value through other comprehensive income | 6(3)       | 65,998            | 1   | 67,524            | -   |
| 1550               | Investments accounted for using equity method                                 | 6(7)       | 46,889            | -   | 28,182            | -   |
| 1600               | Property, plant and equipment                                                 | 6(8) and 8 | 5,537,061         | 38  | 4,814,920         | 35  |
| 1755               | Right-of-use assets                                                           | 6(9)       | 159,011           | 1   | 236,386           | 2   |
| 1780               | Intangible assets                                                             | 6(10)      | 599,938           | 4   | 643,021           | 5   |
| 1840               | Deferred income tax assets                                                    | 6(30)      | 26,637            | -   | 24,799            | -   |
| 1900               | Other non-current assets                                                      |            | 176,951           | 1   | 217,977           | 2   |
| 15XX               | Total non-current assets                                                      |            | 6,612,485         | 45  | 6,032,809         | 44  |
| 1XXX               | Total assets                                                                  |            | \$ 14,774,531     | 100 | \$ 13,714,745     | 100 |

(Continued)

TCI CO., LTD. AND SUBSIDIARIES  
CONSOLIDATED BALANCE SHEETS  
DECEMBER 31, 2025 AND 2024  
(Expressed in thousands of New Taiwan dollars)

| Liabilities and Equity                  |                                                                          | Notes | December 31, 2025 |       | December 31, 2024 |       |
|-----------------------------------------|--------------------------------------------------------------------------|-------|-------------------|-------|-------------------|-------|
|                                         |                                                                          |       | AMOUNT            | %     | AMOUNT            | %     |
| Current liabilities                     |                                                                          |       |                   |       |                   |       |
| 2100                                    | Short-term borrowings                                                    | 6(12) | \$ 2,000,000      | 14    | \$ 429,888        | 3     |
| 2120                                    | Financial liabilities at fair value through profit or loss - current     | 6(13) | 1,418             | -     | -                 | -     |
| 2130                                    | Current contract liabilities                                             | 6(23) | 669,362           | 4     | 552,566           | 4     |
| 2150                                    | Notes payable                                                            |       | 3,264             | -     | 1,518             | -     |
| 2170                                    | Accounts payable                                                         | 6(14) | 681,007           | 5     | 679,654           | 5     |
| 2180                                    | Accounts payable - related parties                                       | 7     | 426               | -     | -                 | -     |
| 2200                                    | Other payables                                                           | 6(15) | 815,219           | 5     | 706,381           | 5     |
| 2230                                    | Current income tax liabilities                                           |       | 124,269           | 1     | 252,049           | 2     |
| 2280                                    | Current lease liabilities                                                |       | 37,403            | -     | 66,968            | -     |
| 2320                                    | Long-term liabilities, current portion                                   | 6(17) | 329,711           | 2     | 79,469            | 1     |
| 2399                                    | Other current liabilities, others                                        |       | 95,430            | 1     | 136,502           | 1     |
| 21XX                                    | Total current liabilities                                                |       | 4,757,509         | 32    | 2,904,995         | 21    |
| Non-current liabilities                 |                                                                          |       |                   |       |                   |       |
| 2540                                    | Long-term borrowings                                                     | 6(17) | 677,843           | 5     | 1,089,529         | 8     |
| 2570                                    | Deferred income tax liabilities                                          | 6(30) | 71,712            | -     | 82,440            | 1     |
| 2580                                    | Non-current lease liabilities                                            |       | 98,172            | 1     | 149,043           | 1     |
| 2600                                    | Other non-current liabilities                                            |       | 12,509            | -     | 562               | -     |
| 25XX                                    | Total non-current liabilities                                            |       | 860,236           | 6     | 1,321,574         | 10    |
| 2XXX                                    | Total liabilities                                                        |       | 5,617,745         | 38    | 4,226,569         | 31    |
| Equity attributable to owners of parent |                                                                          |       |                   |       |                   |       |
|                                         | Share capital                                                            | 6(19) |                   |       |                   |       |
| 3110                                    | Share capital - common stock                                             |       | 1,177,288         | 8     | 1,182,608         | 8     |
|                                         | Capital surplus                                                          | 6(20) |                   |       |                   |       |
| 3200                                    | Capital surplus                                                          |       | 2,485,184         | 17    | 2,893,400         | 22    |
|                                         | Retained earnings                                                        | 6(21) |                   |       |                   |       |
| 3310                                    | Legal reserve                                                            |       | 1,145,367         | 8     | 1,060,208         | 8     |
| 3320                                    | Special reserve                                                          |       | 229,943           | 2     | 298,894           | 2     |
| 3350                                    | Unappropriated retained earnings                                         |       | 3,321,450         | 22    | 3,324,916         | 24    |
|                                         | Other equity interest                                                    | 6(22) |                   |       |                   |       |
| 3400                                    | Other equity interest                                                    |       | ( 135,869 )       | ( 1 ) | ( 153,980 )       | ( 1 ) |
| 3500                                    | Treasury shares                                                          | 6(19) | ( 438,806 )       | ( 3 ) | ( 509,948 )       | ( 4 ) |
| 31XX                                    | Equity attributable to owners of the parent                              |       | 7,784,557         | 53    | 8,096,098         | 59    |
| 36XX                                    | Non-controlling interest                                                 |       | 1,372,229         | 9     | 1,392,078         | 10    |
| 3XXX                                    | Total equity                                                             |       | 9,156,786         | 62    | 9,488,176         | 69    |
|                                         | Significant contingent liabilities and unrecognized contract commitments | 9     |                   |       |                   |       |
| 3X2X                                    | Total liabilities and equity                                             |       | \$ 14,774,531     | 100   | \$ 13,714,745     | 100   |

The accompanying notes are an integral part of these consolidated financial statements.

**TCI CO., LTD. AND SUBSIDIARIES**  
**CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME**  
**YEARS ENDED DECEMBER 31, 2025 AND 2024**  
(Expressed in thousands of New Taiwan dollars, except earnings per share amounts)

|                                                                                                                                 |                                  |    | Year ended December 31 |       |              |       |
|---------------------------------------------------------------------------------------------------------------------------------|----------------------------------|----|------------------------|-------|--------------|-------|
|                                                                                                                                 |                                  |    | 2025                   |       | 2024         |       |
| Items                                                                                                                           | Notes                            |    | AMOUNT                 | %     | AMOUNT       | %     |
| 4000 Sales revenue                                                                                                              | 6(23) and 7                      |    | \$ 6,989,303           | 100   | \$ 7,240,266 | 100   |
| 5000 Operating costs                                                                                                            | 6(6)(8)(9)(10)(16)(28)(29) and 7 | (  | 3,907,944)             | ( 56) | ( 4,062,460) | ( 56) |
| 5900 Net operating margin                                                                                                       |                                  |    | 3,081,359              | 44    | 3,177,806    | 44    |
| Operating expenses                                                                                                              | 6(8)(9)(10)(28)(29) and 7        |    |                        |       |              |       |
| 6100 Selling expenses                                                                                                           |                                  | (  | 613,133)               | ( 9)  | ( 739,809)   | ( 10) |
| 6200 General and administrative expenses                                                                                        |                                  | (  | 726,458)               | ( 10) | ( 765,941)   | ( 11) |
| 6300 Research and development expenses                                                                                          |                                  | (  | 577,065)               | ( 8)  | ( 616,498)   | ( 9)  |
| 6450 Expected credit impairment loss                                                                                            | 12(3)                            | (  | 7,950)                 | -     | ( 27,831)    | -     |
| 6000 Total operating expenses                                                                                                   |                                  | (  | 1,924,606)             | ( 27) | ( 2,150,079) | ( 30) |
| 6900 Operating profit                                                                                                           |                                  |    | 1,156,753              | 17    | 1,027,727    | 14    |
| Non-operating income and expenses                                                                                               |                                  |    |                        |       |              |       |
| 7100 Interest income                                                                                                            | 6(24)                            |    | 73,004                 | 1     | 70,508       | 1     |
| 7010 Other income                                                                                                               | 6(25)                            |    | 79,182                 | 1     | 28,841       | -     |
| 7020 Other gains and losses                                                                                                     | 6(26)                            | (  | 21,917)                | -     | ( 63,866)    | ( 1)  |
| 7050 Finance costs                                                                                                              | 6(27)                            | (  | 51,237)                | ( 1)  | ( 45,289)    | ( 1)  |
| 7060 Share of loss of associates and joint ventures accounted for using equity method                                           | 6(7)                             | (  | 8,105)                 | -     | ( 11,190)    | -     |
| 7000 Total non-operating income and expenses                                                                                    |                                  |    | 70,927                 | 1     | 106,736      | 1     |
| 7900 <b>Profit before income tax</b>                                                                                            |                                  |    | 1,227,680              | 18    | 1,134,463    | 15    |
| 7950 Income tax expense                                                                                                         | 6(30)                            | (  | 119,701)               | ( 2)  | ( 160,735)   | ( 2)  |
| 8200 <b>Profit for the year</b>                                                                                                 |                                  |    | \$ 1,107,979           | 16    | \$ 973,728   | 13    |
| <b>Other comprehensive (loss) income</b>                                                                                        |                                  |    |                        |       |              |       |
| <b>Components of other comprehensive income that will not be reclassified to profit or loss</b>                                 |                                  |    |                        |       |              |       |
| 8311 Gains (losses) on remeasurements of defined benefit plans                                                                  | 6(16)                            | \$ | 459                    | -     | \$ 378       | -     |
| 8316 Unrealized gains (losses) from investments in equity instruments measured at fair value through other comprehensive income | 6(3)(22)                         | (  | 13,094)                | -     | ( 3,239)     | -     |
| <b>Other comprehensive (loss) income that will be reclassified to profit or loss</b>                                            |                                  |    |                        |       |              |       |
| 8361 Financial statements translation differences of foreign operations                                                         | 6(22)                            |    | 24,186                 | -     | 128,002      | 2     |
| 8300 <b>Total other comprehensive income for the year</b>                                                                       |                                  |    | \$ 11,551              | -     | \$ 131,619   | 2     |
| 8500 <b>Total comprehensive income for the year</b>                                                                             |                                  |    | \$ 1,119,530           | 16    | \$ 1,105,347 | 15    |
| Profit attributable to:                                                                                                         |                                  |    |                        |       |              |       |
| 8610 Owners of the parent                                                                                                       |                                  | \$ | 954,957                | 14    | \$ 851,499   | 12    |
| 8620 Non-controlling interest                                                                                                   |                                  |    | 153,022                | 2     | 122,229      | 1     |
|                                                                                                                                 |                                  |    | \$ 1,107,979           | 16    | \$ 973,728   | 13    |
| Comprehensive income attributable to:                                                                                           |                                  |    |                        |       |              |       |
| 8710 Owners of the parent                                                                                                       |                                  | \$ | 975,269                | 14    | \$ 981,148   | 13    |
| 8720 Non-controlling interest                                                                                                   |                                  |    | 144,261                | 2     | 124,199      | 2     |
|                                                                                                                                 |                                  |    | \$ 1,119,530           | 16    | \$ 1,105,347 | 15    |
| Basic earnings per share (In dollars)                                                                                           |                                  |    |                        |       |              |       |
| 9750 Basic earnings per share                                                                                                   | 6(31)                            |    | \$ 8.68                |       | \$ 7.60      |       |
| 9850 Diluted earnings per share                                                                                                 |                                  |    | \$ 8.63                |       | \$ 7.55      |       |

The accompanying notes are an integral part of these consolidated financial statements.

TCI CO., LTD. AND SUBSIDIARIES  
CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY  
YEARS ENDED DECEMBER 31, 2025 AND 2024  
(Expressed in thousands of New Taiwan dollars)

| Equity attributable to owners of the parent                                            |                              |                                             |                     |                   |                                  |                                                                    |                                                                                                           |                      |                     |                          |                     |
|----------------------------------------------------------------------------------------|------------------------------|---------------------------------------------|---------------------|-------------------|----------------------------------|--------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|----------------------|---------------------|--------------------------|---------------------|
|                                                                                        | Retained earnings            |                                             |                     |                   |                                  | Other equity interest                                              |                                                                                                           |                      |                     |                          |                     |
| Notes                                                                                  | Share capital - common stock | Capital surplus, additional paid-in capital | Legal reserve       | Special reserve   | Unappropriated retained earnings | Financial statements translation differences of foreign operations | Unrealized gains (losses) from financial assets measured at fair value through other comprehensive income | Treasury shares      | Total               | Non-controlling interest | Total equity        |
| <u>For the year ended December 31, 2024</u>                                            |                              |                                             |                     |                   |                                  |                                                                    |                                                                                                           |                      |                     |                          |                     |
| Balance at January 1, 2024                                                             | \$ 1,182,608                 | \$ 2,900,420                                | \$ 970,582          | \$ 194,104        | \$ 3,491,839                     | (\$ 280,381 )                                                      | (\$ 3,152 )                                                                                               | (\$ 232,963 )        | \$ 8,223,057        | \$ 1,654,885             | \$ 9,877,942        |
| Profit for the year                                                                    | -                            | -                                           | -                   | -                 | 851,499                          | -                                                                  | -                                                                                                         | -                    | 851,499             | 122,229                  | 973,728             |
| Other comprehensive income for the year                                                | 6(22)                        | -                                           | -                   | -                 | 96                               | 129,142                                                            | 411                                                                                                       | -                    | 129,649             | 1,970                    | 131,619             |
| Total comprehensive income                                                             | -                            | -                                           | -                   | -                 | 851,595                          | 129,142                                                            | 411                                                                                                       | -                    | 981,148             | 124,199                  | 1,105,347           |
| Appropriations of 2023 earnings                                                        | 6(21)                        |                                             |                     |                   |                                  |                                                                    |                                                                                                           |                      |                     |                          |                     |
| Legal reserve                                                                          | -                            | -                                           | 89,626              | -                 | ( 89,626 )                       | -                                                                  | -                                                                                                         | -                    | -                   | -                        | -                   |
| Special reserve                                                                        | -                            | -                                           | -                   | 104,790           | ( 104,790 )                      | -                                                                  | -                                                                                                         | -                    | -                   | -                        | -                   |
| Cash dividends                                                                         | -                            | -                                           | -                   | -                 | ( 824,102 )                      | -                                                                  | -                                                                                                         | -                    | ( 824,102 )         | -                        | ( 824,102 )         |
| Share-based payments                                                                   | -                            | 1,436                                       | -                   | -                 | -                                | -                                                                  | -                                                                                                         | -                    | 1,436               | -                        | 1,436               |
| Changes in equity of associates and joint ventures                                     | -                            | ( 81,058 )                                  | -                   | -                 | -                                | -                                                                  | -                                                                                                         | ( 15,515 )           | ( 96,573 )          | 15,515                   | ( 81,058 )          |
| Acquisition of parent company's share by subsidiaries recognized as treasury shares    | -                            | 72,602                                      | -                   | -                 | -                                | -                                                                  | -                                                                                                         | -                    | 72,602              | ( 72,602 )               | -                   |
| Adjustment to non-controlling interests                                                | -                            | -                                           | -                   | -                 | -                                | -                                                                  | -                                                                                                         | ( 261,470 )          | ( 261,470 )         | ( 361,968 )              | ( 623,438 )         |
|                                                                                        | -                            | -                                           | -                   | -                 | -                                | -                                                                  | -                                                                                                         | -                    | -                   | 32,049                   | 32,049              |
| Balance at December 31, 2024                                                           | <u>\$ 1,182,608</u>          | <u>\$ 2,893,400</u>                         | <u>\$ 1,060,208</u> | <u>\$ 298,894</u> | <u>\$ 3,324,916</u>              | <u>(\$ 151,239 )</u>                                               | <u>(\$ 2,741 )</u>                                                                                        | <u>(\$ 509,948 )</u> | <u>\$ 8,096,098</u> | <u>\$ 1,392,078</u>      | <u>\$ 9,488,176</u> |
| <u>For the year ended December 31, 2025</u>                                            |                              |                                             |                     |                   |                                  |                                                                    |                                                                                                           |                      |                     |                          |                     |
| Balance at January 1, 2025                                                             | \$ 1,182,608                 | \$ 2,893,400                                | \$ 1,060,208        | \$ 298,894        | \$ 3,324,916                     | (\$ 151,239 )                                                      | (\$ 2,741 )                                                                                               | (\$ 509,948 )        | \$ 8,096,098        | \$ 1,392,078             | \$ 9,488,176        |
| Profit for the year                                                                    | -                            | -                                           | -                   | -                 | 954,957                          | -                                                                  | -                                                                                                         | -                    | 954,957             | 153,022                  | 1,107,979           |
| Other comprehensive income (loss) for the year                                         | 6(22)                        | -                                           | -                   | -                 | 134                              | 24,439                                                             | ( 4,261 )                                                                                                 | -                    | 20,312              | ( 8,761 )                | 11,551              |
| Total comprehensive income (loss)                                                      | -                            | -                                           | -                   | -                 | 955,091                          | 24,439                                                             | ( 4,261 )                                                                                                 | -                    | 975,269             | 144,261                  | 1,119,530           |
| Appropriations of 2024 earnings                                                        | 6(21)                        |                                             |                     |                   |                                  |                                                                    |                                                                                                           |                      |                     |                          |                     |
| Legal reserve                                                                          | -                            | -                                           | 85,159              | -                 | ( 85,159 )                       | -                                                                  | -                                                                                                         | -                    | -                   | -                        | -                   |
| Special reserve                                                                        | -                            | -                                           | -                   | ( 68,951 )        | 68,951                           | -                                                                  | -                                                                                                         | -                    | -                   | -                        | -                   |
| Cash dividends                                                                         | -                            | -                                           | -                   | -                 | ( 835,875 )                      | -                                                                  | -                                                                                                         | -                    | ( 835,875 )         | -                        | ( 835,875 )         |
| Cash distribution from capital surplus                                                 | -                            | ( 341,414 )                                 | -                   | -                 | -                                | -                                                                  | -                                                                                                         | -                    | ( 341,414 )         | -                        | ( 341,414 )         |
| Share-based payments                                                                   | -                            | 680                                         | -                   | -                 | -                                | -                                                                  | -                                                                                                         | -                    | 680                 | -                        | 680                 |
| Changes in equity of associates and joint ventures                                     | -                            | 38,830                                      | -                   | -                 | -                                | -                                                                  | -                                                                                                         | ( 18,087 )           | 20,743              | 18,087                   | 38,830              |
| Transactions with non-controlling interests                                            | 6(32)                        | ( 101,386 )                                 | -                   | -                 | -                                | -                                                                  | -                                                                                                         | ( 101,386 )          | ( 101,386 )         | ( 52,423 )               | ( 153,809 )         |
| Cancellation of treasury shares                                                        | ( 5,320 )                    | ( 4,926 )                                   | -                   | -                 | ( 108,541 )                      | -                                                                  | -                                                                                                         | 118,787              | -                   | -                        | -                   |
| Acquisition of parent company's share by subsidiaries recognized as treasury shares    | -                            | -                                           | -                   | -                 | -                                | -                                                                  | -                                                                                                         | ( 29,558 )           | ( 29,558 )          | ( 40,434 )               | ( 69,992 )          |
| Adjustment to non-controlling interests                                                | -                            | -                                           | -                   | -                 | -                                | -                                                                  | -                                                                                                         | -                    | -                   | ( 89,340 )               | ( 89,340 )          |
| Disposal of financial assets measured at fair value through other comprehensive income | 6(3)                         | -                                           | -                   | -                 | 2,067                            | -                                                                  | ( 2,067 )                                                                                                 | -                    | -                   | -                        | -                   |
| Balance at December 31, 2025                                                           | <u>\$ 1,177,288</u>          | <u>\$ 2,485,184</u>                         | <u>\$ 1,145,367</u> | <u>\$ 229,943</u> | <u>\$ 3,321,450</u>              | <u>(\$ 126,800 )</u>                                               | <u>(\$ 9,069 )</u>                                                                                        | <u>(\$ 438,806 )</u> | <u>\$ 7,784,557</u> | <u>\$ 1,372,229</u>      | <u>\$ 9,156,786</u> |

The accompanying notes are an integral part of these consolidated financial statements.

**TCI CO., LTD. AND SUBSIDIARIES**  
**CONSOLIDATED STATEMENTS OF CASH FLOWS**  
**YEARS ENDED DECEMBER 31, 2025 AND 2024**  
(Expressed in thousands of New Taiwan dollars)

|                                                                                        |             | Year ended December 31 |              |
|----------------------------------------------------------------------------------------|-------------|------------------------|--------------|
|                                                                                        | Notes       | 2025                   | 2024         |
| <b>CASH FLOWS FROM OPERATING ACTIVITIES</b>                                            |             |                        |              |
| Profit before tax                                                                      |             | \$ 1,227,680           | \$ 1,134,463 |
| Adjustments                                                                            |             |                        |              |
| Adjustments to reconcile profit (loss)                                                 |             |                        |              |
| Depreciation                                                                           | 6(8)(9)(28) | 527,375                | 551,452      |
| Amortisation                                                                           | 6(10)(28)   | 44,807                 | 48,627       |
| Expected credit impairment loss                                                        | 12(3)       | 7,950                  | 27,831       |
| Net loss (gain) on financial assets at fair value through profit or loss               | 6(2)(26)    | 10,709                 | 1,481        |
| Net loss on financial liabilities at fair value through profit or loss                 | 6(13)(26)   | 7,409                  | -            |
| Gain on disposal of property, plant and equipment                                      | 6(26)       | ( 1,722 )              | ( 1,492 )    |
| Gain on disposal of investments                                                        | 6(26)       | 3,603                  | 1,167        |
| Interest income                                                                        | 6(24)       | ( 73,004 )             | ( 70,508 )   |
| Dividend income                                                                        | 6(25)       | ( 4,376 )              | ( 3,210 )    |
| Interest expense                                                                       | 6(27)       | 51,237                 | 45,289       |
| Compensation cost arising from employee stock options                                  | 6(18)(29)   | 4,089                  | 8,613        |
| Gains arising from lease modifications                                                 | 6(9)(26)    | ( 2,545 )              | ( 382 )      |
| Share of profit of associates and joint ventures accounted for under the equity method | 6(7)        | 8,105                  | 11,190       |
| Changes in operating assets and liabilities                                            |             |                        |              |
| Changes in operating assets                                                            |             |                        |              |
| Notes receivable                                                                       |             | 57,228                 | ( 55,293 )   |
| Accounts receivable                                                                    | (           | 200,346 )              | 141,319      |
| Accounts receivable - related parties                                                  |             | 23,584                 | ( 48,721 )   |
| Other receivables                                                                      | (           | 1,436 )                | ( 10,953 )   |
| Other receivables - related parties                                                    |             | 45                     | ( 36 )       |
| Inventories                                                                            |             | 119,686                | 85,400       |
| Prepayments                                                                            | (           | 252,379 )              | 77,977       |
| Other current assets                                                                   | (           | 1,718 )                | ( 3,346 )    |
| Changes in operating liabilities                                                       |             |                        |              |
| Financial liabilities at fair value through profit or loss - current                   | (           | 5,991 )                | -            |
| Contract liabilities - current                                                         |             | 116,796                | 56,038       |
| Notes payable                                                                          |             | 1,746                  | 832          |
| Accounts payable                                                                       |             | 1,353                  | ( 54,534 )   |
| Accounts payable - related parties                                                     |             | 426                    | ( 2,903 )    |
| Other payables                                                                         |             | 98,628                 | ( 54,927 )   |
| Other current liabilities                                                              | (           | 41,072 )               | 33,502       |
| Other non-current liabilities                                                          | (           | 562 )                  | 562          |
| Cash inflow generated from operations                                                  |             | 1,727,305              | 1,919,438    |
| Interest received                                                                      |             | 69,781                 | 70,508       |
| Interest paid                                                                          | (           | 45,318 )               | ( 39,454 )   |
| Dividends received                                                                     |             | 4,376                  | 3,210        |
| Income tax paid                                                                        | (           | 260,047 )              | ( 465,306 )  |
| Net cash flows from operating activities                                               |             | 1,496,097              | 1,488,396    |

(Continued)

**TCI CO., LTD. AND SUBSIDIARIES**  
**CONSOLIDATED STATEMENTS OF CASH FLOWS**  
**YEARS ENDED DECEMBER 31, 2025 AND 2024**  
(Expressed in thousands of New Taiwan dollars)

|                                                                                                         |       | Year ended December 31 |                     |
|---------------------------------------------------------------------------------------------------------|-------|------------------------|---------------------|
|                                                                                                         |       | 2025                   | 2024                |
| Notes                                                                                                   |       |                        |                     |
| <b>CASH FLOWS FROM INVESTING ACTIVITIES</b>                                                             |       |                        |                     |
| Acquisition of non-current financial assets at fair value through other comprehensive income            |       | ( \$ 31,200 )          | \$ -                |
| Proceeds from disposal of non-current financial assets at fair value through other comprehensive income |       | 6,540                  | -                   |
| Acquisition of property, plant and equipment                                                            | 6(33) | ( 1,151,505 )          | ( 209,067 )         |
| Proceeds from disposal of property, plant and equipment                                                 |       | 26,312                 | 11,238              |
| Decrease in refundable deposits                                                                         |       | 16,088                 | 3,805               |
| Acquisition of intangible assets                                                                        | 6(10) | ( 1,720 )              | ( 428 )             |
| Decrease in other non-current assets                                                                    |       | -                      | 5,616               |
| Acquisition of financial assets at fair value through profit or loss                                    |       | ( 26,870 )             | ( 2,710 )           |
| Proceeds from disposal of financial assets at fair value through profit or loss                         |       | 25,689                 | 48,359              |
| Decrease (increase) in financial assets at amortised cost                                               |       | 476,440                | ( 653,100 )         |
| Increase in investment accounted for using equity method                                                | 6(7)  | ( 17,137 )             | ( 16,470 )          |
| Proceeds from disposal of investment accounted for using equity method                                  | 6(7)  | 1,020                  | -                   |
| Net cash flows used in investing activities                                                             |       | ( 676,343 )            | ( 812,757 )         |
| <b>CASH FLOWS FROM FINANCING ACTIVITIES</b>                                                             |       |                        |                     |
| Proceeds from short-term borrowings                                                                     |       | 2,000,000              | 6,627,856           |
| Repayments of short-term borrowings                                                                     |       | ( 429,888 )            | ( 6,547,968 )       |
| Proceeds from long-term borrowings                                                                      |       | -                      | 1,101,650           |
| Redemption of long-term borrowings                                                                      |       | ( 161,444 )            | ( 879,581 )         |
| Lease liabilities paid                                                                                  |       | ( 75,227 )             | ( 76,137 )          |
| Decrease in guarantee deposits                                                                          |       | 12,509                 | ( 6,510 )           |
| Cash dividends paid                                                                                     | 6(21) | ( 1,177,289 )          | ( 824,102 )         |
| Cash dividends paid to non-controlling interests                                                        |       | ( 47,129 )             | -                   |
| Acquisition of the Company's share by subsidiaries recognized as treasury shares                        |       | ( 69,992 )             | ( 623,438 )         |
| Consideration for transactions with non-controlling interests                                           | 6(32) | ( 153,809 )            | -                   |
| Net cash flows used in financing activities                                                             |       | ( 102,269 )            | ( 1,228,230 )       |
| Effects due to changes in exchange rate                                                                 |       | ( 13,965 )             | ( 43,623 )          |
| Net increase (decrease) in cash and cash equivalents                                                    |       | 703,520                | ( 596,214 )         |
| Cash and cash equivalents at beginning of year                                                          | 6(1)  | 4,767,212              | 5,363,426           |
| Cash and cash equivalents at end of year                                                                | 6(1)  | <u>\$ 5,470,732</u>    | <u>\$ 4,767,212</u> |

The accompanying notes are an integral part of these consolidated financial statements.

TCI CO., LTD. AND SUBSIDIARIES  
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS  
FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024

(Expressed in thousands of New Taiwan dollars, except as otherwise indicated)

1. HISTORY AND ORGANIZATION

TCI CO., LTD. (the “Company”) was incorporated as a company limited by shares under the provisions of the Company Act of the Republic of China (R.O.C.). The Company and its subsidiaries (collectively referred herein as the “Group”) are primarily engaged in manufacturing, wholesale and retail of health foods and cosmetics.

2. THE DATE OF AUTHORIZATION FOR ISSUANCE OF THE CONSOLIDATED FINANCIAL STATEMENTS AND PROCEDURES FOR AUTHORIZATION

These consolidated financial statements were reported to the Board of Directors on March 11, 2026.

3. APPLICATION OF NEW STANDARDS, AMENDMENTS AND INTERPRETATIONS

(1) Effect of the adoption of new issuances of or amendments to International Financial Reporting Standards (“IFRS®”) Accounting Standards that came into effect as endorsed by the Financial Supervisory Commission (“FSC”)

New standards, interpretations and amendments endorsed by the FSC and became effective from 2025 are as follows:

| <u>New Standards, Interpretations and Amendments</u>                                                                                | <u>Effective date by<br/>International Accounting<br/>Standards Board</u> |
|-------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------|
| Specific provisions of Amendments to IFRS 9 and IFRS 7, ‘Amendments to the classification and measurement of financial instruments’ | January 1, 2026                                                           |
| Amendments to IAS 21, ‘Lack of exchangeability’                                                                                     | January 1, 2025                                                           |

The above standards and interpretations have no significant impact to the Group’s financial condition and financial performance based on the Group’s assessment.

(2) Effect of new issuances of or amendments to IFRS Accounting Standards as endorsed by the FSC but not yet adopted by the Group

New standards, interpretations and amendments endorsed by the FSC effective from 2026 are as follows:

| New Standards, Interpretations and Amendments                                                                                       | Effective date by International Accounting Standards Board |
|-------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------|
| Specific provisions of Amendments to IFRS 9 and IFRS 7, ‘Amendments to the classification and measurement of financial instruments’ | January 1, 2026                                            |
| Amendments to IFRS 9 and IFRS 7, ‘Contracts referencing nature-dependent electricity’                                               | January 1, 2026                                            |
| IFRS 17, ‘Insurance contracts’                                                                                                      | January 1, 2023                                            |
| Amendments to IFRS 17, ‘Insurance contracts’                                                                                        | January 1, 2023                                            |
| Amendment to IFRS 17, ‘Initial application of IFRS 17 and IFRS 9 – comparative information’                                         | January 1, 2023                                            |
| Annual Improvements to IFRS Accounting Standards—Volume 11                                                                          | January 1, 2026                                            |

The above standards and interpretations have no significant impact to the Group’s financial condition and financial performance based on the Group’s assessment.

(3) IFRS Accounting Standards issued by IASB but not yet endorsed by the FSC

New standards, interpretations and amendments issued by IASB but not yet included in the IFRS Accounting Standards as endorsed by the FSC are as follows:

| New Standards, Interpretations and Amendments                                                                             | Effective date by International Accounting Standards Board   |
|---------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------|
| Amendments to IFRS 10 and IAS 28, ‘Sale or contribution of assets between an investor and its associate or joint venture’ | To be determined by International Accounting Standards Board |
| IFRS 18, ‘Presentation and disclosure in financial statements’                                                            | January 1, 2027(Note)                                        |
| IFRS 19, ‘Subsidiaries without public accountability: disclosures’                                                        | January 1, 2027                                              |
| Amendments to IAS 21, ‘Translation to a Hyperinflationary Presentation Currency’                                          | January 1, 2027                                              |

Note : The FSC has announced in a press release on September 25, 2025 that public companies will apply IFRS 18 starting from the fiscal year 2028. Additionally, entities can choose to adopt IFRS 18 earlier based on their requirements after the FSC endorses IFRS 18.

Except for the following, the above standards and interpretations have no significant impact to the Group’s financial condition and financial performance based on the Group’s assessment.

IFRS 18, ‘Presentation and disclosure in financial statements’

IFRS 18, ‘Presentation and disclosure in financial statements’ replaces IAS 1. The standard introduces a defined structure of the statement of profit or loss, disclosure requirements related to management-

defined performance measures, and enhanced principles on aggregation and disaggregation which apply to the primary financial statements and notes.

#### 4. SUMMARY OF MATERIAL ACCOUNTING POLICIES

The principal accounting policies applied in the preparation of these consolidated financial statements are set out below. These policies have been consistently applied to all the periods presented, unless otherwise stated.

##### (1) Compliance statement

The consolidated financial statements of the Group have been prepared in accordance with the “ Regulations Governing the Preparation of Financial Reports by Securities Issuers ”, International Financial Reporting Standards, International Accounting Standards, IFRIC Interpretations, and SIC Interpretations that came into effect as endorsed by the FSC (collectively referred herein as the “IFRSs”).

##### (2) Basis of preparation

- A. Except for the following items, the consolidated financial statements have been prepared under the historical cost convention:
  - (a) Financial assets and financial liabilities (including derivative instruments) at fair value through profit or loss.
  - (b) Financial assets at fair value through other comprehensive income.
  - (c) Liabilities on cash-settled share-based payment arrangements measured at fair value.
  - (d) Defined benefit liabilities recognized based on the net amount of pension fund assets less present value of defined benefit obligation.
- B. The preparation of financial statements in conformity with “IFRSs” requires the use of certain critical accounting estimates. It also requires management to exercise its judgement in the process of applying the Group’s accounting policies. The areas involving a higher degree of judgement or complexity, or areas where assumptions and estimates are significant to the consolidated financial statements are disclosed in Note 5.

##### (3) Basis of consolidation

- A. Basis for preparation of consolidated financial statements:
  - (a) All subsidiaries are included in the Group’s consolidated financial statements. Subsidiaries are all entities (including structured entities) controlled by the Group. The Group controls an entity when the Group is exposed, or has rights, to variable returns from its involvement with the entity and has the ability to affect those returns through its power over the entity. Consolidation of subsidiaries begins from the date the Group obtains control of the subsidiaries and ceases when the Group loses control of the subsidiaries.
  - (b) Inter-company transactions, balances and unrealized gains or losses on transactions between companies within the Group are eliminated. Accounting policies of subsidiaries have been adjusted where necessary to ensure consistency with the policies adopted by the Group.
  - (c) Profit or loss and each component of other comprehensive income are attributed to the owners

of the parent and to the non-controlling interests. Total comprehensive income is attributed to the owners of the parent and to the non-controlling interests even if this results in the non-controlling interests having a deficit balance.

- (d) Changes in a parent's ownership interest in a subsidiary that do not result in the parent losing control of the subsidiary (transactions with non-controlling interests) are accounted for as equity transactions, i.e. transactions with owners in their capacity as owners. Any difference between the amount by which the non-controlling interests are adjusted and the fair value of the consideration paid or received is recognized directly in equity.
- (e) When the Group loses control of a subsidiary, the Group remeasures any investment retained in the former subsidiary at its fair value. That fair value is regarded as the fair value on initial recognition of a financial asset or the cost on initial recognition of the associate or joint venture. Any difference between fair value and carrying amount is recognized in profit or loss. All amounts previously recognized in other comprehensive income in relation to the subsidiary are reclassified to profit or loss on the same basis as would be required if the related assets or liabilities were disposed of. That is, when the Group loses control of a subsidiary, all gains or losses previously recognized in other comprehensive income in relation to the subsidiary should be reclassified from equity to profit or loss, if such gains or losses would be reclassified to profit or loss when the related assets or liabilities are disposed of.

B. Subsidiaries included in the consolidated financial statements:

| Name of investor | Name of subsidiary   | Main business activities                               | Ownership (%)     |                   | Description |
|------------------|----------------------|--------------------------------------------------------|-------------------|-------------------|-------------|
|                  |                      |                                                        | December 31, 2025 | December 31, 2024 |             |
| TCI CO., LTD.    | TCI FIRSTEK CORP.    | Wholesale and retail of health foods and cosmetics     | 100               | 100               |             |
| TCI CO., LTD.    | GENE & NEXT INC.     | Research and development of biotechnology and genetics | 42.23             | 42.23             |             |
| TCI CO., LTD.    | TCI Biotech Co., Ltd | Producing health foods                                 | 36.73             | 36.73             |             |

| Name of investor                   | Name of subsidiary                 | Main business activities                                                               | Ownership (%)     |                   | Description |
|------------------------------------|------------------------------------|----------------------------------------------------------------------------------------|-------------------|-------------------|-------------|
|                                    |                                    |                                                                                        | December 31, 2025 | December 31, 2024 |             |
| TCI CO., LTD.                      | TCI HK LIMITED                     | Trading health foods and cosmetics                                                     | 100               | 100               |             |
| TCI CO., LTD.                      | BIOCOSME CO., LTD.                 | Trading health foods and cosmetics                                                     | 100               | 100               |             |
| TCI CO., LTD.                      | PETFOOD BIOTECHNOLOGY CO., LTD.    | Trading health foods for pets                                                          | -                 | -                 | Note 3      |
| TCI FIRSTEK CORP.                  | TCI International Trading Co., Ltd | Wholesale of health foods, cosmetics and chemical productions; cosmetics manufacturing | 100               | 100               |             |
| GENE & NEXT INC.                   | GLUX HK LIMITED                    | Trading health foods and cosmetics                                                     | -                 | 100               | Note 5      |
| TCI International Trading Co., Ltd | SHANGHAI BIOSCIENCE CO., LTD.      | Wholesale of health foods, cosmetics and chemical productions; cosmetics manufacturing | 100               | 100               |             |
| TCI International Trading Co., Ltd | SHANGHAI BIOCOSME CO., LTD.        | Producing cosmetics                                                                    | 100               | 100               |             |
| SHANGHAI BIOSCIENCE CO., LTD.      | TCI Biotech Co., Ltd               | Producing health foods                                                                 | 63.27             | 63.27             |             |
| GENE & NEXT INC.                   | TCI LIVING CO., LTD.               | Trading health foods and cosmetics                                                     | 79.31             | 79.31             |             |
| TCI LIVING CO., LTD.               | TCI LIVING (HK) LIMITED            | Trading health foods and cosmetics                                                     | 100               | 100               |             |
| TCI CO., LTD.                      | TCI JAPAN CO., LTD.                | Trading health foods and cosmetics                                                     | 100               | 100               |             |

| Name of investor              | Name of subsidiary                         | Main business activities                                                     | Ownership (%)     |                   | Description |
|-------------------------------|--------------------------------------------|------------------------------------------------------------------------------|-------------------|-------------------|-------------|
|                               |                                            |                                                                              | December 31, 2025 | December 31, 2024 |             |
| TCI CO., LTD.                 | PT TCI BIOTEK INDO                         | Trading health foods and cosmetics                                           | 100               | 100               | Note 1      |
| SHANGHAI BIOSCIENCE CO., LTD. | SHANGHAI BIOTECH GENE TECHNOLOGY CO., LTD. | Research and development of biotechnology and genetics                       | -                 | -                 | Note 2      |
| TCI CO., LTD.                 | TCI BIOTECH NETHERLANDS B.V.               | Trading health foods and cosmetics                                           | 100               | 100               |             |
| TCI LIVING CO., LTD.          | TCI LIVING SHANGHAI CO., LTD.              | Trading health foods and cosmetics                                           | 100               | 100               |             |
| TCI CO., LTD.                 | QUANTUM BIOLOGY INC.                       | Research and development of biotechnology                                    | 100               | 100               |             |
| TCI CO., LTD.                 | AYURGA INDIA PRIVATE LIMITED               | Trading health foods and cosmetics                                           | 100               | -                 | Note 4      |
| TCI CO., LTD.                 | TCI BIOTECH LLC                            | Trading health foods and cosmetics                                           | 3.85              | 3.85              |             |
| TCI BIOTECH LLC               | TCI BIOTECH USA LLC                        | Trading health foods and cosmetics                                           | 100               | 100               |             |
| TCI BIOTECH NETHERLANDS B.V.  | TCI BIOTECH LLC                            | Trading health foods and cosmetics                                           | 96.15             | 96.15             |             |
| TCI CO., LTD.                 | MAXIGEN BIOTECH INC.                       | Research and development, producing and sales of biotechnology and cosmetics | 29.19             | 25.42             |             |
| MAXIGEN BIOTECH INC.          | Maxigen Biotech Shanghai Co., Ltd.         | Selling medical machinery and trading cosmetics                              | 100               | 100               |             |

Note 1: There was capital injection of \$17,635 on June 12, 2024.

Note 2: The company was dissolved and liquidated on April 23, 2024.

Note 3: The company underwent dissolution and liquidation in 2024. However, as of December 31, 2025, the liquidation process had not yet been completed.

Note 4: There was capital injection of \$9,209 on June 1, 2025.

Note 5: The company was dissolved and liquidated on October 24, 2025.

C. Subsidiaries not included in the consolidated financial statements: None.

D. Adjustments for subsidiaries with different balance sheet dates: None.

E. Significant restrictions:

Cash and short-term deposits of \$2,560,040 deposited in mainland China are under local foreign exchange control which restricts the capital to be remitted outside the borders (except for normal dividend distribution).

F. Subsidiaries that have non-controlling interests that are material to the Group:

Information on subsidiaries that have non-controlling interests that are material to the Group is as follows:

| Name of subsidiary   | Principal place of business | Non-controlling interests |               |                   |               |
|----------------------|-----------------------------|---------------------------|---------------|-------------------|---------------|
|                      |                             | December 31, 2025         |               | December 31, 2024 |               |
|                      |                             | Amount                    | Ownership (%) | Amount            | Ownership (%) |
| GENE & NEXT INC.     | Taiwan                      | \$ 136,142                | 57.77%        | \$ 284,623        | 57.77%        |
| MAXIGEN BIOTECH INC. | Taiwan                      | 1,236,087                 | 70.81%        | 1,091,940         | 74.58%        |

Summarized financial information of the subsidiaries:

Balance sheets

|                     | GENE & NEXT INC.  |                   |
|---------------------|-------------------|-------------------|
|                     | December 31, 2025 | December 31, 2024 |
| Current assets      | \$ 914,289        | \$ 994,284        |
| Non-current assets  | 97,259            | 104,819           |
| Current liabilities | ( 98,643)         | ( 101,291)        |
| Total net assets    | <u>\$ 912,905</u> | <u>\$ 997,812</u> |

  

|                         | MAXIGEN BIOTECH INC. |                     |
|-------------------------|----------------------|---------------------|
|                         | December 31, 2025    | December 31, 2024   |
| Current assets          | \$ 1,121,464         | \$ 830,334          |
| Non-current assets      | 771,678              | 752,155             |
| Current liabilities     | ( 354,060)           | ( 205,869)          |
| Non-current liabilities | ( 6,434)             | ( 1,493)            |
| Total net assets        | <u>\$ 1,532,648</u>  | <u>\$ 1,375,127</u> |

## Statements of comprehensive income

|                                                               |     | GENE & NEXT INC.         |            |
|---------------------------------------------------------------|-----|--------------------------|------------|
|                                                               |     | Years ended December 31, |            |
|                                                               |     | 2025                     | 2024       |
| Revenue                                                       |     | \$ 273,606               | \$ 347,539 |
| Profit before income tax                                      |     | 39,809                   | 67,557     |
| Income tax benefit (expense)                                  |     | 109                      | ( 11,032)  |
| Profit attributable to non-controlling interest               | (   | 1,486)                   | 214        |
| Profit attributable to owners of the parent                   |     | 41,404                   | 56,311     |
| Other comprehensive loss, net of tax                          | (   | 66,514)                  | ( 43,293)  |
| Total comprehensive (loss) income for the year                | (\$ | 26,596)                  | \$ 13,232  |
| Comprehensive income attributable to non-controlling interest | \$  | 3,940                    | \$ 29,053  |
| Dividends paid to non-controlling interest                    | \$  | 28,972                   | \$ 18,289  |
|                                                               |     | MAXIGEN BIOTECH INC.     |            |
|                                                               |     | Years ended December 31, |            |
|                                                               |     | 2025                     | 2024       |
| Revenue                                                       |     | \$ 811,564               | \$ 680,651 |
| Profit before income tax                                      |     | 298,699                  | 225,545    |
| Income tax expense                                            | (   | 38,338)                  | ( 35,378)  |
| Profit for the year                                           |     | 260,361                  | 190,167    |
| Other comprehensive loss, net of tax                          | (   | 31,931)                  | ( 122,560) |
| Total comprehensive income for the year                       | \$  | 228,430                  | \$ 67,607  |
| Comprehensive income attributable to non-controlling interest | \$  | 140,321                  | \$ 104,320 |
| Dividends paid to non-controlling interest                    | \$  | 18,157                   | \$ 13,678  |
| Statements of cash flows                                      |     |                          |            |

|                                                       |    | GENE & NEXT INC.         |            |
|-------------------------------------------------------|----|--------------------------|------------|
|                                                       |    | Years ended December 31, |            |
|                                                       |    | 2025                     | 2024       |
| Net cash provided by operating activities             | \$ | 153,520                  | \$ 56,966  |
| Net cash provided by (used in) investing activities   |    | 59,744                   | ( 619,343) |
| Net cash used in financing activities                 | (  | 59,829)                  | ( 35,523)  |
| Effect of exchange rates on cash and cash equivalents | (  | 1,174)                   | 280        |
| Increase (decrease) in cash and cash equivalents      |    | 152,261                  | ( 597,620) |
| Cash and cash equivalents at beginning of year        |    | 98,426                   | 696,046    |
| Cash and cash equivalents at end of year              | \$ | 250,687                  | \$ 98,426  |

| MAXIGEN BIOTECH INC.                                         |            |    |         |
|--------------------------------------------------------------|------------|----|---------|
| Years ended December 31,                                     |            |    |         |
|                                                              | 2025       |    | 2024    |
| Net cash provided by operating activities                    | \$ 290,220 | \$ | 298,223 |
| Net cash used in investing activities                        | ( 382,990) | (  | 29,072) |
| Net cash provided by (used in) financing activities          | 30,660     | (  | 59,729) |
| Effect of exchange rate changes on cash and cash equivalents | ( 753)     | (  | 1,450)  |
| Decrease (increase) in cash and cash equivalents             | ( 62,863)  |    | 207,972 |
| Cash and cash equivalents at beginning of year               | 639,054    |    | 431,082 |
| Cash and cash equivalents at end of year                     | \$ 576,191 | \$ | 639,054 |

(4) Foreign currency translation

Items included in the financial statements of each of the Group's entities are measured using the currency of the primary economic environment in which the entity operates (the "functional currency"). The consolidated financial statements are presented in New Taiwan dollars (NTD), which is the Company's functional and the Group's presentation currency.

A. Foreign currency transactions and balances

- (a) Foreign currency transactions are translated into the functional currency using the exchange rates prevailing at the dates of the transactions or valuation where items are remeasured. Foreign exchange gains and losses resulting from the settlement of such transactions are recognized in profit or loss in the period in which they arise.
- (b) Monetary assets and liabilities denominated in foreign currencies at the period end are retranslated at the exchange rates prevailing at the balance sheet date. Exchange differences arising upon re-translation at the balance sheet date are recognized in profit or loss.
- (c) Non-monetary assets and liabilities denominated in foreign currencies held at fair value through profit or loss are re-translated at the exchange rates prevailing at the balance sheet date; their translation differences are recognized in profit or loss. Non-monetary assets and liabilities denominated in foreign currencies held at fair value through other comprehensive income are re-translated at the exchange rates prevailing at the balance sheet date; their translation differences are recognized in other comprehensive income. However, non-monetary assets and liabilities denominated in foreign currencies that are not measured at fair value are translated using the historical exchange rates at the dates of the initial transactions.
- (d) All foreign exchange gains and losses are presented in the statement of comprehensive income within 'other gains and losses'.

B. Translation of foreign operations

- (a) The operating results and financial position of all the group entities arrangements that have a functional currency different from the presentation currency are translated into the presentation currency as follows:
  - i. Assets and liabilities for each balance sheet presented are translated at the closing exchange rate at the date of that balance sheet;

- ii. Income and expenses for each statement of comprehensive income are translated at average exchange rates of that period; and
  - iii. All resulting exchange differences are recognized in other comprehensive income.
- (b) When the foreign operation partially disposed of or sold is a subsidiary, cumulative exchange differences that were recorded in other comprehensive income are proportionately transferred to the non-controlling interest in this foreign operation. In addition, even when the Group retains partial interest in the former foreign subsidiary after losing control of the former foreign subsidiary, such transactions should be accounted for as disposal of all interest in the foreign operation.

(5) Classification of current and non-current items

- A. Assets that meet one of the following criteria are classified as current assets; otherwise they are classified as non-current assets:
- (a) Assets that are expected to be realized, or are intended to be sold or consumed in the normal operating cycle;
  - (b) Assets that are held primarily for the purpose of trading;
  - (c) Assets that are expected to be realized within twelve months after the reporting period;
  - (d) Cash and cash equivalents, excluding restricted cash and cash equivalents and those that are to be exchanged or used to settle liabilities for at least twelve months after the reporting period.
- B. Liabilities that meet one of the following criteria are classified as current liabilities; otherwise they are classified as non-current liabilities:
- (a) Liabilities that are expected to be settle in the normal operating cycle;
  - (b) Liabilities that are held primarily for the purpose of trading;
  - (c) Liabilities that are due to be settle within twelve months after the reporting period;
  - (d) It does not have the right at the end of the reporting period to defer settlement of the liability at least twelve months after the reporting period.

(6) Cash equivalents

Cash equivalents refer to short-term, highly liquid investments that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value. Time deposits that meet the definition above and are held for the purpose of meeting short-term cash commitments in operations are classified as cash equivalents.

(7) Financial assets at fair value through profit or loss

- A. Financial assets at fair value through profit or loss are financial assets that are not measured at amortized cost or fair value through other comprehensive income.
- B. On a regular way purchase or sale basis, financial assets at fair value through profit or loss are recognized and derecognized using trade date accounting.
- C. At initial recognition, the Group measures the financial assets at fair value and recognizes the transaction costs in profit or loss. The Group subsequently measures the financial assets at fair value, and recognizes the gain or loss in profit or loss.

D. The Group recognizes the dividend income when the right to receive payment is established, future economic benefits associated with the dividend will flow to the Group and the amount of the dividend can be measured reliably.

(8) Financial assets at fair value through other comprehensive income

A. Financial assets at fair value through other comprehensive income comprise equity securities which are not held for trading, and for which the Group has made an irrevocable election at initial recognition to recognize changes in fair value in other comprehensive income and debt instruments.

B. On a regular way purchase or sale basis, financial assets at fair value through other comprehensive income are recognized and derecognized using trade date accounting.

C. At initial recognition, the Group measures the financial assets at fair value plus transaction costs. The Group subsequently measures the financial assets at fair value:

The changes in fair value of equity investments that were recognized in other comprehensive income are reclassified to retained earnings and are not reclassified to profit or loss following the derecognition of the investment. Dividends are recognized as revenue when the right to receive payment is established, future economic benefits associated with the dividend will flow to the Group and the amount of the dividend can be measured reliably.

(9) Financial assets at amortized cost

A. Financial assets at amortized cost are those that meet all of the following criteria:

- (a) The objective of the Group's business model is achieved by collecting contractual cash flows.
- (b) The assets' contractual cash flows represent solely payments of principal and interest.

B. On a regular way purchase or sale basis, financial assets at amortized cost are recognized and derecognized using trade date accounting.

C. The Group's time deposits which do not fall under cash equivalents are those with a short maturity period and are measured at initial investment amount as the effect of discounting is immaterial.

(10) Accounts and notes receivable

A. Accounts and notes receivable entitle the Group a legal right to receive consideration in exchange for transferred goods or rendered services.

B. The short-term accounts and notes receivable without bearing interest are subsequently measured at initial invoice amount as the effect of discounting is immaterial.

(11) Impairment of financial assets

For debt instruments measured at fair value through other comprehensive income and financial assets at amortized cost including accounts receivable that have a significant financing component, at each reporting date, the Group recognizes the impairment provision for 12 months expected credit losses if there has not been a significant increase in credit risk since initial recognition or recognizes the impairment provision for the lifetime expected credit losses (ECLs) if such credit risk has increased since initial recognition after taking into consideration all reasonable and verifiable information that includes forecasts. On the other hand, for accounts receivable or contract assets that

do not contain a significant financing component, the Group recognizes the impairment provision for lifetime ECLs.

(12) Derecognition of financial assets

The Group derecognizes a financial asset when one of the following conditions is met:

- A. The contractual rights to receive the cash flows from the financial asset expire.
- B. The contractual rights to receive cash flows of the financial asset have been transferred and the Group has transferred substantially all risks and rewards of ownership of the financial asset.
- C. The contractual rights to receive cash flows of the financial asset have been transferred; however, the Group has not retained control of the financial asset.

(13) Leasing arrangements (lessor) — lease receivables/ operating leases

Lease income from an operating lease (net of any incentives given to the lessee) is recognized in profit or loss on a straight-line basis over the lease term.

(14) Inventories

Inventories are stated at the lower of cost and net realizable value. Cost is determined using the weighted-average method. The cost of finished goods and work in progress comprises raw materials, direct labor, other direct costs and related production overheads (allocated based on normal operating capacity). It excludes borrowing costs. The item by item approach is used in applying the lower of cost and net realizable value. Net realizable value is the estimated selling price in the ordinary course of business, less the estimated cost of completion and the estimated costs necessary to make the sale.

(15) Investments accounted for using equity method / associates

- A. Associates are all entities over which the Group has significant influence but not control. In general, it is presumed that the investor has significant influence, if an investor holds, directly or indirectly 20 percent or more of the voting power of the investee. Investments in associates are accounted for using the equity method and are initially recognized at cost.
- B. The Group's share of its associates' post-acquisition profits or losses is recognized in profit or loss, and its share of post-acquisition movements in other comprehensive income is recognized in other comprehensive income. When the Group's share of losses in an associate equals or exceeds its interest in the associate, including any other unsecured receivables, the Group does not recognize further losses, unless it has incurred legal or constructive obligations or made payments on behalf of the associate.
- C. When changes in an associate's equity do not arise from profit or loss or other comprehensive income of the associate and such changes do not affect the Group's ownership percentage of the associate, the Group recognizes the Group's share of change in equity of the associate in 'capital surplus' in proportion to its ownership.
- D. Unrealized gains on transactions between the Group and its associates are eliminated to the extent of the Group's interest in the associates. Unrealized losses are also eliminated unless the transaction provides evidence of an impairment of the asset transferred. Accounting policies of

associates have been adjusted where necessary to ensure consistency with the policies adopted by the Group.

- E. In the case that an associate issues new shares and the Group does not subscribe or acquire new shares proportionately, which results in a change in the Group's ownership percentage of the associate but maintains significant influence on the associate, then 'capital surplus' and 'investments accounted for under the equity method' shall be adjusted for the increase or decrease of its share of equity interest. If the above condition causes a decrease in the Group's ownership percentage of the associate, in addition to the above adjustment, the amounts previously recognized in other comprehensive income in relation to the associate are reclassified to profit or loss proportionately on the same basis as would be required if the relevant assets or liabilities were disposed of.
- F. When the Group disposes its investment in an associate and loses significant influence over this associate, the amounts previously recognized in other comprehensive income in relation to the associate, are reclassified to profit or loss, on the same basis as would be required if the relevant assets or liabilities were disposed of. If it retains significant influence over this associate, the amounts previously recognized in other comprehensive income in relation to the associate are reclassified to profit or loss proportionately in accordance with the aforementioned approach.
- G. At the balance sheet date, the Group performs an impairment test for an investment in an associate when there is an indication that the investment may be impaired. The entire carrying amount of the investment (including goodwill) is tested for impairment as a single asset, by comparing its recoverable amount (higher of value in use and fair value less costs of disposal) with its carrying amount. Any impairment loss recognized forms part of the carrying amount of the investment. Any reversal of impairment loss is recognized to the extent that the recoverable amount of the investment subsequently increases.

(16) Property, plant and equipment

- A. Property, plant and equipment are initially recorded at cost. Borrowing costs incurred during the construction period are capitalized.
- B. Subsequent costs are included in the asset's carrying amount or recognized as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the Group and the cost of the item can be measured reliably. The carrying amount of the replaced part is derecognized. All other repairs and maintenance are charged to profit or loss during the financial period in which they are incurred.
- C. Land is not depreciated. Other property, plant and equipment apply cost model and are depreciated using the straight-line method to allocate their cost over their estimated useful lives. Each part of an item of property, plant, and equipment with a cost that is significant in relation to the total cost of the item must be depreciated separately.
- D. The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted if appropriate, at each financial year-end. If expectations for the assets' residual values and useful

lives differ from previous estimates or the patterns of consumption of the assets' future economic benefits embodied in the assets have changed significantly, any change is accounted for as a change in estimate under IAS 8, 'Accounting Policies, Changes in Accounting Estimates and Errors', from the date of the change. The estimated useful lives of property, plant and equipment are as follows:

|                          |              |
|--------------------------|--------------|
| Buildings and structures | 2 ~ 50 years |
| Machinery and equipment  | 1 ~ 10 years |
| Office equipment         | 2 ~ 16 years |
| Others                   | 1 ~ 16 years |

(17) Leasing arrangements (lessee)-right-of-use assets/ lease liabilities

- A. Leases are recognized as a right-of-use asset and a corresponding lease liability at the date at which the leased asset is available for use by the Group. For short-term leases or leases of low-value assets, lease payments are recognized as an expense on a straight-line basis over the lease term.
- B. Lease liabilities include the net present value of the remaining lease payments at the commencement date, discounted using the incremental borrowing interest rate. Lease payments are comprised of the following:

- (a) Fixed payments, less any lease incentives receivable;
- (b) Variable lease payments that depend on an index or a rate.

The Group subsequently measures the lease liability at amortized cost using the interest method and recognizes interest expense over the lease term. The lease liability is remeasured and the amount of remeasurement is recognized as an adjustment to the right-of-use asset when there are changes in the lease term or lease payments and such changes do not arise from contract modifications.

- C. At the commencement date, the right-of-use asset is stated at cost comprising the following:
  - (a) The amount of the initial measurement of lease liability;
  - (b) Any lease payments made at or before the commencement date.

The right-of-use asset is measured subsequently using the cost model and is depreciated from the commencement date to the earlier of the end of the asset's useful life or the end of the lease term. When the lease liability is remeasured, the amount of remeasurement is recognized as an adjustment to the right-of-use asset.

- D. For lease modifications that decrease the scope of the lease, the lessee shall decrease the carrying amount of the right-of-use asset to reflect the partial or full termination of the lease, and recognize the difference between remeasured lease liability in profit or loss. For all other lease modifications, the lessee shall remeasure the lease liability and adjust the right-of-use asset, correspondingly.

(18) Intangible assets

- A. Trademarks and patents

Separately acquired trademarks and patents are stated at historical cost. Trademarks, patents and other intangible assets acquired in a business combination are recognized at fair value at the acquisition date. Trademarks and patents have a finite useful life and are amortized on a straight-line basis over their estimated useful lives of 10 to 20 years.

**B. Computer software**

Computer software is stated at cost and amortized on a straight-line basis over its estimated useful life of 1 to 10 years.

**C. Goodwill**

Goodwill arises in a business combination accounted for by applying the acquisition method.

**D. Customer relationship**

Customer relationship arises in a business combination accounted for by applying the acquisition method and amortized on a straight-line basis over their estimated useful life of 10 years.

**(19) Impairment of non-financial assets**

A. The Group assesses at each balance sheet date the recoverable amounts of those assets where there is an indication that they are impaired. An impairment loss is recognized for the amount by which the asset's carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset's fair value less costs to sell or value in use. When the circumstances or reasons for recognizing impairment loss for an asset in prior years no longer exist or diminish, the impairment loss is reversed. The increased carrying amount due to reversal should not be more than what the depreciated or amortized historical cost would have been if the impairment had not been recognized.

B. The recoverable amounts of goodwill, intangible assets with an indefinite useful life and intangible assets that have not yet been available for use are evaluated periodically. An impairment loss is recognized for the amount by which the asset's carrying amount exceeds its recoverable amount. Impairment loss of goodwill previously recognized in profit or loss shall not be reversed in the following years.

C. For the purpose of impairment testing, goodwill acquired in a business combination is allocated to each of the cash-generating units, or groups of cash-generating units, that is/are expected to benefit from the synergies of the business combination. Each unit or group of units to which the goodwill is allocated represents the lowest level within the entity at which the goodwill is monitored for internal management purposes. Goodwill is monitored at the operating segment level.

**(20) Borrowings**

Borrowings comprise long-term and short-term bank borrowings. Borrowings are recognized initially at fair value, net of transaction costs incurred. Borrowings are subsequently stated at amortized cost; any difference between the proceeds (net of transaction costs) and the redemption value is recognized in profit or loss over the period of the borrowings using the effective interest method.

(21) Notes and accounts payable

- A. Notes and accounts payable are liabilities for purchases of raw materials, goods or services and notes payable are those resulting from operating and non-operating activities.
- B. The short-term notes and accounts payable without bearing interest are subsequently measured at initial invoice amount as the effect of discounting is immaterial.

(22) Financial liabilities at fair value through profit or loss

- A. Financial liabilities are classified in this category of held for trading if acquired principally for the purpose of repurchasing in the short-term. Derivatives are also categorized as financial liabilities held for trading unless they are designated as hedges.
- B. At initial recognition, the Group measures the financial liabilities at fair value. All related transaction costs are recognized in profit or loss. The Group subsequently measures these financial liabilities at fair value with any gain or loss recognized in profit or loss.

(23) Derecognition of financial liabilities

A financial liability is derecognized when the obligation under the liability specified in the contract is discharged or cancelled or expires.

(24) Offsetting financial instruments

Financial assets and liabilities are offset and reported in the net amount in the balance sheet when there is a legally enforceable right to offset the recognized amounts and there is an intention to settle on a net basis or realize the asset and settle the liability simultaneously.

(25) Non-hedging and embedded derivatives

Non-hedging derivatives are initially recognized at fair value on the date a derivative contract is entered into and recorded as financial assets or financial liabilities at fair value through profit or loss. They are subsequently remeasured at fair value and the gains or losses are recognised in profit or loss.

(26) Employee benefits

A. Short-term employee benefits

Short-term employee benefits are measured at the undiscounted amount of the benefits expected to be paid in respect of service rendered by employees in a period and should be recognized as expense in that period when the employees render service.

B. Pensions

(a) Defined contribution plans

For defined contribution plans, the contributions are recognized as pension expense when they are due on an accrual basis. Prepaid contributions are recognized as an asset to the extent of a cash refund or a reduction in the future payments.

(b) Defined benefit plans

- i. Net obligation under a defined benefit plan is defined as the present value of an amount of pension benefits that employees will receive on retirement for their services with the Group in current period or prior periods. The liability recognized in the balance sheet in respect

of defined benefit pension plans is the present value of the defined benefit obligation at the balance sheet date less the fair value of plan assets. The net defined benefit obligation is calculated annually by independent actuaries using the projected unit credit method. The rate used to discount is determined by using interest rates of high-quality corporate bonds that are denominated in the currency in which the benefits will be paid, and that have terms to maturity approximating to the terms of the related pension liability; when there is no deep market in high-quality corporate bonds, the Group uses interest rates of government bonds (at the balance sheet date) instead.

ii. Remeasurements arising on defined benefit plans are recognized in other comprehensive income in the period in which they arise and are recorded as retained earnings.

C. Termination benefits

Termination benefits are employee benefits provided in exchange for the termination of employment as a result from either the Group's decision to terminate an employee's employment before the normal retirement date, or an employee's decision to accept an offer of redundancy benefits in exchange for the termination of employment. The Group recognizes expense as it can no longer withdraw an offer of termination benefits or it recognizes relating restructuring costs, whichever is earlier. Benefits that are expected to be due more than 12 months after balance sheet date shall be discounted to their present value.

D. Employees' compensation and directors' and supervisors' remuneration

Employees' compensation and directors' and supervisors' remuneration are recognized as expense and liability, provided that such recognition is required under legal or constructive obligation and those amounts can be reliably estimated. Any difference between the resolved amounts and the subsequently actual distributed amounts is accounted for as changes in estimates.

(27) Employee share-based payment

A. For the equity-settled share-based payment arrangements, the employee services received are measured at the fair value of the equity instruments granted at the grant date, and are recognized as compensation cost over the vesting period, with a corresponding adjustment to equity. The fair value of the equity instruments granted shall reflect the impact of market vesting conditions and vesting conditions. Compensation cost is subject to adjustment based on the service conditions that are expected to be satisfied and the estimates of the number of equity instruments that are expected to vest under the non-market vesting conditions at each balance sheet date. Ultimately, the amount of compensation cost recognized is based on the number of equity instruments that eventually vest.

B. Restricted stocks:

- (a) Restricted stocks issued to employees are measured at the fair value of the equity instruments granted at the grant date, and are recognized as compensation cost over the vesting period.
- (b) For restricted stocks where those stocks do not restrict distribution of dividends to employees but employees must return the dividends received if they resign during the vesting period, and the Group recognizes the fair value of the dividends received by the employees who are

expected to resign during the vesting period as compensation cost at the date of dividends declared.

- (c) For restricted stocks where employees have to pay to acquire those stocks, if the employees resign during the vesting period, they must return the stocks to the Group and the Group must refund their payments on the stocks, the Group recognizes the payments from the employees who are expected to resign during the vesting period as liabilities at the grant date, and recognizes the payments from the employees who are expected to be eventually vested with the stocks in 'capital surplus – others'.

(28) Income tax

- A. The tax expense for the period comprises current and deferred tax. Tax is recognized in profit or loss, except to the extent that it relates to items recognized in other comprehensive income or items recognized directly in equity, in which cases the tax is recognized in other comprehensive income or equity.
- B. The current income tax expense is calculated on the basis of the tax laws enacted or substantively enacted at the balance sheet date in the countries where the Company and its subsidiaries operate and generate taxable income. Management periodically evaluates positions taken in tax returns with respect to situations in accordance with applicable tax regulations. It establishes provisions where appropriate based on the amounts expected to be paid to the tax authorities. An additional tax is levied on the unappropriated retained earnings and is recorded as income tax expense in the year the stockholders resolve to retain the earnings.
- C. Deferred tax is recognized, using the balance sheet liability method, on temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the consolidated balance sheet. However, the deferred tax is not accounted for if it arises from initial recognition of goodwill or of an asset or liability in a transaction other than a business combination that at the time of the transaction affects neither accounting nor taxable profit or loss and does not give rise to equal taxable and deductible temporary differences. Deferred tax is provided on temporary differences arising on investments in subsidiaries, except where the timing of the reversal of the temporary difference is controlled by the Group and it is probable that the temporary difference will not reverse in the foreseeable future. Deferred tax is determined using tax rates (and laws) that have been enacted or substantially enacted by the balance sheet date and are expected to apply when the related deferred tax asset is realized or the deferred tax liability is settled.
- D. Deferred tax assets are recognized only to the extent that it is probable that future taxable profit will be available against which the temporary differences can be utilized. At each balance sheet date, unrecognized and recognized deferred tax assets are reassessed.
- E. Current income tax assets and liabilities are offset and the net amount reported in the balance sheet when there is a legally enforceable right to offset the recognized amounts and there is an intention to settle on a net basis or realize the asset and settle the liability simultaneously.

Deferred tax assets and liabilities are offset on the balance sheet when the entity has the legally enforceable right to offset current tax assets against current tax liabilities and they are levied by the same taxation authority on either the same entity or different entities that intend to settle on a net basis or realize the asset and settle the liability simultaneously.

- F. A deferred tax asset shall be recognized for the carryforward of unused tax credits resulting from acquisitions of equipment or technology, research and development expenditures and equity investments to the extent that it is possible that future taxable profit will be available against which the unused tax credits can be utilized.

(29) Share capital

- A. Ordinary shares are classified as equity. Incremental costs directly attributable to the issue of new shares or stock options are shown in equity as a deduction, net of tax, from the proceeds.
- B. Where the Company repurchases the Company's equity share capital that has been issued, the consideration paid, including any directly attributable incremental costs (net of income taxes) is deducted from equity attributable to the Company's equity holders. Where such shares are subsequently reissued, the difference between their carrying amount and any consideration received, net of any directly attributable incremental transaction costs and the related income tax effects, is included in equity attributable to the Company's equity holders.

(30) Dividends

The distribution of cash dividends was recognized as liabilities in the financial statements after the special resolution of the Board of Directors according to Article 240 of the amended Company Act and the Company's Articles of Incorporation.

(31) Revenue recognition

- A. The Group manufactures and sells health foods and cosmetics products. Sales are recognized when control of the products has transferred, being when the products are delivered to the customer who has full discretion over the channel and price to sell the products, and there is no unfulfilled obligation that could affect the customer's acceptance of the products. Delivery occurs when the products have been shipped to the specific location, the risks of obsolescence and loss have been transferred to the customer, and either the customer has accepted the products in accordance with the sales contract, or the Group has objective evidence that all criteria for acceptance have been satisfied.
- B. The products are often sold with price break based on aggregate sales. Revenue from these sales is recognized based on the price specified in the contract, net of the estimated price break. Accumulated experience is used to estimate and provide for the price break, using the expected value method, and revenue is only recognized to the extent that it is highly probable that a significant reversal will not occur. The estimation is subject to an assessment at each reporting date. A refund liability is recognized for expected price break payable to customers in relation to sales made until the end of the reporting period.

### C. Service revenue

The Group provides health examination services for customers. Revenue from providing services is recognized at a point in time in which the services are rendered.

#### (32) Government grants

Government grants are recognized at their fair value only when there is reasonable assurance that the Group will comply with any conditions attached to the grants and the grants will be received.

#### (33) Business Combinations

- A. The Group applies the acquisition method for business combinations. The consideration for the combination is calculated based on the fair value of the assets transferred, liabilities incurred or assumed, and equity instruments issued. The consideration transferred includes the fair value of any assets and liabilities arising from contingent consideration arrangements. Costs related to the acquisition are recognized as expenses when incurred. Identifiable assets acquired and liabilities assumed in a business combination are measured at their fair value on the acquisition date. For each individual acquisition transaction, the Group measures non-controlling interests that represent current ownership interests and entitle their holders to a proportionate share of the entity's net assets upon liquidation either at fair value on the acquisition date or at the non-controlling interests' proportionate share of the acquiree's identifiable net assets; all other components of non-controlling interests are measured at fair value on the acquisition date.
- B. If the sum of the consideration transferred, the non-controlling interests in the acquiree, and the fair value of previously held equity interests in the acquiree exceeds the fair value of identifiable assets acquired and liabilities assumed, the excess is recognized as goodwill on the acquisition date. If the fair value of identifiable assets acquired and liabilities assumed exceeds the sum of the consideration transferred, the non-controlling interests in the acquiree, and the fair value of previously held equity interests in the acquiree, the difference is recognized as a gain in the current period on the acquisition date.

#### (34) Operating segments

Operating segments are reported in a manner consistent with the internal reporting provided to the chief operating decision-maker. The Group's chief operating decision-maker, who is responsible for allocating resources and assessing performance of the operating segments, has been identified as the Board of Directors that makes strategic decisions.

### 5. CRITICAL ACCOUNTING JUDGEMENTS, ESTIMATES AND KEY SOURCES OF ASSUMPTION UNCERTAINTY

The preparation of these consolidated financial statements requires management to make critical judgements in applying the Group's accounting policies and make critical assumptions and estimates concerning future events. Assumptions and estimates may differ from the actual results and are continually evaluated and adjusted based on historical experience and other factors. Such assumptions and estimates have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year; and the related information is addressed below:

(1) Critical judgements in applying the Group's accounting policies

None.

(2) Critical accounting estimates and assumptions

None.

6. DETAILS OF SIGNIFICANT ACCOUNT

(1) Cash and cash equivalents

|                                                                       | <u>December 31, 2025</u> | <u>December 31, 2024</u> |
|-----------------------------------------------------------------------|--------------------------|--------------------------|
| Cash on hand and revolving funds                                      | \$ 9,350                 | \$ 12,218                |
| Checking accounts and demand deposits                                 | 3,886,755                | 3,314,555                |
| Time deposits                                                         | <u>1,963,353</u>         | <u>2,305,605</u>         |
|                                                                       | 5,859,458                | 5,632,378                |
| Less: Shown as 'current financial assets at amortized cost'           | ( 359,998)               | ( 860,166)               |
| Less: Shown as 'current financial assets at amortized cost - pledged' | <u>( 28,728)</u>         | <u>( 5,000)</u>          |
|                                                                       | <u>\$ 5,470,732</u>      | <u>\$ 4,767,212</u>      |

A. The Group transacts with a variety of financial institutions all with high credit quality to disperse credit risk, so it expects that the probability of counterparty default is remote.

B. As of December 31, 2025 and 2024, the Group recognized time deposits with maturity over 3 months of \$388,726 and \$865,166, respectively, and shown as 'current financial assets at amortized cost'.

C. Details of the Group's cash and cash equivalents pledged to others are provided in Note 8.

(2) Financial assets at fair value through profit or loss

| <u>Items</u>                                                               | <u>December 31, 2025</u> | <u>December 31, 2024</u> |
|----------------------------------------------------------------------------|--------------------------|--------------------------|
| Current items:                                                             |                          |                          |
| Financial assets mandatorily measured at fair value through profit or loss |                          |                          |
| Listed stocks                                                              | \$ 39,148                | \$ 39,693                |
| Valuation adjustment                                                       | <u>( 19,388)</u>         | <u>( 8,679)</u>          |
|                                                                            | <u>\$ 19,760</u>         | <u>\$ 31,014</u>         |

A. Amounts recognized in profit or loss in relation to financial assets/liabilities at fair value through profit or loss are listed below:

|                                                                                        | <u>Years ended December 31,</u> |                   |
|----------------------------------------------------------------------------------------|---------------------------------|-------------------|
|                                                                                        | <u>2025</u>                     | <u>2024</u>       |
| Financial assets/liabilities mandatorily measured at fair value through profit or loss |                                 |                   |
| Equity instruments                                                                     | (\$ 10,709)                     | (\$ 5,222)        |
| Derivatives                                                                            | <u>-</u>                        | <u>3,741</u>      |
|                                                                                        | <u>(\$ 10,709)</u>              | <u>(\$ 1,481)</u> |

B. The Group has no financial assets at fair value through profit or loss pledged to others as collateral.

C. Information relating to price risk and fair value of financial assets at fair value through profit or loss is provided in Notes 12(2) and (3).

(3) Financial assets at fair value through other comprehensive income

| Items                | December 31, 2025 | December 31, 2024 |
|----------------------|-------------------|-------------------|
| Current items:       |                   |                   |
| Equity instruments   |                   |                   |
| Listed stocks        | \$ 31,200         | \$ -              |
| Valuation adjustment | (17,525)          | -                 |
|                      | <u>\$ 13,675</u>  | <u>\$ -</u>       |
| Non-current items:   |                   |                   |
| Equity instruments   |                   |                   |
| Listed stocks        | \$ 12,604         | \$ 12,604         |
| Unlisted stocks      | 22,581            | 27,054            |
|                      | <u>35,185</u>     | <u>39,658</u>     |
| Valuation adjustment | <u>30,813</u>     | <u>27,866</u>     |
|                      | <u>\$ 65,998</u>  | <u>\$ 67,524</u>  |

A. The Group has elected to classify equity investments that are considered to be strategic investments as financial assets at fair value through other comprehensive income. The fair value of such investments amounted to \$79,673 and \$67,524 as at December 31, 2025, and 2024, respectively.

B. Amounts recognized in profit or loss and other comprehensive income in relation to the financial assets at fair value through other comprehensive income are listed below:

|                                                                                  | Years ended December 31, |                 |
|----------------------------------------------------------------------------------|--------------------------|-----------------|
|                                                                                  | 2025                     | 2024            |
| <u>Equity instruments at fair value through other comprehensive income</u>       |                          |                 |
| Fair value change recognized in other comprehensive income                       | (\$ 13,094)              | \$ 3,239        |
| Cumulative (losses) gains reclassified to retained earnings due to derecognition | \$ 2,067                 | \$ -            |
| Dividend income recognized in profit or loss                                     |                          |                 |
| Held at end of period                                                            | \$ 3,684                 | \$ 1,862        |
| Derecognized during the period                                                   | -                        | -               |
|                                                                                  | <u>\$ 3,684</u>          | <u>\$ 1,862</u> |

C. As of December 31, 2025, and 2024, without taking into account any collateral held or other credit enhancements, the maximum exposure to credit risk in respect of the amount that best represents the financial assets at fair value through other comprehensive income held by the Group amounted to \$79,673 and \$67,524, respectively.

D. The Group's financial assets at fair value through other comprehensive income were not pledged to others as collateral.

E. Information relating to credit risk of financial assets at fair value through other comprehensive income is provided in Notes 12(2) and (3).

(4) Financial assets at amortized cost

| Items          | December 31, 2025 | December 31, 2024 |
|----------------|-------------------|-------------------|
| Current items: |                   |                   |
| Time deposits  | \$ 388,726        | \$ 865,166        |

A. Amounts recognized in profit or loss in relation to financial assets at amortized cost are listed below:

|                 | Years ended December 31, |          |
|-----------------|--------------------------|----------|
|                 | 2025                     | 2024     |
| Interest income | \$ 6,488                 | \$ 2,856 |

C. As at December 31, 2025, and 2024, without taking into account any collateral held or other credit enhancements, the maximum exposure to credit risk in respect of the amount that best represents the financial assets at amortized cost held by the Group was \$388,726 and \$865,166, respectively.

C. Details of the Group's financial assets at amortized cost pledged to others as collateral are provided in Note 8.

D. Information relating to credit risk of financial assets at amortized cost is provided in Note 12(2). The counterparties of the Group's investments in certificates of deposit are financial institutions with high credit quality, so the Group expects that the probability of counterparty default is remote.

(5) Notes and accounts receivable

|                                            | December 31, 2025 | December 31, 2024 |
|--------------------------------------------|-------------------|-------------------|
| Notes receivable                           | \$ 23,803         | \$ 81,031         |
| Less: Allowance for uncollectible accounts | -                 | -                 |
|                                            | \$ 23,803         | \$ 81,031         |
| Accounts receivable                        | \$ 1,066,940      | \$ 873,742        |
| Less: Allowance for uncollectible accounts | ( 98,128)         | ( 97,326)         |
|                                            | \$ 968,812        | \$ 776,416        |

A. The aging analysis of accounts receivable and notes receivable that were past due but not impaired is as follows:

|               | December 31, 2025 | December 31, 2024 |
|---------------|-------------------|-------------------|
| Not past due  | \$ 803,256        | \$ 692,427        |
| Up to 30 days | 112,936           | 120,067           |
| 31 to 90 days | 71,231            | 25,675            |
| Over 90 days  | 5,192             | 19,278            |
|               | \$ 992,615        | \$ 857,447        |

The above aging analysis was based on past due date.

B. As of December 31, 2025 and 2024, without taking into account any collateral held or other credit enhancements, the maximum exposure to credit risk in respect of the amount that best represents the Group's notes and accounts receivable amounted to \$23,803 and \$81,031; \$968,812 and \$776,416, respectively.

C. Information relating to credit risk of accounts receivable and notes receivable is provided in Note 12(2).

(6) Inventories

|                  | December 31, 2025 |                              |                   |
|------------------|-------------------|------------------------------|-------------------|
|                  | Cost              | Allowance for valuation loss | Book value        |
| Raw materials    | \$ 468,892        | (\$ 60,307)                  | \$ 408,585        |
| Work in progress | 133,750           | ( 24,968)                    | 108,782           |
| Finished goods   | 244,830           | ( 25,975)                    | 218,855           |
|                  | <u>\$ 847,472</u> | <u>(\$ 111,250)</u>          | <u>\$ 736,222</u> |

  

|                  | December 31, 2024 |                              |                   |
|------------------|-------------------|------------------------------|-------------------|
|                  | Cost              | Allowance for valuation loss | Book value        |
| Raw materials    | \$ 496,224        | (\$ 41,775)                  | \$ 454,449        |
| Work in progress | 127,783           | ( 10,983)                    | 116,800           |
| Finished goods   | 319,880           | ( 35,221)                    | 284,659           |
|                  | <u>\$ 943,887</u> | <u>(\$ 87,979)</u>           | <u>\$ 855,908</u> |

The cost of inventories recognized as expense for the years ended December 31, 2025 and 2024, were \$3,907,944 and \$4,062,460, respectively, including the amounts of \$37,803 and \$41,167 respectively, that the Group wrote down from cost to net realizable value accounted for as cost of goods sold.

(7) Investments accounted for using equity method

|                                                                | 2025                     | 2024                     |
|----------------------------------------------------------------|--------------------------|--------------------------|
| At January 1                                                   | \$ 28,182                | \$ 19,896                |
| Addition of investments accounted for using equity method      | 17,137                   | 16,470                   |
| Disposal of investments accounted for using equity method      | ( 1,020)                 | -                        |
| Changes in capital surplus                                     | ( 5,394)                 | 3,006                    |
| Share of loss of investments accounted for using equity method | ( 8,105)                 | ( 11,190)                |
| Changes in other equity items                                  | 16,089                   | -                        |
| At December 31                                                 | <u>\$ 46,889</u>         | <u>\$ 28,182</u>         |
|                                                                | <u>December 31, 2025</u> | <u>December 31, 2024</u> |
| Associates                                                     | <u>\$ 46,889</u>         | <u>\$ 28,182</u>         |

(8) Property, plant and equipment

|                             | Land                | Buildings and<br>structures | Machinery           | Machinery<br>for lease | Office<br>equipment | Others            | Unfinished<br>construction and<br>equipment under<br>acceptance | Total              |
|-----------------------------|---------------------|-----------------------------|---------------------|------------------------|---------------------|-------------------|-----------------------------------------------------------------|--------------------|
| <u>At January 1, 2025</u>   |                     |                             |                     |                        |                     |                   |                                                                 |                    |
| Cost                        | \$ 957,972          | \$ 2,521,898                | \$ 2,571,919        | \$ 14,980              | \$ 789,372          | \$422,938         | \$ 380,990                                                      | \$7,660,069        |
| Accumulated depreciation    | -                   | ( 587,167)                  | ( 1,524,606)        | ( 14,980)              | ( 384,819)          | ( 333,577)        | -                                                               | ( 2,845,149)       |
|                             | <u>\$ 957,972</u>   | <u>\$ 1,934,731</u>         | <u>\$ 1,047,313</u> | <u>\$ -</u>            | <u>\$ 404,553</u>   | <u>\$ 89,361</u>  | <u>\$ 380,990</u>                                               | <u>\$4,814,920</u> |
| <u>2025</u>                 |                     |                             |                     |                        |                     |                   |                                                                 |                    |
| At January 1                | \$ 957,972          | \$ 1,934,731                | \$ 1,047,313        | \$ -                   | \$ 404,553          | \$ 89,361         | \$ 380,990                                                      | \$4,814,920        |
| Additions                   | 135,653             | 836,915                     | 89,693              | -                      | 10,956              | 29,369            | 58,369                                                          | 1,160,955          |
| Disposals                   | ( 1,785)            | ( 6,543)                    | ( 15,022)           | -                      | ( 558)              | ( 460)            | -                                                               | ( 24,368)          |
| Transfers                   | -                   | -                           | 30,761              | -                      | 2,257               | 4,043             | 18,521                                                          | 55,582             |
| Depreciation charge         | -                   | ( 80,255)                   | ( 263,518)          | -                      | ( 77,814)           | ( 35,918)         | -                                                               | ( 457,505)         |
| Net exchange differences    | ( 5)                | ( 3,244)                    | ( 6,698)            | -                      | ( 2,237)            | ( 339)            | -                                                               | ( 12,523)          |
| At December 31              | <u>\$ 1,091,835</u> | <u>\$ 2,681,604</u>         | <u>\$ 882,529</u>   | <u>\$ -</u>            | <u>\$ 337,157</u>   | <u>\$ 86,056</u>  | <u>\$ 457,880</u>                                               | <u>\$5,537,061</u> |
| <u>At December 31, 2025</u> |                     |                             |                     |                        |                     |                   |                                                                 |                    |
| Cost                        | \$ 1,091,835        | \$ 3,349,723                | \$ 2,599,513        | \$ 14,980              | \$ 797,832          | \$450,797         | \$ 457,880                                                      | \$8,762,560        |
| Accumulated depreciation    | -                   | ( 668,119)                  | ( 1,716,984)        | ( 14,980)              | ( 460,675)          | ( 364,741)        | -                                                               | ( 3,225,499)       |
|                             | <u>\$ 1,091,835</u> | <u>\$ 2,681,604</u>         | <u>\$ 882,529</u>   | <u>\$ -</u>            | <u>\$ 337,157</u>   | <u>\$ 86,056</u>  | <u>\$ 457,880</u>                                               | <u>\$5,537,061</u> |
|                             | Land                | Buildings and<br>structures | Machinery           | Machinery<br>for lease | Office<br>equipment | Others            | Unfinished<br>construction and<br>equipment under<br>acceptance | Total              |
| <u>At January 1, 2024</u>   |                     |                             |                     |                        |                     |                   |                                                                 |                    |
| Cost                        | \$ 957,972          | \$ 2,419,408                | \$ 2,371,004        | \$ 35,982              | \$ 798,239          | \$421,919         | \$ 392,873                                                      | \$7,397,397        |
| Accumulated depreciation    | -                   | ( 502,254)                  | ( 1,270,207)        | ( 35,982)              | ( 328,918)          | ( 319,566)        | -                                                               | ( 2,456,927)       |
|                             | <u>\$ 957,972</u>   | <u>\$ 1,917,154</u>         | <u>\$ 1,100,797</u> | <u>\$ -</u>            | <u>\$ 469,321</u>   | <u>\$ 102,353</u> | <u>\$ 392,873</u>                                               | <u>\$4,940,470</u> |
| <u>2024</u>                 |                     |                             |                     |                        |                     |                   |                                                                 |                    |
| At January 1                | \$ 957,972          | \$ 1,917,154                | \$ 1,100,797        | \$ -                   | \$ 469,321          | \$ 102,353        | \$ 392,873                                                      | \$4,940,470        |
| Additions                   | -                   | 4,052                       | 157,450             | -                      | 9,072               | 18,691            | 16,166                                                          | 205,431            |
| Disposals                   | -                   | ( 366)                      | ( 3,522)            | -                      | ( 4,989)            | ( 869)            | -                                                               | ( 9,746)           |
| Transfers                   | -                   | 85,182                      | 56,988              | -                      | 10,412              | 10,214            | ( 28,049)                                                       | 134,747            |
| Depreciation charge         | -                   | ( 80,980)                   | ( 273,496)          | -                      | ( 82,668)           | ( 41,538)         | -                                                               | ( 478,682)         |
| Net exchange differences    | -                   | 9,689                       | 9,096               | -                      | 3,405               | 510               | -                                                               | 22,700             |
| At December 31              | <u>\$ 957,972</u>   | <u>\$ 1,934,731</u>         | <u>\$ 1,047,313</u> | <u>\$ -</u>            | <u>\$ 404,553</u>   | <u>\$ 89,361</u>  | <u>\$ 380,990</u>                                               | <u>\$4,814,920</u> |
| <u>At December 31, 2024</u> |                     |                             |                     |                        |                     |                   |                                                                 |                    |
| Cost                        | \$ 957,972          | 2,521,898                   | \$ 2,571,919        | \$ 14,980              | \$ 789,372          | \$422,938         | \$ 380,990                                                      | \$7,660,069        |
| Accumulated depreciation    | -                   | ( 587,167)                  | ( 1,524,606)        | ( 14,980)              | ( 384,819)          | ( 333,577)        | -                                                               | ( 2,845,149)       |
|                             | <u>\$ 957,972</u>   | <u>\$ 1,934,731</u>         | <u>\$ 1,047,313</u> | <u>\$ -</u>            | <u>\$ 404,553</u>   | <u>\$ 89,361</u>  | <u>\$ 380,990</u>                                               | <u>\$4,814,920</u> |

Information about the property, plant and equipment that were pledged to others as collateral is provided in Note 8.

(9) Leasing arrangements-lessee

A. The Group leases various assets including land and buildings. Rental contracts are typically made for periods of 2 to 50 years. Lease terms are negotiated on an individual basis and contain a wide range of different terms and conditions. The lease agreements do not impose covenants, but leased assets may not be used as security for borrowing purposes.

B. The carrying amount of right-of-use assets and the depreciation charge are as follows:

|           | <u>December 31, 2025</u> | <u>December 31, 2024</u> |
|-----------|--------------------------|--------------------------|
|           | <u>Carrying amount</u>   | <u>Carrying amount</u>   |
| Land      | \$ 25,987                | \$ 26,584                |
| Buildings | 133,024                  | 209,802                  |
|           | <u>\$ 159,011</u>        | <u>\$ 236,386</u>        |

  

|           | <u>Years ended December 31,</u> | <u>Years ended December 31,</u> |
|-----------|---------------------------------|---------------------------------|
|           | <u>2025</u>                     | <u>2024</u>                     |
|           | <u>Depreciation charge</u>      | <u>Depreciation charge</u>      |
| Land      | \$ 678                          | \$ 698                          |
| Buildings | 69,192                          | 72,072                          |
|           | <u>\$ 69,870</u>                | <u>\$ 72,770</u>                |

C. In March 2013, the Group signed a land use right contract with Shanghai Municipal Planning, Land and Resources Administration for use of the land in Jinshan District, Shanghai City with a term of 50 years. All rentals had been paid on the contract date.

D. For the years ended December 31, 2025 and 2024, the additions to right-of-use amounted to \$15,031 and \$111,193, respectively.

E. The information on profit and loss accounts relating to lease contracts is as follows:

|                                       | <u>Years ended December 31,</u> | <u>Years ended December 31,</u> |
|---------------------------------------|---------------------------------|---------------------------------|
|                                       | <u>2025</u>                     | <u>2024</u>                     |
| <u>Items affecting profit or loss</u> |                                 |                                 |
| Interest expense on lease liabilities | \$ 5,159                        | \$ 5,823                        |
| Expense on short-term lease contracts | \$ 58,323                       | \$ 54,135                       |
| Expense on leases of low-value assets | \$ 1,630                        | \$ 1,863                        |
| Gain or loss on lease modification    | \$ 2,545                        | \$ 382                          |

F. For the years ended December 31, 2025 and 2024, the Group's total cash outflow for leases amounted to \$135,180 and \$132,135, respectively.

(10) Intangible assets

|                             |                   |                   | Customer          |                 |                |                   |                   |
|-----------------------------|-------------------|-------------------|-------------------|-----------------|----------------|-------------------|-------------------|
|                             | <u>Goodwill</u>   | <u>Trademarks</u> | <u>relation</u>   | <u>Software</u> | <u>Royalty</u> | <u>Others</u>     | <u>Total</u>      |
| <u>At January 1, 2025</u>   |                   |                   |                   |                 |                |                   |                   |
| Cost                        | \$ 299,689        | \$ 132,821        | \$ 220,000        | \$ 36,740       | \$ 7,400       | \$ 143,856        | \$ 840,506        |
| Accumulated amortization    | -                 | ( 25,983)         | ( 77,000)         | ( 33,005)       | ( 6,808)       | ( 54,689)         | ( 197,485)        |
|                             | <u>\$ 299,689</u> | <u>\$ 106,838</u> | <u>\$ 143,000</u> | <u>\$ 3,735</u> | <u>\$ 592</u>  | <u>\$ 89,167</u>  | <u>\$ 643,021</u> |
| <u>2025</u>                 |                   |                   |                   |                 |                |                   |                   |
| At January 1                | \$ 299,689        | \$ 106,838        | \$ 143,000        | \$ 3,735        | \$ 592         | \$ 89,167         | \$ 643,021        |
| Additions —                 |                   |                   |                   |                 |                |                   |                   |
| acquired separately         | -                 | -                 | -                 | 1,720           | -              | -                 | 1,720             |
| Amortization charge         | -                 | ( 6,824)          | ( 22,000)         | ( 2,364)        | ( 260)         | ( 13,359)         | ( 44,807)         |
| Net exchange differences    | -                 | -                 | -                 | ( 8)            | -              | 12                | 4                 |
| At December 31              | <u>\$ 299,689</u> | <u>\$ 100,014</u> | <u>\$ 121,000</u> | <u>\$ 3,083</u> | <u>\$ 332</u>  | <u>\$ 75,820</u>  | <u>\$ 599,938</u> |
| <u>At December 31, 2025</u> |                   |                   |                   |                 |                |                   |                   |
| Cost                        | \$ 299,689        | \$ 132,821        | \$ 220,000        | \$ 38,441       | \$ 7,400       | \$ 143,868        | \$ 842,219        |
| Accumulated amortization    | -                 | ( 32,807)         | ( 99,000)         | ( 35,358)       | ( 7,068)       | ( 68,048)         | ( 242,281)        |
|                             | <u>\$ 299,689</u> | <u>\$ 100,014</u> | <u>\$ 121,000</u> | <u>\$ 3,083</u> | <u>\$ 332</u>  | <u>\$ 75,820</u>  | <u>\$ 599,938</u> |
|                             |                   |                   | Customer          |                 |                |                   |                   |
|                             | <u>Goodwill</u>   | <u>Trademarks</u> | <u>relation</u>   | <u>Software</u> | <u>Royalty</u> | <u>Others</u>     | <u>Total</u>      |
| <u>At January 1, 2024</u>   |                   |                   |                   |                 |                |                   |                   |
| Cost                        | \$ 299,689        | \$ 132,720        | \$ 220,000        | \$ 36,358       | \$ 7,400       | \$ 143,817        | \$ 839,984        |
| Accumulated amortization    | -                 | ( 19,074)         | ( 55,000)         | ( 26,962)       | ( 6,548)       | ( 41,251)         | ( 148,835)        |
|                             | <u>\$ 299,689</u> | <u>\$ 113,646</u> | <u>\$ 165,000</u> | <u>\$ 9,396</u> | <u>\$ 852</u>  | <u>\$ 102,566</u> | <u>\$ 691,149</u> |
| <u>2024</u>                 |                   |                   |                   |                 |                |                   |                   |
| At January 1                | \$ 299,689        | \$ 113,646        | \$ 165,000        | \$ 9,396        | \$ 852         | \$ 102,566        | \$ 691,149        |
| Additions —                 |                   |                   |                   |                 |                |                   |                   |
| acquired separately         | -                 | 95                | -                 | 333             | -              | -                 | 428               |
| Amortization charge         | -                 | ( 6,907)          | ( 22,000)         | ( 6,022)        | ( 260)         | ( 13,438)         | ( 48,627)         |
| Net exchange differences    | -                 | 4                 | -                 | 28              | -              | 39                | 71                |
| At December 31              | <u>\$ 299,689</u> | <u>\$ 106,838</u> | <u>\$ 143,000</u> | <u>\$ 3,735</u> | <u>\$ 592</u>  | <u>\$ 89,167</u>  | <u>\$ 643,021</u> |
| <u>At December 31, 2024</u> |                   |                   |                   |                 |                |                   |                   |
| Cost                        | \$ 299,689        | \$ 132,821        | \$ 220,000        | \$ 36,740       | \$ 7,400       | \$ 143,856        | \$ 840,506        |
| Accumulated amortization    | -                 | ( 25,983)         | ( 77,000)         | ( 33,005)       | ( 6,808)       | ( 54,689)         | ( 197,485)        |
|                             | <u>\$ 299,689</u> | <u>\$ 106,838</u> | <u>\$ 143,000</u> | <u>\$ 3,735</u> | <u>\$ 592</u>  | <u>\$ 89,167</u>  | <u>\$ 643,021</u> |

A. Details of amortization on intangible assets are as follows:

|                                     | Years ended December 31, |                  |
|-------------------------------------|--------------------------|------------------|
|                                     | 2025                     | 2024             |
| Overhead                            | \$ 13,157                | \$ 14,184        |
| Selling expenses                    | 2,372                    | 1,898            |
| General and administrative expenses | 23,561                   | 28,589           |
| Research and development expenses   | 5,717                    | 3,956            |
|                                     | <u>\$ 44,807</u>         | <u>\$ 48,627</u> |

B. Goodwill is allocated as follows to the Group's cash-generating units identified according to operating segment:

|        | December 31, 2025 | December 31, 2024 |
|--------|-------------------|-------------------|
| Taiwan | <u>\$ 299,689</u> | <u>\$ 299,689</u> |

(11) Impairment of non-financial assets

Goodwill is allocated to the Group's cash-generating units identified according to operating segment. The recoverable amount of all cash-generating units has been determined based on value-in-use calculations. These calculations use pre-tax cash flow projections based on financial budgets approved by the management covering a five-year period. As of December 31, 2025 and 2024, the recoverable amount of the Group's cash-generating units calculated using the value-in use exceeded their carrying amount, so goodwill was not impaired. The key assumptions used for value-in-use calculations are as follows:

|        | 2025          | 2024          |
|--------|---------------|---------------|
|        | Discount rate | Discount rate |
| Taiwan | 8.63%         | 7.97%         |

(12) Short-term borrowings

| Type of Borrowings   | December 31, 2025   | Interest rate range | Collateral         |
|----------------------|---------------------|---------------------|--------------------|
| Bank borrowings      |                     |                     |                    |
| Unsecured borrowings | \$ 1,560,000        | 0.3795%~1.98%       | None               |
| Secured borrowings   | 440,000             | 1.80%               | Land and Buildings |
|                      | <u>\$ 2,000,000</u> |                     |                    |
| Type of Borrowings   | December 31, 2024   | Interest rate range | Collateral         |
| Bank borrowings      |                     |                     |                    |
| Unsecured borrowings | <u>\$ 429,888</u>   | 3.65%               | None               |

(13) Financial liabilities at fair value through profit or loss

| Items                                  | December 31, 2025 | December 31, 2024 |
|----------------------------------------|-------------------|-------------------|
| Current items:                         |                   |                   |
| Financial liabilities held for trading |                   |                   |
| Derivative instruments                 | <u>\$ 1,418</u>   | <u>\$ -</u>       |

A. Amounts recognized in profit or loss and other comprehensive income in relation to financial liabilities at fair value through profit or loss are as follows:

|                                                 | 2025       | 2024 |
|-------------------------------------------------|------------|------|
| Net gains (losses) recognized in profit or loss |            |      |
| Financial liabilities held for trading          |            |      |
| Derivative instruments                          | (\$ 7,409) | \$ - |

B. Explanations of the transactions and contract information in respect of derivative financial liabilities that the Group does not adopt hedge accounting are as follows:

| Derivative financial liabilities   | December 31, 2025                       |        |                          | December 31, 2024                       |   |                 |
|------------------------------------|-----------------------------------------|--------|--------------------------|-----------------------------------------|---|-----------------|
|                                    | Contract amount<br>(Notional principal) |        | Contract period          | Contract amount<br>(Notional principal) |   | Contract period |
| Current items:                     |                                         |        |                          |                                         |   |                 |
| Forward foreign exchange contracts | EUR \$                                  | 2,000  | 2025.11.18<br>~2026.1.14 | - \$                                    | - |                 |
| Forward foreign exchange contracts | EUR                                     | 2,000  | 2025.11.27<br>~2026.2.11 | -                                       | - |                 |
| Forward foreign exchange contracts | USD                                     | 23,000 | 2025.12.16<br>~2026.3.17 | -                                       | - |                 |

The Group entered into forward foreign exchange contracts to (buy) sell forward foreign transactions to hedge exchange rate risk of (import) export proceeds. However, these forward foreign exchange contracts are not accounted for under hedge accounting.

C. Information relating to price risk and fair value of financial liabilities at fair value through profit or loss is provided in Notes 12(2) and (3).

(14) Account payable

|                  | December 31, 2025 | December 31, 2024 |
|------------------|-------------------|-------------------|
| Accounts payable | \$ 681,007        | \$ 679,654        |

(15) Other payables

|                                      | December 31, 2025 | December 31, 2024 |
|--------------------------------------|-------------------|-------------------|
| Employee bonus payable               | \$ 410,757        | \$ 392,619        |
| Salaries and bonuses payable         | 239,198           | 196,765           |
| Tax payables                         | 17,444            | 11,390            |
| Payable on machinery and equipment   | 15,941            | 6,491             |
| Payable on inspection and repairment | 3,307             | 2,455             |
| Other payables                       | 128,572           | 96,661            |
|                                      | \$ 815,219        | \$ 706,381        |

(16) Pensions

A.(a) The Company and its domestic subsidiaries have a defined benefit pension plan in accordance with the Labor Standards Law, covering all regular employees' service years prior to the enforcement of the Labor Pension Act on July 1, 2005 and service years thereafter of employees who chose to continue to be subject to the pension mechanism under the Law. Under the defined benefit pension plan, two units are accrued for each year of service for the first 15 years and one unit for each additional year thereafter, subject to a maximum of 45 units. Pension benefits are based on the number of units accrued and the average monthly salaries and wages of the last 6 months prior to retirement. The Company and its domestic subsidiaries contribute monthly an amount equal to 2% of the employees' monthly salaries and wages to the retirement fund deposited with Bank of Taiwan, the trustee, under the name of the independent retirement fund committee. Also, the Company and its domestic subsidiaries would assess the balance in the aforementioned labor pension reserve account by December 31, every year. If the account balance is insufficient to pay the pension calculated by the aforementioned method to the employees expected to qualify for retirement in the following year, the Company and its domestic subsidiaries will make contributions for the deficit by next March.

(b) The amounts recognized in the balance sheet are as follows:

|                                              | December 31, 2025 | December 31, 2024 |
|----------------------------------------------|-------------------|-------------------|
| Present value of defined benefit obligations | \$ -              | (\$ 131)          |
| Fair value of plan assets                    | 5,046             | 4,647             |
| Net defined benefit liability                | <u>\$ 5,046</u>   | <u>\$ 4,516</u>   |

(c) Movements in net defined benefit liabilities are as follows:

|                                                                                           | 2025                                               |                              |                                  |
|-------------------------------------------------------------------------------------------|----------------------------------------------------|------------------------------|----------------------------------|
|                                                                                           | Present value of<br>defined benefit<br>obligations | Fair value of<br>plan assets | Net defined<br>benefit liability |
| At January 1                                                                              | (\$ 131)                                           | \$ 4,647                     | \$ 4,516                         |
| Interest (expense) income                                                                 | ( 1)                                               | 70                           | 69                               |
|                                                                                           | ( 132)                                             | 4,717                        | 4,585                            |
| Remeasurements:                                                                           |                                                    |                              |                                  |
| Return on plan assets<br>(excluding amounts<br>included in interest<br>income or expense) | -                                                  | 327                          | 327                              |
| Experience adjustments                                                                    | 132                                                | -                            | 132                              |
|                                                                                           | 132                                                | 327                          | 459                              |
| Pension fund contribution                                                                 | -                                                  | 2                            | 2                                |
| At December 31                                                                            | <u>\$ -</u>                                        | <u>\$ 5,046</u>              | <u>\$ 5,046</u>                  |

|                                                                                           | 2024                                               |                                 |                                  |
|-------------------------------------------------------------------------------------------|----------------------------------------------------|---------------------------------|----------------------------------|
|                                                                                           | Present value of<br>defined benefit<br>obligations | Fair value of<br>plan<br>assets | Net defined<br>benefit liability |
| At January 1                                                                              | (\$ 137)                                           | \$ 4,218                        | \$ 4,081                         |
| Interest (expense) income                                                                 | ( 2)                                               | 58                              | 56                               |
|                                                                                           | ( 139)                                             | 4,276                           | 4,137                            |
| Remeasurements:                                                                           |                                                    |                                 |                                  |
| Return on plan assets<br>(excluding amounts<br>included in interest<br>income or expense) | -                                                  | 370                             | 370                              |
| Change in financial<br>assumptions                                                        | 2                                                  | -                               | 2                                |
| Experience adjustments                                                                    | 6                                                  | -                               | 6                                |
|                                                                                           | 8                                                  | 370                             | 378                              |
| Pension fund contribution                                                                 | -                                                  | 1                               | 1                                |
| At December 31                                                                            | (\$ 131)                                           | \$ 4,647                        | \$ 4,516                         |

(d) The Bank of Taiwan was commissioned to manage the Fund of the Company's and domestic subsidiaries' defined benefit pension plan in accordance with the Fund's annual investment and utilization plan and the "Regulations for Revenues, Expenditures, Safeguard and Utilization of the Labor Retirement Fund" (Article 6: The scope of utilization for the Fund includes deposit in domestic or foreign financial institutions, investment in domestic or foreign listed, over-the-counter, or private placement equity securities, investment in domestic or foreign real estate securitization products, etc.). With regard to the utilization of the Fund, its minimum earnings in the annual distributions on the final financial statements shall be no less than the earnings attainable from the amounts accrued from two-year time deposits with the interest rates offered by local banks. If the earnings is less than aforementioned rates, government shall make payment for the deficit after being authorized by the Regulator. The Company and domestic subsidiaries have no right to participate in managing and operating that fund and hence the Company and domestic subsidiaries are unable to disclose the classification of plan assets fair value in accordance with IAS 19 paragraph 142. The composition of fair value of plan assets as of December 31, 2025 and 2024 is given in the Annual Labor Retirement Fund Utilization Report announced by the government.

(e) The principal actuarial assumptions used were as follows:

|                         | Years ended December 31, |        |
|-------------------------|--------------------------|--------|
|                         | 2025                     | 2024   |
| Discount rate           | 1.250%                   | 1.500% |
| Future salary increases | 2.000%                   | 2.000% |

Assumptions regarding future mortality experience are set based on actuarial advice in accordance with published statistics and experience in each territory.

Because the main actuarial assumption changed, the present value of defined benefit obligation is affected. The analysis was as follows:

| <u>December 31, 2025</u>                              | <u>Discount rate</u> |                     | <u>Future salary increases</u> |                     |
|-------------------------------------------------------|----------------------|---------------------|--------------------------------|---------------------|
|                                                       | <u>Increase 25%</u>  | <u>Decrease 25%</u> | <u>Increase 25%</u>            | <u>Decrease 25%</u> |
| Effect on present value of defined benefit obligation | \$ -                 | \$ -                | \$ -                           | \$ -                |

  

| <u>December 31, 2024</u>                              | <u>Discount rate</u> |                     | <u>Future salary increases</u> |                     |
|-------------------------------------------------------|----------------------|---------------------|--------------------------------|---------------------|
|                                                       | <u>Increase 25%</u>  | <u>Decrease 25%</u> | <u>Increase 25%</u>            | <u>Decrease 25%</u> |
| Effect on present value of defined benefit obligation | (\$ 4)               | \$ 4                | \$ 4                           | (\$ 4)              |

The sensitivity analysis above is based on one assumption which changed while the other conditions remain unchanged. In practice, more than one assumption may change all at once. The method of analysing sensitivity and the method of calculating net pension liability in the balance sheet are the same.

The methods and types of assumptions used in preparing the sensitivity analysis did not change compared to the previous period.

- (f) Expected contributions to the defined benefit pension plans of the Group for the year ending December 31, 2026 amount to \$2.
- (g) As of December 31, 2025, the weighted average duration of the retirement plan is 0 years.
- B.(a) Effective July 1, 2005, the Company and its domestic subsidiaries have established a defined contribution pension plan (the “New Plan”) under the Labor Pension Act (the “Act”), covering all regular employees with R.O.C. nationality. Under the New Plan, the Company and its domestic subsidiaries contribute monthly an amount based on 6% of the employees’ monthly salaries and wages to the employees’ individual pension accounts at the Bureau of Labor Insurance. The benefits accrued are paid monthly or in lump sum upon termination of employment.
- (b) The Group’s mainland China subsidiaries have a defined contribution plan. Monthly contributions to an independent fund administered by the government in accordance with the pension regulations in the People’s Republic of China (PRC) are based on certain percentage of employees’ monthly salaries and wages. The contribution percentage for the years ended December 31, 2025 and 2024, were both 16%. Other than the monthly contributions, the Group has no further obligations.
- (c) The pension costs under the defined contribution pension plans of the Group for the years ended December 31, 2025 and 2024 were \$55,863 and \$56,208, respectively.

(17) Long-term borrowings

| <u>Type of borrowings</u> | <u>Borrowing period and repayment term</u>                                                         | <u>Interest rate range</u> | <u>Collateral</u> | <u>December 31, 2025</u> |
|---------------------------|----------------------------------------------------------------------------------------------------|----------------------------|-------------------|--------------------------|
| Long-term bank borrowings |                                                                                                    |                            |                   |                          |
| Unsecured borrowings      | Borrowing period is from March 3, 2020, to January 15, 2028; interest is repayable monthly.        | 1.875%                     | None              | \$ 40,972                |
| Unsecured borrowings      | Borrowing period is from August 14, 2024, to August 14, 2027; interest is repayable monthly.       | 1.98%                      | None              | 418,034                  |
| Secured borrowings        | Borrowing period is from September 11, 2020, to September 11, 2035; interest is repayable monthly. | 2.13%                      | Factory           | 548,548                  |
|                           |                                                                                                    |                            |                   | 1,007,554                |
| Less:Current portion      |                                                                                                    |                            |                   | ( 329,711)               |
|                           |                                                                                                    |                            |                   | <u>\$ 677,843</u>        |
| <u>Type of borrowings</u> | <u>and repayment term</u>                                                                          | <u>range</u>               | <u>Collateral</u> | <u>December 31, 2024</u> |
| Long-term bank borrowings |                                                                                                    |                            |                   |                          |
| Unsecured borrowings      | Borrowing period is from March 3, 2020, to January 15, 2028; interest is repayable monthly.        | 1.875%                     | None              | \$ 70,359                |
| Unsecured borrowings      | Borrowing period is from August 14, 2024, to August 14, 2027; interest is repayable monthly.       | 1.98%                      | None              | 500,000                  |
| Secured borrowings        | Borrowing period is from March 29, 2020, to August 14, 2035; interest is repayable monthly.        | 2.13%                      | Factory           | 598,639                  |
|                           |                                                                                                    |                            |                   | 1,168,998                |
| Less:Current portion      |                                                                                                    |                            |                   | ( 79,469)                |
|                           |                                                                                                    |                            |                   | <u>\$ 1,089,529</u>      |

(18) Share-based payment

A. For the years ended December 31, 2025 and 2024, the Group's share-based payment arrangements were as follows:

| Type of arrangement    | Issuance date | Quantity granted | Contract period | Vesting conditions                                                                                                                                              |
|------------------------|---------------|------------------|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Employee stock options | 2018.05.15    | 2,000            | 6 years         | Employees with 2 service years are entitled to 40%<br>Employees with 3 service years are entitled to 80%<br>Employees with 4 service years are entitled to 100% |
| Employee stock options | 2021.11.03    | 2,630            | 6 years         | Employees with 2 service years are entitled to 40%<br>Employees with 3 service years are entitled to 80%<br>Employees with 4 service years are entitled to 100% |
| Employee stock options | 2022.08.03    | 770              | 6 years         | Employees with 2 service years are entitled to 40%<br>Employees with 3 service years are entitled to 80%<br>Employees with 4 service years are entitled to 100% |

The restricted stocks issued by the Group cannot be transferred during the vesting period, but voting right and dividend right are not restricted on these stocks. Employees are required to return the stocks but not required to return the dividends received if they resign during the vesting period. The share-based payment arrangements above are settled by equity.

B. Details of the share-based payment arrangements are as follows:

|                                              | Years ended December 31, |                                              |                |                                              |
|----------------------------------------------|--------------------------|----------------------------------------------|----------------|----------------------------------------------|
|                                              | 2025                     |                                              | 2024           |                                              |
|                                              | No. of options           | Weighted-average exercise price (in dollars) | No. of options | Weighted-average exercise price (in dollars) |
| Options outstanding at January 1             | -                        |                                              | 1,385          | \$ 448                                       |
| Options expired                              | -                        | -                                            | ( 1,385)       | 448                                          |
| Options outstanding at the end of the period | -                        | \$ -                                         | -              | 448                                          |
| Options exercisable at the end of the period | -                        | \$ -                                         | -              | 448                                          |

|                                              | Years ended December 31, |                                              |                |                                              |
|----------------------------------------------|--------------------------|----------------------------------------------|----------------|----------------------------------------------|
|                                              | 2025                     |                                              | 2024           |                                              |
|                                              | No. of options           | Weighted-average exercise price (in dollars) | No. of options | Weighted-average exercise price (in dollars) |
| Options outstanding at January 1             | 1,872                    | \$ 67.91                                     | 2,762          | \$ 49.17                                     |
| Options exercisable                          | ( 12)                    | \$ 32.70                                     | ( 719)         | \$ 39.90                                     |
| Options exercised                            | ( 260)                   | ( 41.20)                                     | ( 171)         | 50.80                                        |
| Options outstanding at the end of the period | <u>1,600</u>             | <u>\$ 86.15</u>                              | <u>1,872</u>   | <u>\$ 67.91</u>                              |
| Options exercisable at the end of the period | <u>1,483</u>             | <u>\$ 48.48</u>                              | <u>1,129</u>   | <u>\$ 39.85</u>                              |

C. The expiry date and exercise price of stock options outstanding at balance sheet date are as follows:

| Issue date approved | Expiry date | December 31, 2025            |                             | December 31, 2024            |                             |
|---------------------|-------------|------------------------------|-----------------------------|------------------------------|-----------------------------|
|                     |             | No. of shares (in thousands) | Exercise price (in dollars) | No. of shares (in thousands) | Exercise price (in dollars) |
| 2018.05.15          | 2024.05.14  | -                            | \$ -                        | -                            | \$ 448                      |
| 2021.11.03          | 2027.11.02  | 1,124                        | 50.8                        | 1,379                        | 50.8                        |
| 2022.08.03          | 2028.08.03  | 476                          | 41.2                        | 493                          | 41.2                        |

D. The fair value of stock options granted on grant date is measured using the Black-Scholes option-pricing model. Relevant information is as follows:

| Type of arrangement    | Issuance date | Stock price (in dollars) | Exercise price (in dollars) | Expected price volatility (%) | Expected option life (year) | Expected dividends | Risk-free interest rate(%) | Fair value per unit (in dollars) |
|------------------------|---------------|--------------------------|-----------------------------|-------------------------------|-----------------------------|--------------------|----------------------------|----------------------------------|
| Employee stock options | 2018.05.15    | \$ 440.00                | \$ 448                      | 26.10~30.25                   | 5.75                        | -                  | 0.5636~0.6814              | \$ 63.16~106.15                  |
| Employee stock options | 2021.11.03    | \$ 50.80                 | \$ 50.80                    | 43.63~47.84                   | 3.00                        | -                  | 0.41~0.44                  | \$ 18.94~19.37                   |
| Employee stock options | 2022.08.03    | \$ 41.20                 | \$ 41.20                    | 45.89~48.46                   | 4.00                        | -                  | 1.00~1.03                  | \$ 15.11~16.98                   |

Note: Expected price volatility rate was estimated by using the stock prices of the most recent period with length of this period approximate to the length of the stock options' expected life, and the standard deviation of return on the stock during this period.

E. Expenses incurred on share-based payment transactions are shown below:

|                | Years ended December 31, |                 |
|----------------|--------------------------|-----------------|
|                | 2025                     | 2024            |
| Equity-settled | <u>\$ 4,089</u>          | <u>\$ 8,613</u> |

(19) Share capital

A. As of December 31, 2025, the Company's authorized capital was \$3,000,000, and the paid-in capital was \$1,177,288, with a par value of \$10 (in dollars) per share. All proceeds from shares issued have been collected.

B. Treasury shares

(a) Reason for share reacquisition and movements in the number of the Company's treasury shares are as follows:

| Name of company<br>holding the shares | Reason for reacquisition                         | December 31, 2025   |                          |
|---------------------------------------|--------------------------------------------------|---------------------|--------------------------|
|                                       |                                                  | Number of<br>shares | Carrying<br>amount(Note) |
| Subsidiary-<br>MAXIGEN BIOTECH INC.   | To improve the Group's<br>operational efficiency | 2,531,000           | \$ 500,084               |
| Subsidiary-<br>GENE & NEXT INC.       | To improve the Group's<br>operational efficiency | 5,015,000           | 693,431                  |
| Less:Non-controlling interest         |                                                  |                     | ( 754,709)               |
|                                       |                                                  |                     | <u>\$ 438,806</u>        |
| Name of company<br>holding the shares | Reason for reacquisition                         | December 31, 2024   |                          |
|                                       |                                                  | Number of<br>shares | Carrying<br>amount(Note) |
| The Company                           | To be reissued to employees                      | 532,000             | \$ 118,787               |
| Subsidiary-<br>MAXIGEN BIOTECH INC.   | To improve the Group's<br>operational efficiency | 2,531,000           | 500,084                  |
| Subsidiary-<br>GENE & NEXT INC.       | To improve the Group's<br>operational efficiency | 4,500,000           | 623,438                  |
| Less:Non-controlling interest         |                                                  |                     | ( 732,361)               |
|                                       |                                                  |                     | <u>\$ 509,948</u>        |

Note : The Company's subsidiary - MAXIGEN BIOTECH INC. and GENE & NEXT INC. are both a subsidiary of the Company with substantial control, but the Company's shareholding in it is 29.19% and 42.23% respectively but not up to 50%. Therefore, the company's repurchase of the Company's stock is not subject to the Company Law Section 167 Restrictions.

- (b) Pursuant to the R.O.C. Securities and Exchange Act, the number of shares bought back as treasury share should not exceed 10% of the number of the Company's issued and outstanding shares and the amount bought back should not exceed the sum of retained earnings, paid-in capital in excess of par value and realized capital surplus.
- (c) Pursuant to the R.O.C. Securities and Exchange Act, treasury shares should not be pledged as collateral and is not entitled to dividends before it is reissued.
- (d) Pursuant to the R.O.C. Securities and Exchange Act, treasury shares should be reissued to the employees within five years from the reacquisition date and shares not reissued within

the five-year period are to be retired. Treasury shares to enhance the Company's credit rating and the stockholders' equity should be retired within six months of acquisition.

(20) Capital surplus

Pursuant to the R.O.C. Company Act, capital surplus arising from paid-in capital in excess of par value on issuance of common stocks and donations can be used to cover accumulated deficit or to issue new stocks or cash to shareholders in proportion to their share ownership, provided that the Company has no accumulated deficit. Further, the R.O.C. Securities and Exchange Act requires that the amount of capital surplus to be capitalized mentioned above should not exceed 10% of the paid-in capital each year. Capital surplus should not be used to cover accumulated deficit unless the legal reserve is insufficient.

(21) Retained earnings

A. Under the Company's Articles of Incorporation, the current year's earnings, if any, shall first be used to pay all taxes and offset prior years' operating losses and then 10% of the remaining amount shall be set aside as legal reserve. The remainder, if any, to be retained or to be appropriated shall be resolved by the stockholders at the stockholders' meeting.

In accordance with Article 240 of the Company Act, the Board of Directors is authorized by the Company to resolve the distribution of dividends and bonuses or legal reserve and capital reserve, in whole or in part, in accordance with Article 241 of the Company Act in the form of cash by a resolution adopted by the majority vote at its meeting attended by two-thirds of the total number of directors, and then reported to the shareholders. The aforesaid requirement that resolution shall be resolved at the shareholders' meeting is not applicable.

B. The Company's dividend policy is summarized below: as the Company operates in a volatile business environment and is in the stable growth stage, the residual dividend policy is adopted taking into consideration the Company's financial structure, operating results and future expansion plans, and cash dividends shall account for at least 10% of the total dividends distributed. However, if the Company has sufficient retained earnings and capital, the Company may increase cash dividends in proportion to total dividends.

C. Except for covering accumulated deficit or issuing new stocks or cash to shareholders in proportion to their share ownership, the legal reserve shall not be used for any other purpose. The use of legal reserve for the issuance of stocks or cash to shareholders in proportion to their share ownership is permitted, provided that the distribution of the reserve is limited to the portion in excess of 25% of the Company's paid-in capital.

D. Special reserve

(a) In accordance with the regulations, the Company shall set aside special reserve from the debit balance on other equity items at the balance sheet date before distributing earnings. When debit balance on other equity items is reversed subsequently, the reversed amount could be included in the distributable earnings.

(b) The amounts previously set aside by the Company as special reserve on initial application of IFRSs according to Order No. Financial-Supervisory-Securities-Corporate-1090150022, dated March 31, 2021, shall be reversed proportionately when the relevant assets are used, disposed of or reclassified subsequently.

E. On May 9, 2024, the shareholders at the shareholders' meeting approved the distribution of dividends from the 2023 earnings in the amount of \$824,102, with cash dividends of \$7 (in dollars) per share. On June 26, 2025, the Board of Directors proposed the distribution of dividends from the 2024 earnings in the amounts of \$835,875 and \$341,414, with cash dividends of \$7.1 (in dollars) per common share from the earnings and an additional cash dividend of \$2.9 (in dollars) per common share from the capital reserve - premium on common stock.

(22) Other equity items

| 2025                                              |                                              |                         |              |
|---------------------------------------------------|----------------------------------------------|-------------------------|--------------|
|                                                   | Unrealized<br>gains (losses)<br>on valuation | Currency<br>translation | Total        |
| At January 1                                      | (\$ 2,741)                                   | (\$ 151,239)            | (\$ 153,980) |
| Currency translation differences                  | -                                            | 24,439                  | 24,439       |
| Subsidiaries accounted for<br>using equity method | ( 6,457)                                     | -                       | ( 6,457)     |
| Revaluation transferred to retained<br>earnings   | 2,196                                        | -                       | 2,196        |
| Revaluation                                       | ( 2,067)                                     | -                       | ( 2,067)     |
| At December 31                                    | (\$ 9,069)                                   | (\$ 126,800)            | (\$ 135,869) |
| 2024                                              |                                              |                         |              |
|                                                   | Unrealized<br>gains (losses)<br>on valuation | Currency<br>translation | Total        |
| At January 1                                      | (\$ 3,152)                                   | (\$ 280,381)            | (\$ 283,533) |
| Currency translation differences                  | -                                            | 129,142                 | 129,142      |
| Subsidiaries accounted for using<br>equity method | 2,068                                        | -                       | 2,068        |
| Revaluation                                       | ( 1,657)                                     | -                       | ( 1,657)     |
| At December 31                                    | (\$ 2,741)                                   | (\$ 151,239)            | (\$ 153,980) |

(23) Operating revenue

| Years ended December 31,              |              |              |
|---------------------------------------|--------------|--------------|
|                                       | 2025         | 2024         |
| Revenue from contracts with customers | \$ 6,989,303 | \$ 7,240,266 |

A. Disaggregation of revenue from contracts with customers

The Group derives revenue from the transfer of goods and services at a point in time in the following major geographical regions:

| Year ended<br>December 31, 2025          | Europe and<br>America region | Asia<br>Pacific region | Total               |
|------------------------------------------|------------------------------|------------------------|---------------------|
| Segment revenue                          | \$ 3,670,446                 | \$ 5,594,237           | \$ 9,264,683        |
| Inter-segment revenue                    | ( 577,841)                   | ( 1,697,539)           | ( 2,275,380)        |
| Revenue from external customer contracts | <u>\$ 3,092,605</u>          | <u>\$ 3,896,698</u>    | <u>\$ 6,989,303</u> |
| Year ended<br>December 31, 2024          | Europe and<br>America region | Asia<br>Pacific region | Total               |
| Segment revenue                          | \$ 4,301,133                 | \$ 5,775,720           | \$ 10,076,853       |
| Inter-segment revenue                    | ( 1,519,221)                 | ( 1,317,366)           | ( 2,836,587)        |
| Revenue from external customer contracts | <u>\$ 2,781,912</u>          | <u>\$ 4,458,354</u>    | <u>\$ 7,240,266</u> |

Timing of revenue mentioned above is all at a point in time.

B. Contract assets and liabilities

As of December 31, 2025, December 31, 2024, and January 1, 2024, the Group has not recognized any revenue-related contract assets, while the Group has recognized contract liabilities below:

|                          | December 31, 2025 | December 31, 2024 | January 1, 2024   |
|--------------------------|-------------------|-------------------|-------------------|
| Contract liabilities     |                   |                   |                   |
| – advance sales receipts | <u>\$ 669,362</u> | <u>\$ 552,566</u> | <u>\$ 496,528</u> |

(a) Significant changes in contract assets and liabilities: None.

(b) Revenue recognized that was included in the contract liability balance at the beginning of the period:

|                                                                                                       | Years ended December 31, |                   |
|-------------------------------------------------------------------------------------------------------|--------------------------|-------------------|
|                                                                                                       | 2025                     | 2024              |
| Revenue recognized that was included in the contract liability balance at the beginning of the period |                          |                   |
| Advance sales receipts                                                                                | <u>\$ 343,811</u>        | <u>\$ 317,764</u> |

(24) Interest income

|                                           | Years ended December 31, |                  |
|-------------------------------------------|--------------------------|------------------|
|                                           | 2025                     | 2024             |
| Interest income from bank deposits (Note) | <u>\$ 73,004</u>         | <u>\$ 70,508</u> |

Note: Including interest income from financial assets measured at amortized cost.

(25) Other income

|                                        | Years ended December 31, |                  |
|----------------------------------------|--------------------------|------------------|
|                                        | 2025                     | 2024             |
| Dividend income                        | \$ 4,376                 | \$ 3,210         |
| Subsidy income                         | 12,990                   | 642              |
| Other income - others                  | 29,773                   | 24,989           |
| Gains on write-off of past due payable | 32,043                   | -                |
|                                        | <u>\$ 79,182</u>         | <u>\$ 28,841</u> |

(26) Other gains and losses

|                                                                                   | Years ended December 31, |                  |
|-----------------------------------------------------------------------------------|--------------------------|------------------|
|                                                                                   | 2025                     | 2024             |
| Gains on disposal of property, plant and equipment                                | \$ 1,722                 | \$ 1,492         |
| Losses on disposal of investments                                                 | ( 3,603)                 | ( 1,167)         |
| Gains arising from lease modifications                                            | 2,545                    | 382              |
| Foreign exchange gains                                                            | 8,437                    | 67,310           |
| Net losses on financial assets (liabilities) at fair value through profit or loss | ( 18,118)                | ( 1,481)         |
| Miscellaneous disbursements                                                       | ( 12,900)                | ( 2,670)         |
|                                                                                   | <u>(\$ 21,917)</u>       | <u>\$ 63,866</u> |

(27) Finance costs

|                                  | Years ended December 31, |                  |
|----------------------------------|--------------------------|------------------|
|                                  | 2025                     | 2024             |
| Interest expense                 |                          |                  |
| Bank borrowings                  | \$ 46,078                | \$ 39,454        |
| Interest from lease liabilities  | 5,159                    | 5,823            |
| Imputed interest on rent deposit | -                        | 12               |
|                                  | <u>\$ 51,237</u>         | <u>\$ 45,289</u> |

(28) Expenses by nature

|                                                                                                       | Years ended December 31, |              |
|-------------------------------------------------------------------------------------------------------|--------------------------|--------------|
|                                                                                                       | 2025                     | 2024         |
| Employee benefit expense                                                                              | \$ 1,349,101             | \$ 1,395,415 |
| Depreciation charges on property, plant and equipment and depreciation charges on right-of-use assets | 527,375                  | 551,452      |
| Operating lease payments                                                                              | 59,953                   | 55,998       |
| Amortization charges on intangible assets                                                             | 44,807                   | 48,627       |

(29) Employee benefit expense

|                                 | Years ended December 31, |                     |
|---------------------------------|--------------------------|---------------------|
|                                 | 2025                     | 2024                |
| Wages and salaries              | \$ 1,132,827             | \$ 1,159,188        |
| Employee stock options (Note)   | 4,089                    | 8,613               |
| Labor and health insurance fees | 108,690                  | 117,134             |
| Pension costs                   | 55,794                   | 56,152              |
| Other personnel expenses        | 47,701                   | 54,328              |
|                                 | <u>\$ 1,349,101</u>      | <u>\$ 1,395,415</u> |

Note: It was equity-settled.

- A. In accordance with the Articles of Incorporation of the Company, a ratio of distributable profit of the current year, after covering accumulated losses, shall be distributed as employees' compensation and directors' and supervisors' remuneration. The ratio shall be 5%~15% for employees' compensation (with not less than 25% distributed to grassroots employees) and shall not be higher than 3% for directors' and supervisors' remuneration.
- B. For the years ended December 31, 2025 and 2024, employees' compensation was accrued at \$55,082 and \$83,119, respectively; while directors' and supervisors' remuneration was accrued at \$3,900 and \$4,100, respectively. The aforementioned amounts were recognized in salary expenses.
- C. The employees' compensation and directors' and supervisors' remuneration were estimated and accrued based on 5%~15% and not be higher than 3% of distributable profit of current year for the year ended December 31, 2025. The Board of Directors resolved that the actual distribution amount is \$55,082 and \$3,900, respectively, and the employees' compensation was distributed in the form of cash.
- D. Employees' compensation and directors' and supervisors' remuneration for 2024 amounting to \$83,119 and \$4,100, respectively, as resolved at the meeting of Board of Directors were in agreement with those amounts recognized in the 2024 financial statements, and the employees' compensation was distributed in the form of cash.
- E. Information about employees' compensation and directors' and supervisors' remuneration of the Company as resolved by the Board of Directors will be posted in the "Market Observation Post System" at the website of the Taiwan Stock Exchange.

(30) Income tax

A. Income tax expense

Components of income tax expense:

|                                                   | Years ended December 31, |            |
|---------------------------------------------------|--------------------------|------------|
|                                                   | 2025                     | 2024       |
| Current tax:                                      |                          |            |
| Current tax on profits for the period             | \$ 220,136               | \$ 209,542 |
| Effect from investment tax credits                | ( 99,411)                | ( 60,473)  |
| Prior year income tax under estimation            | 11,542                   | 5,378      |
| Total current tax                                 | 132,267                  | 154,447    |
| Deferred tax:                                     |                          |            |
| Origination and reversal of temporary differences | ( 12,566)                | 6,288      |
| Total deferred tax                                | ( 12,566)                | 6,288      |
| Income tax expense                                | \$ 119,701               | \$ 160,735 |

B. Reconciliation between income tax expense and accounting profit:

|                                                                    | Years ended December 31, |            |
|--------------------------------------------------------------------|--------------------------|------------|
|                                                                    | 2025                     | 2024       |
| Tax calculated based on profit before tax and statutory tax rate   | \$ 289,366               | \$ 272,976 |
| Effect from items not recognized in accordance with tax regulation | ( 71,968)                | ( 53,516)  |
| Effect from investment tax credits                                 | ( 99,411)                | ( 60,473)  |
| Temporary differences were not recognized as deferred tax assets   | 4,766                    | -          |
| Prior year income tax over estimation                              | 11,542                   | 5,378      |
| Change in assessment of realization of deferred tax assets         | ( 18,153)                | ( 4,238)   |
| Taxable loss not recognized as deferred tax assets                 | 3,559                    | 608        |
| Income tax expense                                                 | \$ 119,701               | \$ 160,735 |

C. Amounts of deferred tax assets or liabilities as a result of temporary differences are as follows:

|                                                                             | 2025               |                                 |                    |
|-----------------------------------------------------------------------------|--------------------|---------------------------------|--------------------|
|                                                                             | January 1          | Recognized in<br>profit or loss | December 31        |
| Temporary differences:                                                      |                    |                                 |                    |
| -Deferred tax assets:                                                       |                    |                                 |                    |
| Allowance for obsolescence<br>and decline in market value<br>of inventories | \$ 9,183           | \$ 4,733                        | \$ 13,916          |
| Unused vacation time bonus<br>tax differences                               | 270                | ( 167)                          | 103                |
| Unrealized exchange loss                                                    | 114                | ( 114)                          | -                  |
| Unrealized gross profit                                                     | 12,769             | ( 4,729)                        | 8,040              |
| Tax losses                                                                  | -                  | 2,189                           | 2,189              |
| Others                                                                      | 2,463              | ( 74)                           | 2,389              |
|                                                                             | <u>\$ 24,799</u>   | <u>\$ 1,838</u>                 | <u>\$ 26,637</u>   |
| -Deferred tax liabilities:                                                  |                    |                                 |                    |
| Pension tax differences                                                     | (\$ 491)           | (\$ 1)                          | (\$ 492)           |
| Unrealized exchange gain                                                    | ( 7,554)           | 2,907                           | ( 4,647)           |
| Others                                                                      | ( 74,395)          | 7,822                           | ( 66,573)          |
|                                                                             | <u>(\$ 82,440)</u> | <u>\$ 10,728</u>                | <u>(\$ 71,712)</u> |
|                                                                             | <u>(\$ 57,641)</u> | <u>\$ 12,566</u>                | <u>(\$ 45,075)</u> |
|                                                                             | 2024               |                                 |                    |
|                                                                             | January 1          | Recognized in<br>profit or loss | December 31        |
| Temporary differences:                                                      |                    |                                 |                    |
| -Deferred tax assets:                                                       |                    |                                 |                    |
| Allowance for obsolescence<br>and decline in market value<br>of inventories | \$ 9,271           | (\$ 88)                         | \$ 9,183           |
| Unused vacation time bonus<br>tax differences                               | 244                | 26                              | 270                |
| Unrealized exchange loss                                                    | 4,526              | ( 4,412)                        | 114                |
| Unrealized gross profit                                                     | 15,373             | ( 2,604)                        | 12,769             |
| Others                                                                      | 2,536              | ( 73)                           | 2,463              |
|                                                                             | <u>\$ 31,950</u>   | <u>(\$ 7,151)</u>               | <u>\$ 24,799</u>   |
| -Deferred tax liabilities:                                                  |                    |                                 |                    |
| Pension tax differences                                                     | (\$ 491)           | \$ -                            | (\$ 491)           |
| Unrealized exchange gain                                                    | -                  | ( 7,554)                        | ( 7,554)           |
| Others                                                                      | ( 82,812)          | 8,417                           | ( 74,395)          |
|                                                                             | <u>(\$ 83,303)</u> | <u>\$ 863</u>                   | <u>(\$ 82,440)</u> |
|                                                                             | <u>(\$ 51,353)</u> | <u>(\$ 6,288)</u>               | <u>(\$ 57,641)</u> |

D. The amounts of deductible temporary differences that were not recognized as deferred tax assets are as follows:

|                                  | <u>December 31, 2025</u> | <u>December 31, 2024</u> |
|----------------------------------|--------------------------|--------------------------|
| Deductible temporary differences | \$ 184,266               | \$ 215,075               |

E. The Company's income tax returns through 2020 have been assessed and approved by the Tax Authority.

(31) Earnings per share

|                                                                                                    | <u>Year ended December 31, 2025</u> |                                                                                          |                                       |
|----------------------------------------------------------------------------------------------------|-------------------------------------|------------------------------------------------------------------------------------------|---------------------------------------|
|                                                                                                    | Amount after<br>tax                 | Weighted average<br>number<br>of ordinary shares<br>outstanding<br>(shares in thousands) | Earnings<br>per share<br>(in dollars) |
| <u>Basic earnings per share</u>                                                                    |                                     |                                                                                          |                                       |
| Profit attributable to the parent                                                                  | \$ 954,957                          | 109,986                                                                                  | \$ 8.68                               |
| <u>Diluted earnings per share</u>                                                                  |                                     |                                                                                          |                                       |
| Profit attributable to ordinary<br>shareholders of the parent                                      | \$ 954,957                          |                                                                                          |                                       |
| Assumed conversion of all dilutive<br>potential ordinary shares                                    |                                     |                                                                                          |                                       |
| Employees' compensation                                                                            | -                                   | 608                                                                                      |                                       |
| Shareholders of the parent plus<br>assumed conversion of all dilutive<br>potential ordinary shares | \$ 954,957                          | 110,594                                                                                  | \$ 8.63                               |
|                                                                                                    | <u>Year ended December 31, 2024</u> |                                                                                          |                                       |
|                                                                                                    | Amount after<br>tax                 | Weighted average<br>number<br>of ordinary shares<br>outstanding<br>(shares in thousands) | Earnings<br>per share<br>(in dollars) |
| <u>Basic earnings per share</u>                                                                    |                                     |                                                                                          |                                       |
| Profit attributable to the parent                                                                  | \$ 851,499                          | 111,989                                                                                  | \$ 7.60                               |
| <u>Diluted earnings per share</u>                                                                  |                                     |                                                                                          |                                       |
| Profit attributable to ordinary<br>shareholders of the parent                                      | \$ 851,499                          |                                                                                          |                                       |
| Assumed conversion of all dilutive<br>potential ordinary shares                                    |                                     |                                                                                          |                                       |
| Employees' compensation                                                                            | -                                   | 842                                                                                      |                                       |
| Shareholders of the parent plus<br>assumed conversion of all dilutive<br>potential ordinary shares | \$ 851,499                          | 112,831                                                                                  | \$ 7.55                               |

(32) Transactions with non-controlling interest

Acquisition of additional equity interest in a subsidiary

On December 31, 2025, the Group acquired an additional 3.77% of shares of its subsidiary—MAXIGEN BIOTECH INC. for a total cash consideration of \$153,809. The carrying amount of non-controlling interest in MAXIGEN BIOTECH INC. was \$52,423 at the acquisition date. This transaction resulted in a decrease in the non-controlling interest by \$153,809 and a decrease in the equity attributable to owners of the parent by \$101,386. The effect of changes in interests in 2025 on the equity attributable to owners of the parent is shown below:

|                                                                                                                                               | Years ended December 31, |      |
|-----------------------------------------------------------------------------------------------------------------------------------------------|--------------------------|------|
|                                                                                                                                               | 2025                     | 2024 |
| Carrying amount of non-controlling interest acquired                                                                                          | \$ 52,423                | \$ - |
| Consideration paid to non-controlling interest                                                                                                | ( 153,809)               | -    |
| Capital surplus - difference between proceeds on actual acquisition of or disposal of equity interest in a subsidiary and its carrying amount | (\$ 101,386)             | \$ - |

(33) Supplemental cash flow information

Investing activities with partial cash payments

|                                              | Years ended December 31, |            |
|----------------------------------------------|--------------------------|------------|
|                                              | 2025                     | 2024       |
| Purchase of property, plant and equipment    | \$ 1,160,955             | \$ 205,431 |
| Add: Opening balance of payable on equipment | 6,491                    | 10,127     |
| Less: Ending balance of payable on equipment | ( 15,941)                | ( 6,491)   |
| Cash paid during the period                  | \$ 1,151,505             | \$ 209,067 |

7. RELATED PARTY TRANSACTIONS

(1) Names of related parties and relationship

| Names of related parties          | Relationship with the Company                                                 |
|-----------------------------------|-------------------------------------------------------------------------------|
| Daido Pharmaceutical Corporation  | Note                                                                          |
| PURE MILK CO., LTD.               | Other related party (The Company is the company's institutional shareholder.) |
| CHUN LING INTERNATIONAL CO.,      | Other related party                                                           |
| Vegan Joy Global Company Limited  | Other related party                                                           |
| Corpowell B.V.                    | Other related party                                                           |
| SMY INTERNET OF PACKAGE CO., LTD. | Associate                                                                     |

Note: The company is no longer a related party of the Company since the company transferred its owned shares to Yong Jiang Investment Co. (which is the Company's institutional shareholder) in the second quarter of 2024.

(2) Significant related party transactions

A. Operating revenue:

|                       | Years ended December 31, |                  |
|-----------------------|--------------------------|------------------|
|                       | 2025                     | 2024             |
| Sales of goods:       |                          |                  |
| Other related parties | \$ 64,799                | \$ 87,023        |
| Associates            | -                        | 1,268            |
|                       | <u>\$ 64,799</u>         | <u>\$ 88,291</u> |

Goods are sold based on the price lists in force and terms that would be available to third parties.

B. Purchases:

|                               | Years ended December 31, |                 |
|-------------------------------|--------------------------|-----------------|
|                               | 2025                     | 2024            |
| Purchase and processing fees: |                          |                 |
| Other related parties         | \$ -                     | \$ 3,074        |
| Associates                    | -                        | 98              |
|                               | <u>\$ -</u>              | <u>\$ 3,172</u> |

The transaction prices and payment terms to associates have no similar transactions for comparison. The payment term is 30~60 days after monthly billings.

C. Other income

|              | Years ended December 31, |       |
|--------------|--------------------------|-------|
|              | 2025                     | 2024  |
| Rent income: |                          |       |
| Associates   | \$ -                     | \$ 37 |

The Company leases offices to associates. Rents are negotiated based on the mutual agreement and are collected monthly.

D. Other expenses

|                       | Years ended December 31, |             |
|-----------------------|--------------------------|-------------|
|                       | 2025                     | 2024        |
| Other expenses:       |                          |             |
| Other related parties | \$ 487                   | \$ -        |
| Associates            | 1,242                    | -           |
|                       | <u>\$ 1,729</u>          | <u>\$ -</u> |

Other expenses include entertainment expenses and professional services fees.

E. Receivables from related parties:

|                       | December 31, 2025 | December 31, 2024 |
|-----------------------|-------------------|-------------------|
| Accounts receivable:  |                   |                   |
| Other related parties | \$ 25,244         | \$ 48,400         |
| Associates            | -                 | 428               |
|                       | <u>25,244</u>     | <u>48,828</u>     |
| Other receivables:    |                   |                   |
| Associates            | \$ 59             | \$ 104            |
|                       | <u>\$ 25,303</u>  | <u>\$ 48,932</u>  |

The receivables from related parties arise mainly from sales of goods. The receivables are due 60 to 90 days after the date of sales. The receivables are unsecured in nature and bear no interest. There are no allowances for uncollectible accounts held against receivables from related parties.

F. Payables to related parties:

|                   | December 31, 2025 | December 31, 2024 |
|-------------------|-------------------|-------------------|
| Accounts payable: |                   |                   |
| Associates        | \$ 426            | \$ -              |

The payables to related parties arise mainly from purchase transactions and are due two months after the date of purchase. The payables bear no interest.

(3) Key management compensation

|                              | Years ended December 31, |                  |
|------------------------------|--------------------------|------------------|
|                              | 2025                     | 2024             |
| Short-term employee benefits | \$ 72,568                | \$ 81,302        |
| Share-based payments         | 1,696                    | 4,092            |
|                              | <u>\$ 74,264</u>         | <u>\$ 85,394</u> |

8. PLEDGED ASSETS

The Group's assets pledged as collateral are as follows:

| Pledged asset                              | Book value          |                     | Purpose                                             |
|--------------------------------------------|---------------------|---------------------|-----------------------------------------------------|
|                                            | December 31, 2025   | December 31, 2024   |                                                     |
| Property, plant and equipment              | \$ 1,388,464        | \$ 1,733,370        | Short-term and long-term borrowings                 |
| Current financial assets at amortized cost | 28,728              | 5,000               | Performance guarantee and customs bills negotiation |
|                                            | <u>\$ 1,417,192</u> | <u>\$ 1,738,370</u> |                                                     |

9. SIGNIFICANT CONTINGENT LIABILITIES AND UNRECOGNIZED CONTRACT COMMITMENTS

(1) Contingencies

None.

(2) Commitments

A. Capital expenditures contracted for at the balance sheet date but not yet incurred are as follows:

|                               | <u>December 31, 2025</u> | <u>December 31, 2024</u> |
|-------------------------------|--------------------------|--------------------------|
| Property, plant and equipment | <u>\$ 153,184</u>        | <u>\$ 157,069</u>        |

B. As of December 31, 2025, and 2024, the Group's total unused letters of credit was \$7,956 and \$2,013, respectively.

10. SIGNIFICANT DISASTER LOSS

None.

11. SIGNIFICANT EVENTS AFTER THE BALANCE SHEET DATE

None.

12. OTHERS

(1) Financial statement presentation

Certain accounts in the financial statements of the Group for the year 2024 have been reclassified to ensure consistency and comparability with the financial statement presentation for the year 2025.

(2) Capital management

The Group's objectives when managing capital are based on the Group's operating industrial scale, considering the future growth of the industry and product development, setting up appropriate market share, and planning corresponding capital expenditures. Then, determining the required working capital based on the financial operation plan. Finally, taking into consideration the operating income and cash flows that can be generated by the product competitiveness to decide the appropriate capital structure.

(3) Financial instruments

A. Financial instruments by category

|                                                                                      | <u>December 31, 2025</u> | <u>December 31, 2024</u> |
|--------------------------------------------------------------------------------------|--------------------------|--------------------------|
| <u>Financial assets</u>                                                              |                          |                          |
| Financial assets at fair value through profit or loss                                |                          |                          |
| Financial assets mandatorily measured at fair value through profit or loss - current | <u>\$ 19,760</u>         | <u>\$ 31,014</u>         |
| Financial assets at fair value through other comprehensive income                    |                          |                          |
| Designation of equity instrument                                                     | <u>\$ 79,673</u>         | <u>\$ 67,524</u>         |
| <u>Financial assets</u>                                                              |                          |                          |
| Financial assets at amortized cost                                                   |                          |                          |
| Cash and cash equivalents                                                            | \$ 5,470,732             | \$ 4,767,212             |
| Financial assets at amortized cost - current                                         | 388,726                  | 865,166                  |
| Notes receivable                                                                     | 23,803                   | 81,031                   |
| Accounts receivable                                                                  | 968,812                  | 776,416                  |
| Accounts receivable - related parties                                                | 25,244                   | 48,828                   |
| Other receivables                                                                    | 43,967                   | 39,308                   |
| Other receivables - related parties                                                  | 59                       | 104                      |
| Guarantee deposits paid                                                              | <u>21,024</u>            | <u>37,112</u>            |
|                                                                                      | <u>\$ 6,942,367</u>      | <u>\$ 6,615,177</u>      |
| <u>Financial liabilities</u>                                                         |                          |                          |
| Financial liabilities at fair value through profit or loss                           |                          |                          |
| Financial liabilities held for trading                                               | <u>\$ 1,418</u>          | <u>\$ -</u>              |
| <u>Financial liabilities</u>                                                         |                          |                          |
| Financial liabilities at amortized cost                                              |                          |                          |
| Short-term borrowings                                                                | \$ 2,000,000             | \$ 429,888               |
| Notes payable                                                                        | 3,264                    | 1,518                    |
| Accounts payable                                                                     | 681,007                  | 679,654                  |
| Accounts payable - related parties                                                   | 426                      | -                        |
| Other accounts payable                                                               | 815,219                  | 706,381                  |
| Long-term borrowings (including current portion)                                     | 1,007,554                | 1,168,998                |
| Deposits received                                                                    | <u>12,509</u>            | <u>-</u>                 |
|                                                                                      | <u>\$ 4,519,979</u>      | <u>\$ 2,986,439</u>      |
| Lease liability                                                                      | <u>\$ 135,575</u>        | <u>\$ 216,011</u>        |

## B. Financial risk management policies

Risk management is carried out by a central treasury department (Group treasury) under policies approved by the Board of Directors. Group treasury identifies, evaluates and hedges financial risks in close co-operation with the Group's operating units. The Board provides written principles for overall risk management, as well as written policies covering specific areas and matters, such as foreign exchange risk, interest rate risk, credit risk, use of derivative financial instruments and non-derivative financial instruments, and investment of excess liquidity.

## C. Significant financial risks and degrees of financial risks

### (a) Market risk

#### Foreign exchange risk

- i. The Group operates internationally and is exposed to foreign exchange risk arising from various currency exposures, primarily with respect to the USD and RMB. Foreign exchange risk arises from future commercial transactions, recognized assets and liabilities and net investments in foreign operations.
- ii. The Group's businesses involve some non-functional currency operations (the Company's and certain subsidiaries' functional currency: NTD; other certain subsidiaries' functional currency: RMB). The information on assets and liabilities denominated in foreign currencies whose values would be materially affected by the exchange rate fluctuations is as follows:

|                                            |     | December 31, 2025                         |               |                     |
|--------------------------------------------|-----|-------------------------------------------|---------------|---------------------|
| (Foreign currency:<br>functional currency) |     | Foreign currency<br>amount (in thousands) | Exchange rate | Book value<br>(NTD) |
| <u>Financial assets</u>                    |     |                                           |               |                     |
| <u>Monetary items</u>                      |     |                                           |               |                     |
| USD:NTD                                    | USD | 21,916                                    | 31.4300       | \$ 688,820          |
| RMB:NTD                                    | RMB | 197,783                                   | 4.4960        | 889,232             |
| EUR:NTD                                    | EUR | 6,190                                     | 36.9000       | 228,411             |
| JPY:NTD                                    | JPY | 1,215,577                                 | 0.2008        | 244,088             |
| <u>Financial liabilities</u>               |     |                                           |               |                     |
| <u>Monetary items</u>                      |     |                                           |               |                     |
| JPY:NTD                                    | JPY | 495,961                                   | 0.2008        | \$ 99,589           |
| RMB:NTD                                    | RMB | 44,175                                    | 4.4960        | 198,611             |
| USD:NTD                                    | USD | 5,421                                     | 31.4300       | 170,382             |
| EUR:NTD                                    | EUR | 702                                       | 36.9000       | 25,904              |

|                                            |                       | December 31, 2024 |            |            |
|--------------------------------------------|-----------------------|-------------------|------------|------------|
| (Foreign currency:<br>functional currency) | Foreign currency      |                   | Book value |            |
|                                            | amount (in thousands) | Exchange rate     | (NTD)      |            |
| <u>Financial assets</u>                    |                       |                   |            |            |
| <u>Monetary items</u>                      |                       |                   |            |            |
| USD:NTD                                    | USD                   | 23,542            | 32.7850    | \$ 771,824 |
| RMB:NTD                                    | RMB                   | 188,875           | 4.4780     | 845,782    |
| EUR:NTD                                    | EUR                   | 10,637            | 34.1400    | 363,147    |
| JPY:NTD                                    | JPY                   | 959,241           | 0.2099     | 201,345    |
| <u>Financial liabilities</u>               |                       |                   |            |            |
| <u>Monetary items</u>                      |                       |                   |            |            |
| JPY:NTD                                    | JPY                   | 471,630           | 0.2099     | \$ 98,995  |
| RMB:NTD                                    | RMB                   | 129,012           | 4.4780     | 577,716    |
| USD:NTD                                    | USD                   | 4,488             | 32.7850    | 147,139    |
| EUR:NTD                                    | EUR                   | 1,148             | 34.1400    | 39,193     |

iii. The total exchange gain, including realized and unrealized, arising from significant foreign exchange variation on the monetary items held by the Group for the years ended December 31, 2025 and 2024, amounted to \$8,437 and \$67,310, respectively.

iv. Analysis of foreign currency market risk arising from significant foreign exchange variation:

|                                            | Year ended December 31, 2025 |    |                             |    |                                         |
|--------------------------------------------|------------------------------|----|-----------------------------|----|-----------------------------------------|
|                                            | Sensitivity analysis         |    |                             |    |                                         |
| (Foreign currency:<br>functional currency) | Degree of<br>variation       |    | Effect on<br>profit or loss |    | Effect on other<br>comprehensive income |
| <u>Financial assets</u>                    |                              |    |                             |    |                                         |
| <u>Monetary items</u>                      |                              |    |                             |    |                                         |
| USD:NTD                                    | 1%                           | \$ | 6,888                       | \$ | -                                       |
| RMB:NTD                                    | "                            |    | 8,892                       |    | -                                       |
| EUR:NTD                                    | "                            |    | 2,284                       |    | -                                       |
| JPY:NTD                                    | "                            |    | 2,441                       |    | -                                       |
| <u>Financial liabilities</u>               |                              |    |                             |    |                                         |
| <u>Monetary items</u>                      |                              |    |                             |    |                                         |
| JPY:NTD                                    | 1%                           | \$ | 996                         | \$ | -                                       |
| RMB:NTD                                    | "                            |    | 1,986                       |    | -                                       |
| USD:NTD                                    | "                            |    | 1,704                       |    | -                                       |
| EUR:NTD                                    | "                            |    | 259                         |    | -                                       |

| (Foreign currency:<br>functional currency) | Year ended December 31, 2024 |                             |                                         |
|--------------------------------------------|------------------------------|-----------------------------|-----------------------------------------|
|                                            | Sensitivity analysis         |                             |                                         |
|                                            | Degree of<br>variation       | Effect on<br>profit or loss | Effect on other<br>comprehensive income |
| <u>Financial assets</u>                    |                              |                             |                                         |
| <u>Monetary items</u>                      |                              |                             |                                         |
| USD:NTD                                    | 1%                           | \$ 7,718                    | \$ -                                    |
| RMB:NTD                                    | "                            | 8,458                       | -                                       |
| EUR:NTD                                    | "                            | 3,631                       | -                                       |
| JPY:NTD                                    | "                            | 2,013                       | -                                       |
| <u>Financial liabilities</u>               |                              |                             |                                         |
| <u>Monetary items</u>                      |                              |                             |                                         |
| JPY:NTD                                    | 1%                           | \$ 990                      | \$ -                                    |
| RMB:NTD                                    | "                            | 5,777                       | -                                       |
| USD:NTD                                    | "                            | 1,471                       | -                                       |
| EUR:NTD                                    | "                            | 392                         | -                                       |

#### Price risk

- i. The Group's equity securities, which are exposed to price risk, are the held financial assets at fair value through profit or loss and financial assets at fair value through other comprehensive income. To manage its price risk arising from investments in equity securities, the Group diversifies its portfolio. Diversification of the portfolio is done in accordance with the limits set by the Group.
- ii. The Group's investments in equity securities comprise shares issued by the domestic or foreign companies. The prices of equity securities would change due to the change of the future value of investee companies. If the prices of these equity securities had increased/decreased by 1% with all other variables held constant, profit for the years ended December 31, 2025 and 2024 would have increased/decreased by \$198 and \$310, respectively, as a result of gains/losses on equity securities classified as at fair value through profit or loss. Other components of equity would have increased/decreased by \$797 and \$675, respectively, as a result of other comprehensive income classified as equity investment at fair value through other comprehensive income.

#### Cash flow and fair value interest rate risk

- i. The Group's main interest rate risk arises from long-term and short-term borrowings with variable rates, which expose the Group to cash flow interest rate risk. During the years ended December 31, 2025 and 2024, the Group's borrowings at variable rate were denominated in New Taiwan dollars and Chinese Renminbi.

- ii. If the borrowing interest rate of New Taiwan dollars had increased/decreased by 0.1% with all other variables held constant, profit, net of tax for the years ended December 31, 2025 and 2024 would have increased/decreased by \$2,406 and \$1,279, respectively. The main factor is that changes in interest expense result in floating-rate borrowings.

(b) Credit risk

- i. Credit risk refers to the risk of financial loss to the Group arising from default by the clients or counterparties of financial instruments on the contract obligations. The main factor is that counterparties could not repay in full the accounts receivable based on the agreed terms, and the contract cash flows of debt instruments stated at amortized cost, at fair value through profit or loss and at fair value through other comprehensive income.
- ii. The Group manages their credit risk taking into consideration the entire group's concern. For banks and financial institutions, only independently rated parties with a minimum rating of 'A' are accepted. According to the Group's credit policy, each local entity in the Group is responsible for managing and analyzing the credit risk for each of their new clients before standard payment and delivery terms and conditions are offered. Internal risk control assesses the credit quality of the customers, taking into account their financial position, past experience and other factors. Individual risk limits are set based on internal or external ratings in accordance with limits set by the Board of Directors. The utilization of credit limits is regularly monitored.
- iii. The Group adopts following assumptions under IFRS 9 to assess whether there has been a significant increase in credit risk on that instrument since initial recognition:  
If the contract payments were past due over 30 days based on the terms, there has been a significant increase in credit risk on that instrument since initial recognition.
- iv. In accordance with the Group's credit risk management policies, the default occurs when the contract payments are past due over certain days.
- v. The Group classifies customers' accounts receivable in accordance with credit risk on trade. The Group applies the modified approach using loss rate methodology to estimate expected credit loss.
- vi. The Group used the forecastability to adjust historical and timely information to assess the default possibility of accounts receivable. As of December 31, 2025, and 2024, the loss rate methodology is as follows:

| <u>At December 31, 2025</u> | <u>Group A</u> | <u>Group B</u> | <u>Group C</u> | <u>Group D</u> | <u>Total</u> |
|-----------------------------|----------------|----------------|----------------|----------------|--------------|
| Expected loss rate          | 0%~1.44%       | 0%~20.23%      | 0%~100%        | 100.00%        |              |
| Total book value            | \$ 803,319     | \$ 202,579     | \$ 25,044      | \$ 59,801      | \$ 1,090,743 |
| Loss allowance              | \$ 3,218       | \$ 13,611      | \$ 21,498      | \$ 59,801      | \$ 98,128    |

| <u>At December 31, 2024</u> | <u>Group A</u> | <u>Group B</u> | <u>Group C</u> | <u>Group D</u> | <u>Total</u> |
|-----------------------------|----------------|----------------|----------------|----------------|--------------|
| Expected loss rate          | 0%~1.44%       | 0%~20.23%      | 0%~100%        | 100.00%        |              |
| Total book value            | \$ 692,792     | \$ 146,155     | \$ 48,601      | \$ 67,225      | \$ 954,773   |
| Loss allowance              | \$ 364         | \$ 6,401       | \$ 23,336      | \$ 67,225      | \$ 97,326    |

vii. Movements in relation to the Group applying the modified approach to provide loss allowance for accounts receivable are as follows:

|                            | <u>2025</u>                |                         |
|----------------------------|----------------------------|-------------------------|
|                            | <u>Accounts receivable</u> | <u>Notes receivable</u> |
| At January 1               | \$ 97,326                  | \$ -                    |
| Provision for impairment   | 1,817                      | 6,133                   |
| Write-offs                 | - (                        | 6,133)                  |
| Effect of foreign exchange | ( 1,015)                   | -                       |
| At December 31             | <u>\$ 98,128</u>           | <u>\$ -</u>             |
|                            | <u>2024</u>                |                         |
|                            | <u>Accounts receivable</u> | <u>Notes receivable</u> |
| At January 1               | \$ 67,363                  | \$ -                    |
| Provision for impairment   | 27,831                     | -                       |
| Effect of foreign exchange | 2,132                      | -                       |
| At December 31             | <u>\$ 97,326</u>           | <u>\$ -</u>             |

(c) Liquidity risk

- i. Cash flow forecasting is performed in the operating entities of the Group and aggregated by Group treasury. Group treasury monitors rolling forecasts of the Group's liquidity requirements to ensure it has sufficient cash to meet operational needs while maintaining sufficient headroom on its undrawn committed borrowing facilities at all times so that the Group does not breach borrowing limits or covenants (where applicable) on any of its borrowing facilities. Such forecasting takes into consideration the Group's debt financing plans, covenant compliance, compliance with internal balance sheet ratio targets and, if applicable external regulatory or legal requirements.
- ii. As of December 31, 2025, and 2024, the Group has undrawn borrowing facilities of \$2,790,075 and \$5,862,445, respectively.
- iii. The table below analyzes the Group's non-derivative financial liabilities into relevant maturity groupings based on the remaining period at the balance sheet date to the contractual maturity date. The amounts disclosed in the table are the contractual undiscounted cash flows.

Non-derivative financial liabilities:

| <u>December 31, 2025</u>                            | <u>Less than<br/>1 year</u> | <u>Between 1<br/>and 2 years</u> | <u>Between 2<br/>and 5 years</u> | <u>More than<br/>5 years</u> |
|-----------------------------------------------------|-----------------------------|----------------------------------|----------------------------------|------------------------------|
| Short-term borrowings                               | \$ 2,000,000                | \$ -                             | \$ -                             | \$ -                         |
| Notes payable                                       | 3,264                       | -                                | -                                | -                            |
| Accounts payable<br>(including related parties)     | 681,433                     | -                                | -                                | -                            |
| Other payables<br>(including related parties)       | 815,219                     | -                                | -                                | -                            |
| Lease liability                                     | 37,403                      | 7,396                            | 14,886                           | 75,890                       |
| Guarantee deposits received                         | -                           | 12,509                           | -                                | -                            |
| Long-term borrowings<br>(including current portion) | 329,711                     | 250,516                          | 202,781                          | 224,546                      |

Non-derivative financial liabilities:

| <u>December 31, 2024</u>                            | <u>Less than<br/>1 year</u> | <u>Between 1<br/>and 2 years</u> | <u>Between 2<br/>and 5 years</u> | <u>More than<br/>5 years</u> |
|-----------------------------------------------------|-----------------------------|----------------------------------|----------------------------------|------------------------------|
| Short-term borrowings                               | \$ 429,888                  | \$ -                             | \$ -                             | \$ -                         |
| Notes payable                                       | 1,518                       | -                                | -                                | -                            |
| Accounts payable<br>(including related parties)     | 679,654                     | -                                | -                                | -                            |
| Other payables<br>(including related parties)       | 706,381                     | -                                | -                                | -                            |
| Lease liability                                     | 66,968                      | 50,811                           | 17,279                           | 80,953                       |
| Long-term borrowings<br>(including current portion) | 79,469                      | 80,546                           | 671,809                          | 337,174                      |

(4) Fair value information

A. The different levels that the inputs to valuation techniques are used to measure fair value of financial and non-financial instruments have been defined as follows:

Level 1: Quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date. A market is regarded as active where a market in which transactions for the asset or liability take place with sufficient frequency and volume to provide pricing information on an ongoing basis. The fair value of the Group's investment in listed stocks is included in Level 1.

Level 2: Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly.

Level 3: Unobservable inputs for the asset or liability. The fair value of the Group's investment in equity investment without active market is included in Level 3.

B. Financial instruments not measured at fair value

The carrying amounts of cash and cash equivalents, notes receivable, accounts receivable, other receivables, short-term borrowings, notes payable, accounts payable and other payables are approximate to their fair values.

C. The related information of financial and non-financial instruments measured at fair value by level on the basis of the nature, characteristics and risks of the assets and liabilities is as follows:

(a) The related information of natures of the assets and liabilities is as follows:

| <u>December 31, 2025</u>                                          | <u>Level 1</u>   | <u>Level 2</u>  | <u>Level 3</u>   | <u>Total</u>     |
|-------------------------------------------------------------------|------------------|-----------------|------------------|------------------|
| Assets                                                            |                  |                 |                  |                  |
| <u>Recurring fair value measurements</u>                          |                  |                 |                  |                  |
| Financial assets at fair value through profit or loss             |                  |                 |                  |                  |
| Equity securities                                                 | \$ 19,760        | \$ -            | \$ -             | \$ 19,760        |
| Financial assets at fair value through other comprehensive income |                  |                 |                  |                  |
| Equity securities                                                 | <u>16,521</u>    | <u>-</u>        | <u>63,152</u>    | <u>79,673</u>    |
|                                                                   | <u>\$ 36,281</u> | <u>\$ -</u>     | <u>\$ 63,152</u> | <u>\$ 99,433</u> |
| Liabilities                                                       |                  |                 |                  |                  |
| <u>Recurring fair value measurements</u>                          |                  |                 |                  |                  |
| Financial liabilities at fair value through profit or loss        |                  |                 |                  |                  |
| Derivative instruments                                            | <u>\$ -</u>      | <u>\$ 1,418</u> | <u>\$ -</u>      | <u>\$ 1,418</u>  |
| <u>December 31, 2024</u>                                          | <u>Level 1</u>   | <u>Level 2</u>  | <u>Level 3</u>   | <u>Total</u>     |
| Assets                                                            |                  |                 |                  |                  |
| <u>Recurring fair value measurements</u>                          |                  |                 |                  |                  |
| Financial assets at fair value through profit or loss             |                  |                 |                  |                  |
| Equity securities                                                 | \$ 31,014        | \$ -            | \$ -             | \$ 31,014        |
| Financial assets at fair value through other comprehensive income |                  |                 |                  |                  |
| Equity securities                                                 | <u>3,689</u>     | <u>-</u>        | <u>63,835</u>    | <u>67,524</u>    |
|                                                                   | <u>\$ 34,703</u> | <u>\$ -</u>     | <u>\$ 63,835</u> | <u>\$ 98,538</u> |

(b) The methods and assumptions the Group used to measure fair value are as follows:

i. The instruments the Group used market quoted prices as their fair values (that is, Level 1) are listed below by characteristics:

|                     | <u>Listed shares</u> |
|---------------------|----------------------|
| Market quoted price | Closing price        |

ii. Except for financial instruments with active markets, the fair value of other financial instruments is measured by using valuation techniques. The fair value of financial instruments measured by using valuation techniques can be referred to current fair value of instruments with similar terms and characteristics in substance, discounted cash flow method or other valuation methods, including calculated by applying model using market information available at the consolidated balance sheet date (i.e. yield curves on the Taipei Exchange, average commercial paper interest rates quoted from Reuters).

iii. The output of valuation model is an estimated value and the valuation technique may not be able to capture all relevant factors of the Group's financial and non-financial instruments. Therefore, the estimated value derived using valuation model is adjusted accordingly with additional inputs, for example, model risk or liquidity risk and etc. In accordance with the Group's management policies and relevant control procedures relating to the valuation models used for fair value measurement, management believes adjustment to valuation is necessary in order to reasonably represent the fair value of financial and non-financial instruments at the consolidated balance sheet. The inputs and pricing information used during valuation are carefully assessed and adjusted based on current market conditions.

iv. The Group takes into account adjustments for credit risks to measure the fair value of financial and non-financial instruments to reflect credit risk of the counterparty and the Group's credit quality.

D. For the years ended December 31, 2025 and 2024, there was no transfer between Level 1 and Level 2.

E. The following chart is the movement of Level 3 for the years ended December 31, 2025 and 2024:

|                                                       | Non-derivative equity instrument |           |
|-------------------------------------------------------|----------------------------------|-----------|
|                                                       | 2025                             | 2024      |
| At January 1                                          | \$ 63,835                        | \$ 57,620 |
| Gain or loss recognized in other comprehensive income | 3,790                            | 6,215     |
| Sold in the period                                    | (4,473)                          | -         |
| At December 31                                        | \$ 63,152                        | \$ 63,835 |

F. Financial segment is in charge of valuation procedures for fair value measurements being categorised within Level 3, which is to verify independent fair value of financial instruments. Such assessment is to ensure the valuation results are reasonable by applying independent information to make results close to current market conditions, confirming the resource of information is independent, reliable and in line with other resources and represented as the exercisable price, and frequently calibrating valuation model, performing back-testing, updating inputs used to the valuation model and making any other necessary adjustments to the fair value.

G. The following is the qualitative information of significant unobservable inputs and sensitivity analysis of changes in significant unobservable inputs to valuation model used in Level 3 fair value measurement:

F. The following chart is the movement of Level 3 for the years ended December 31, 2025 and 2024:

|                                      | <u>Fair value at<br/>December 31,<br/>2025</u> | <u>Valuation<br/>technique</u>    | <u>Significant<br/>unobservable<br/>input</u>                                                                                       | <u>Range<br/>(weighted<br/>average)</u> | <u>Relationship of<br/>inputs<br/>to fair value</u>                                                                                                               |
|--------------------------------------|------------------------------------------------|-----------------------------------|-------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Non-derivative<br>equity instrument: |                                                |                                   |                                                                                                                                     |                                         |                                                                                                                                                                   |
| Unlisted<br>shares                   | \$ 8,156                                       | Discounted<br>cash flow           | Long-term<br>revenue<br>growth rate<br>Weighted<br>average cost<br>of capital                                                       | 2%<br><br>9.59%                         | The higher the long-<br>term revenue growth<br>rate, the higher the<br>fair value;<br>the higher the<br>discount rate, the<br>lower the fair value.               |
| Unlisted<br>shares                   | \$ 54,996                                      | Market<br>comparable<br>companies | Enterprise<br>value to<br>earnings<br>before<br>interest and<br>taxes<br>multiplier<br><br>Discount for<br>lack of<br>marketability | 9.35%<br><br>25%                        | The higher the<br>multiplier, the higher<br>the fair value.<br><br>The higher the<br>discount due to lack<br>of market liquidity,<br>the lower the fair<br>value. |
|                                      | <u>Fair value at<br/>December 31,<br/>2024</u> | <u>Valuation<br/>technique</u>    | <u>Significant<br/>unobservable<br/>input</u>                                                                                       | <u>Range<br/>(weighted<br/>average)</u> | <u>Relationship of<br/>inputs<br/>to fair value</u>                                                                                                               |
| Non-derivative<br>equity instrument: |                                                |                                   |                                                                                                                                     |                                         |                                                                                                                                                                   |
| Unlisted<br>shares                   | \$ 63,835                                      | Discounted<br>cash flow           | Long-term<br>revenue<br>growth rate<br>Weighted<br>average cost<br>of capital                                                       | 2%<br><br>9.59%                         | The higher the long-<br>term revenue growth<br>rate, the higher the<br>fair value;<br>the higher the<br>discount rate, the<br>lower the fair value.               |

H. The Group has carefully assessed the valuation models and assumptions used to measure fair value. However, use of different valuation models or assumptions may result in different measurement. The following is the effect of profit or loss or of other comprehensive income from financial assets and liabilities categorised within Level 3 if the inputs used to valuation models

have changed:

|                   |                                          |        | December 31, 2025               |                        |                                             |                        |
|-------------------|------------------------------------------|--------|---------------------------------|------------------------|---------------------------------------------|------------------------|
|                   |                                          |        | Recognized in<br>profit or loss |                        | Recognized in other<br>comprehensive income |                        |
|                   |                                          |        | Favourable<br>change            | Unfavourable<br>change | Favourable<br>change                        | Unfavourable<br>change |
| Financial assets  | Input                                    | Change |                                 |                        |                                             |                        |
| Equity instrument | Discount for<br>lack of<br>marketability | ±5%    | \$ -                            | \$ -                   | \$ 3,158                                    | (\$ 3,158)             |

  

|                   |                                          |        | December 31, 2024               |                        |                                             |                        |
|-------------------|------------------------------------------|--------|---------------------------------|------------------------|---------------------------------------------|------------------------|
|                   |                                          |        | Recognized in<br>profit or loss |                        | Recognized in other<br>comprehensive income |                        |
|                   |                                          |        | Favourable<br>change            | Unfavourable<br>change | Favourable<br>change                        | Unfavourable<br>change |
| Financial assets  | Input                                    | Change |                                 |                        |                                             |                        |
| Equity instrument | Discount for<br>lack of<br>marketability | ±5%    | \$ -                            | \$ -                   | \$ 3,192                                    | (\$ 3,192)             |

### 13. SUPPLEMENTARY DISCLOSURES

#### (1) Significant transactions information

- A. Loans to others: Please refer to table 1.
- B. Provision of endorsements and guarantees to others: Please refer to table 2.
- C. Holding of significant marketable securities at the end of the period (not including subsidiaries, associates and joint ventures): Please refer to table 3.
- D. Purchases or sales of goods from or to related parties reaching \$100 million or 20% of paid-in capital or more: Please refer to table 4.
- E. Receivables from related parties reaching \$100 million or 20% of paid-in capital or more: Please refer to table 5.
- F. Significant inter-company transactions during the reporting periods: Please refer to table 6.

#### (2) Information on investees

Names, locations and other information of investee companies (not including investees in Mainland China): Please refer to table 7.

#### (3) Information on investments in Mainland China

- A. Basic information: Please refer to table 8.
- B. Significant transactions, either directly or indirectly through a third area, with investee companies in the Mainland Area: Please refer to table 9.

#### 14. SEGMENT INFORMATION

##### (1) General information

Management has determined the reportable operating segments based on the reports reviewed by the Board of Directors that are used to make strategic decisions.

There is no material change in the basis for formation of entities and division of segments in the Group or in the measurement basis for segment information during this period.

##### (2) Measurement of segment information

The Group's chief operating decision-maker evaluates the performances of the operating segments based on their net profit after tax.

##### (3) Information about segment profit or loss, assets and liabilities

The segment information provided to the Chief Operating Decision-Maker for the reportable segments is as follows:

|                                                                   | Taiwan               | Asia                | America             | Other             | Adjustment<br>and reversal | Total                |
|-------------------------------------------------------------------|----------------------|---------------------|---------------------|-------------------|----------------------------|----------------------|
| <u>Year ended December 31, 2025</u>                               |                      |                     |                     |                   |                            |                      |
| Revenue from external customers                                   | \$ 3,902,812         | \$ 1,207,743        | \$ 1,470,347        | \$ 408,401        | \$ -                       | \$ 6,989,303         |
| Revenue from internal customers                                   | <u>1,598,518</u>     | <u>298,524</u>      | <u>378,338</u>      | <u>-</u>          | <u>( 2,275,380)</u>        | <u>-</u>             |
| Segment revenue                                                   | \$ 5,501,330         | \$ 1,506,267        | \$ 1,848,685        | \$ 408,401        | (\$ 2,275,380)             | \$ 6,989,303         |
| Segment income (loss)                                             | <u>\$ 1,269,904</u>  | <u>\$ 265,201</u>   | <u>\$ 136,422</u>   | <u>\$ 137,878</u> | <u>\$ 701,426</u>          | <u>\$ 1,107,979</u>  |
| Segment income (loss),<br>including:                              |                      |                     |                     |                   |                            |                      |
| Depreciation and amortization                                     | \$ 409,392           | \$ 92,965           | \$ 74,543           | \$ 4,802          | (\$ 9,520)                 | \$ 572,182           |
| Interest income                                                   | <u>28,221</u>        | <u>43,495</u>       | <u>1,093</u>        | <u>195</u>        | <u>-</u>                   | <u>73,004</u>        |
| Interest expense                                                  | <u>40,143</u>        | <u>549</u>          | <u>10,481</u>       | <u>64</u>         | <u>-</u>                   | <u>51,237</u>        |
| Income tax expense                                                | <u>125,932</u>       | <u>2,113</u>        | <u>-</u>            | <u>-</u>          | <u>( 8,344)</u>            | <u>119,701</u>       |
| Profit (loss) of investments<br>accounted for using equity method | <u>272,221</u>       | <u>( 18,163)</u>    | <u>( 152,737)</u>   | <u>131,140</u>    | <u>( 240,566)</u>          | <u>( 8,105)</u>      |
| Segment total assets                                              | <u>\$ 17,493,491</u> | <u>\$ 9,796,471</u> | <u>\$ 1,822,494</u> | <u>\$ 456,347</u> | <u>(\$ 14,794,272)</u>     | <u>\$ 14,774,531</u> |
| Segment assets including:                                         |                      |                     |                     |                   |                            |                      |
| Investments accounted for using<br>equity method                  | <u>\$ 5,001,709</u>  | <u>\$ 1,500,214</u> | <u>(\$ 203,129)</u> | <u>\$ 217,215</u> | <u>(\$ 6,469,120)</u>      | <u>\$ 46,889</u>     |
| Capital expenditure of non-current<br>asset                       | <u>224,949</u>       | <u>94,322</u>       | <u>833,954</u>      | <u>-</u>          | <u>-</u>                   | <u>1,153,225</u>     |
| Segment total liabilities                                         | <u>\$ 5,131,630</u>  | <u>\$ 1,334,661</u> | <u>\$ 1,618,364</u> | <u>\$ 325,078</u> | <u>(\$ 2,791,988)</u>      | <u>\$ 5,617,745</u>  |

|                                                                      | Taiwan               | Asia                | America             | Other             | Adjustment<br>and reversal | Total                |
|----------------------------------------------------------------------|----------------------|---------------------|---------------------|-------------------|----------------------------|----------------------|
| <u>Year ended December 31, 2024</u>                                  |                      |                     |                     |                   |                            |                      |
| Revenue from external customers                                      | \$ 3,521,185         | \$ 1,994,736        | \$ 1,424,358        | \$ 299,987        | \$ -                       | \$ 7,240,266         |
| Revenue from internal customers                                      | 2,043,373            | 285,602             | 546,424             | -                 | ( 2,875,399)               | -                    |
| Segment revenue                                                      | <u>\$ 5,564,558</u>  | <u>\$ 2,280,338</u> | <u>\$ 1,970,782</u> | <u>\$ 299,987</u> | <u>(\$ 2,875,399)</u>      | <u>\$ 7,240,266</u>  |
| Segment income (loss)                                                | <u>\$ 1,179,045</u>  | <u>\$ 454,108</u>   | <u>\$ 38,367</u>    | <u>\$ 11,411</u>  | <u>(\$ 709,203)</u>        | <u>\$ 973,728</u>    |
| Segment income (loss),<br>including:                                 |                      |                     |                     |                   |                            |                      |
| Depreciation and amortization                                        | \$ 443,617           | \$ 87,341           | \$ 62,288           | \$ 4,727          | (\$ 3,894)                 | \$ 600,079           |
| Interest income                                                      | 27,291               | 42,699              | 313                 | 205               | -                          | 70,508               |
| Interest expense                                                     | 36,521               | 879                 | 7,796               | 93                | -                          | 45,289               |
| Income tax expense                                                   | 146,731              | 21,656              | -                   | 96                | ( 7,748)                   | 160,735              |
| Profit (loss) of investments<br>accounted for using equity<br>method | 238,188              | 122,737             | ( 10,168)           | 36,341            | ( 398,288)                 | ( 11,190)            |
| Segment total assets                                                 | <u>\$ 16,140,235</u> | <u>\$ 9,734,694</u> | <u>\$ 1,291,678</u> | <u>\$ 232,675</u> | <u>(\$ 13,684,537)</u>     | <u>\$ 13,714,745</u> |
| Segment assets including:                                            |                      |                     |                     |                   |                            |                      |
| Investments accounted for using<br>equity method                     | \$ 4,715,979         | \$ 1,517,132        | (\$ 51,036)         | \$ 71,179         | (\$ 6,225,072)             | \$ 28,182            |
| Capital expenditure of non-<br>current asset                         | 61,185               | 19,339              | 128,971             | -                 | -                          | 209,495              |
| Segment total liabilities                                            | <u>\$ 3,677,065</u>  | <u>\$ 1,513,197</u> | <u>\$ 1,222,415</u> | <u>\$ 247,549</u> | <u>(\$ 2,433,657)</u>      | <u>\$ 4,226,569</u>  |

For the years ended December 31, 2025 and 2024, sales to Europe and America of reporting department-Taiwan amounted to \$885,734 and \$800,443, respectively, and sales to Europe and America of reporting department-Asia and others amounted to \$2,206,871 and \$1,981,470, respectively.

(4) Reconciliation for segment income

Sales between segments are carried out at arm's length. The revenue from external customers reported to the Chief Operating Decision-Maker is measured in a manner consistent with that in the statement of comprehensive income. The reportable segment income or loss is in accordance with the income before tax from continuing operations for the years ended December 31, 2025 and 2024. Thus, there is no reconciliation.

(5) Information on products

The Group operates business only in a single industry with business scope of healthy foods and beauty products; disclosure of financial information on industry is not applicable.

(6) Geographical information

Geographical information for the years ended December 31, 2025 and 2024 is as follows:

|                | Years ended December 31, |                     |                     |                     |
|----------------|--------------------------|---------------------|---------------------|---------------------|
|                | 2025                     |                     | 2024                |                     |
|                | Revenue                  | Non-current assets  | Revenue             | Non-current assets  |
| Taiwan         | \$ 3,902,812             | \$ 4,606,179        | \$ 3,521,184        | \$ 4,774,093        |
| Mainland China | 1,206,200                | 741,404             | 1,991,977           | 729,916             |
| USA            | 1,470,347                | 1,110,529           | 1,424,358           | 354,758             |
| Others         | 409,944                  | 9,803               | 302,747             | 40,091              |
|                | <u>\$ 6,989,303</u>      | <u>\$ 6,467,915</u> | <u>\$ 7,240,266</u> | <u>\$ 5,898,858</u> |

Revenue is reported based on the countries in which the Group's subsidiaries are located.

(7) Major customer information

Major customer information of the Group for the years ended December 31, 2025 and 2024 is as follows:

|   | Years ended December 31, |         |                   |         |
|---|--------------------------|---------|-------------------|---------|
|   | 2025                     |         | 2024              |         |
|   | Revenue                  | Segment | Revenue           | Segment |
| A | <u>\$ 732,097</u>        | USA     | <u>\$ 436,096</u> | USA     |

TCI CO., LTD. and subsidiaries

Loans to others

Year ended December 31, 2025

Table 1

Expressed in thousands of NTD

(Except as otherwise indicated)

| No.<br>(Note 1) | Creditor                | Borrower               | General<br>ledger<br>account<br>(Note 2)  | Is a<br>related<br>party | Maximum<br>outstanding<br>balance during the<br>year ended<br>December 31, 2025<br>(Note 3) | Balance at<br>December 31, 2025 | Actual amount<br>drawn down | Interest<br>rate | Nature of<br>loan<br>(Note 4, 5) | Amount of<br>transactions<br>with the<br>borrower | Reason<br>for short-term<br>financing | Allowance<br>for<br>uncollectible<br>accounts | Collateral<br>Item | Value | Limit on loans<br>granted to<br>a single party | Ceiling on<br>total loans<br>granted | Footnote                  |
|-----------------|-------------------------|------------------------|-------------------------------------------|--------------------------|---------------------------------------------------------------------------------------------|---------------------------------|-----------------------------|------------------|----------------------------------|---------------------------------------------------|---------------------------------------|-----------------------------------------------|--------------------|-------|------------------------------------------------|--------------------------------------|---------------------------|
| 0               | TCI CO., LTD.           | TCI BIOTECH<br>USA LLC | Other<br>receivables -<br>related parties | Y                        | \$ 724,245                                                                                  | \$ 724,245                      | \$ 724,245                  | 4.50%            | 2                                | \$ -                                              | For operating<br>capital              | \$ -                                          | None               | \$ -  | \$ 1,556,911                                   | \$ 1,556,911                         | Notes 4, 5, 6,<br>7 and 8 |
| 1               | TCI BIOTECH CO.,<br>LTD | TCI BIOTECH<br>USA LLC | Other<br>receivables -<br>related parties | Y                        | 914,600                                                                                     | 550,760                         | 550,760                     | 1.20%            | 2                                | -                                                 | For operating<br>capital              | -                                             | None               | -     | \$ 2,550,057                                   | \$ 2,550,057                         | Notes 6, 7 and<br>8       |
| 2               | TCI BIOTECH CO.,<br>LTD | TCI CO., LTD.          | Other<br>receivables -<br>related parties | Y                        | 1,371,900                                                                                   | -                               | -                           | -                | 2                                | -                                                 | For operating<br>capital              | -                                             | None               | -     | \$ 2,550,057                                   | \$ 2,550,057                         | Notes 6, 7 and<br>8       |

Note 1: The numbers filled in for the loans provided by the Company or subsidiaries are as follows:

(1)The Company is '0'.

(2)The subsidiaries are numbered in order starting from '1'.

Note 2: Fill in the name of account in which the loans are recognized, such as receivables-related parties, current account with stockholders, prepayments, temporary payments, etc.

Note 3: Fill in the maximum outstanding balance of loans to others during the year ended December 31, 2025. The amount is calculated at the closing rate of USD\$1:NTD\$31.4300; RMB\$1:NTD\$4.496, the exchange rate used in original transaction shall be adopted if there was no movement.

Note 4: For lending funds to other entities, ceiling on total loans granted by the Company's subsidiary to others is 20% of the subsidiary's net assets based on the latest financial statements, and limit on loans granted by the Company's subsidiary to a single party is 20% of the subsidiary's net assets based on the latest financial statements.

Note 5: For short-term financing with other entities, ceiling on total loans granted by the Company's subsidiary to others is 20% of the subsidiary's net assets based on the latest financial statements, and limit on loans granted by the Company's subsidiary to a single party is 20% of the subsidiary's net assets based on the latest financial statements.

Note 6: For lending funds or short-term financing with other entities, ceiling on total loans granted by the Company's subsidiary to others is 40% of the subsidiary's net assets based on the latest financial statements, and limit on loans granted by the Company's subsidiary to a single party is 20% of the subsidiary's net assets based on the latest financial statements.

Note 7: Non-Taiwan companies that directly and indirectly hold 100% of the voting shares of the same ultimate parent company as our company, or the ultimate parent company that directly and indirectly holds 100% of the voting shares is not subject to the restrictions of Notes 4, 5, and 6 when engaging in fund lending. The total amount of loans and the limit of loans to a single enterprise must not exceed the loan limit. It is limited to 100% of the net worth of the enterprise.

Note 8: The amounts were approved by the Board of Directors.

TCI CO., LTD. and subsidiaries  
Provision of endorsements and guarantees to others  
Year ended December 31, 2025

Table 2

Table 2

| Expressed in thousands of NTD<br>(Except as otherwise indicated) |                        |                                    |                                                                |                                                                           |                                                               |                                                    |                             |                                                                        |                                                                                                                                         |                                                                             |                                                                                                  |                                                                                                  |                                                                                                 |          |
|------------------------------------------------------------------|------------------------|------------------------------------|----------------------------------------------------------------|---------------------------------------------------------------------------|---------------------------------------------------------------|----------------------------------------------------|-----------------------------|------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------|----------|
| No.<br>(Note 1)                                                  | Endorser/<br>guarantor | Party being<br>endorsed/guaranteed |                                                                | Limit on<br>endorsements/<br>guarantees<br>provided for a<br>single party | Maximum<br>outstanding<br>endorsement/<br>guarantee<br>amount | Outstanding<br>endorsement/<br>guarantee<br>amount | Actual amount<br>drawn down | Amount of<br>endorsements/<br>guarantees<br>secured with<br>collateral | Ratio of<br>accumulated<br>endorsement/<br>guarantee<br>amount to net<br>asset value of<br>the endorser/<br>guarantor<br>company<br>(%) | Ceiling on<br>total amount<br>of<br>endorsements/<br>guarantees<br>provided | Provision of<br>endorsements/<br>guarantees by<br>parent<br>company to<br>subsidiary<br>(Note 4) | Provision of<br>endorsements/<br>guarantees by<br>subsidiary to<br>parent<br>company<br>(Note 4) | Provision of<br>endorsements/<br>guarantees to<br>the party in<br>Mainland<br>China<br>(Note 4) | Footnote |
|                                                                  |                        | Company name                       | Relationship<br>with the<br>endorser/<br>guarantor<br>(Note 2) |                                                                           |                                                               |                                                    |                             |                                                                        |                                                                                                                                         |                                                                             |                                                                                                  |                                                                                                  |                                                                                                 |          |
| 0                                                                | TCI CO., LTD.          | TCI BIOTECH<br>LLC                 | 2                                                              | \$ 1,556,911                                                              | \$ 16,603                                                     | \$ 15,715                                          | \$ 15,715                   | \$ -                                                                   | 0.20                                                                                                                                    | \$ 3,892,279                                                                | Y                                                                                                | N                                                                                                | N                                                                                               | Note 3   |
| 0                                                                | TCI CO., LTD.          | TCI BIOTECH<br>USA LLC             | 2                                                              | \$ 1,556,911                                                              | 149,423                                                       | 141,434                                            | 141,434                     | -                                                                      | 1.82                                                                                                                                    | \$ 3,892,279                                                                | Y                                                                                                | N                                                                                                | N                                                                                               | Note 3   |

Note 1: The numbers filled in for the loans provided by the Company or subsidiaries are as follows:

- (1) The Company is '0'.
- (2) The subsidiaries are numbered in order starting from '1'.

Note 2: Relationship between the endorser/guarantor and the party being endorsed/guaranteed is classified into the following seven categories:

- (1) Having business relationship.
- (2) The endorser/guarantor parent company owns directly and indirectly more than 50% voting shares of the endorsed/guaranteed subsidiary.
- (3) The endorsed/guaranteed company owns directly and indirectly more than 50% voting shares of the endorser/guarantor parent company.
- (4) The endorser/guarantor parent company owns directly and indirectly more than 50% voting shares of the endorsed/guaranteed company.
- (5) Mutual guarantee of the trade made by the endorsed/guaranteed company or joint contractor as required under the construction contract.
- (6) Due to joint venture, all shareholders provide endorsements/guarantees to the endorsed/guaranteed company in proportion to its ownership.
- (7) Joint guarantee of the performance guarantee for pre-sold home sales contract as required under the Consumer Protection Act.

Note 3: In accordance with the Company's policy, the total guarantee amount shall not exceed 50% of Company's net assets based on the latest financial statements, and the guarantee to a single party shall not exceed 20% of the Company's net assets.

Note 4: Amount of endorsements/guarantees between the endorsed/guaranteed companies whose voting shares are more 90% held by the Company directly or/and indirectly shall not exceed 10% of the Company's net assets, except the amount of endorsements/guarantees between the endorsed/guaranteed companies whose voting shares are 100% held by the Company directly and indirectly.

Note 5: In accordance with the Company and subsidiaris's policy, the guarantee shall not exceed 50% of the Company's net assets based on the latest financial statements.

Note 6: In accordance with the Company and subsidiaris's policy, the guarantee to a single party shall not exceed 30% of the Company's net assets based on the latest financial statements.

Note 7: For endorsements and guarantees made due to business transactions, the endorsement and guarantee amount shall not exceed the amount of business transactions between the parties in the most recent year.  
The term "business transaction amount" refers to the higher of the purchase or sales amount between the parties.

Note 8: The subsidiaries and parent companies referred to in these Measures shall be identified in accordance with Financial Reporting Standards of the securities issuer.

Note 9: The financial report is prepared in accordance with the International Financial Reporting Standards, and the term "net value" refers to the equity attributable to the owner of the parent company on the balance sheet stipulated in the Financial Reporting Standards of the securities issuer.

TCI CO., LTD. and subsidiaries  
Holding of marketable securities at the end of the period (not including subsidiaries, associates and joint ventures)  
Year ended December 31, 2025

Table 3

Expressed in thousands of NTD  
(Except as otherwise indicated)

| Securities held by   | Marketable securities             | Relationship with the securities issuer                              | General ledger account                                                          | As of December 31, 2025 |            |               |            | Footnote |
|----------------------|-----------------------------------|----------------------------------------------------------------------|---------------------------------------------------------------------------------|-------------------------|------------|---------------|------------|----------|
|                      |                                   |                                                                      |                                                                                 | Number of shares        | Book value | Ownership (%) | Fair value |          |
| TCI CO., LTD.        | BILLION ELECTRIC CO., LTD.        | None                                                                 | Financial assets at fair value through other comprehensive income - non-current | 125,039                 | \$ 2,844   | 0.11          | \$ 2,844   |          |
| TCI CO., LTD.        | LIN LIE INTEGRATION CO., LTD.     | None                                                                 | Financial assets at fair value through other comprehensive income - non-current | 54,000                  | 372        | 3.48          | 372        |          |
| TCI CO., LTD.        | PURE MILK CO., LTD.               | The Company was an institutional shareholder of PURE MILK CO., LTD.. | Financial assets at fair value through other comprehensive income - non-current | 321,333                 | 7,786      | 7.30          | 7,786      |          |
| TCI LIVING CO., LTD. | Chun Ling International Co., Ltd. | None                                                                 | Financial assets at fair value through other comprehensive income - non-current | 774,046                 | 54,996     | 17.78         | 54,996     |          |
| GENE & NEXT INC.     | TCI CO., LTD.                     | Parent company                                                       | Financial assets at fair value through other comprehensive income - current     | 3,653,000               | 403,656    | 3.10          | 403,656    |          |
| MAXIGEN BIOTECH INC. | TCI CO., LTD.                     | Parent company                                                       | Financial assets at fair value through other comprehensive income - non-current | 2,531,000               | 279,675    | 2.58          | 279,675    |          |
| GENE & NEXT INC.     | BenQ BM Holding Cayman Corp.      | None                                                                 | Financial assets at fair value through other comprehensive income - non-current | 823,984                 | 13,675     | 0.26          | 13,675     |          |
| TCI CO., LTD.        | Abnova Holding Corporation        | None                                                                 | Financial assets at fair value through profit or loss-current                   | 509,000                 | 11,553     | 0.84          | 11,553     |          |
| GENE & NEXT INC.     | TCI CO., LTD.                     | Parent company                                                       | Financial assets at fair value through profit or loss-current                   | 1,362,000               | 150,501    | 1.16          | 150,501    |          |
| GENE & NEXT INC.     | BenQ BM Holding Cayman Corp.      | None                                                                 | Financial assets at fair value through profit or loss-current                   | 494,516                 | 8,207      | 0.16          | 8,207      |          |

TCI CO., LTD. and subsidiaries  
Purchases or sales of goods from or to related parties reaching NT\$100 million or 20% of paid-in capital or more  
Year ended December 31, 2025

Table 4

Expressed in thousands of NTD  
(Except as otherwise indicated)

| Purchaser/seller                   | Counterparty                 | Relationship with the<br>counterparty | Transaction          |            |                                             |             | Differences in transaction terms<br>compared to third party<br>transactions |                                                                               | Notes/accounts receivable (payable) |                                                               | Footnote |
|------------------------------------|------------------------------|---------------------------------------|----------------------|------------|---------------------------------------------|-------------|-----------------------------------------------------------------------------|-------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------------------------|----------|
|                                    |                              |                                       | Purchases<br>(sales) | Amount     | Percentage of<br>total purchases<br>(sales) | Credit term | Unit price                                                                  | Credit term                                                                   | Balance                             | Percentage of<br>total notes/accounts<br>receivable (payable) |          |
|                                    |                              |                                       |                      |            |                                             |             |                                                                             |                                                                               |                                     |                                                               |          |
| TCI CO., LTD.                      | TCI BIOTECH CO., LTD         | Subsidiary                            | (Sales)              | \$ 387,165 | ( 8.77)                                     | 60-90 days  | The prices and terms of sales and purchases are available to third parties. | Terms for collections are approximately the same as those with third parties. | \$ -                                | -                                                             |          |
| TCI CO., LTD.                      | TCI BIOTECH LLC              | Subsidiary                            | (Sales)              | 683,810    | ( 15.49)                                    | 60-90 days  | The prices and terms of sales and purchases are available to third parties. | Terms for collections are approximately the same as those with third parties. | -                                   | -                                                             |          |
| TCI CO., LTD.                      | TCI BIOTECH NETHERLANDS B.V. | Subsidiary                            | (Sales)              | 281,557    | ( 6.38)                                     | 60-90 days  | The prices and terms of sales and purchases are available to third parties. | Terms for collections are approximately the same as those with third parties. | 249,576                             | 32.06                                                         |          |
| TCI BIOTECH USA LLC                | TCI BIOTECH LLC              | Subsidiary                            | (Sales)              | 340,675    | ( 90.72)                                    | 60-90 days  | The prices and terms of sales and purchases are available to third parties. | Terms for collections are approximately the same as those with third parties. | -                                   | -                                                             |          |
| TCI International Trading Co., Ltd | TCI CO., LTD.                | Subsidiary                            | (Sales)              | 134,161    | ( 76.42)                                    | 60-90 days  | The prices and terms of sales and purchases are available to third parties. | Terms for collections are approximately the same as those with third parties. | 65,199                              | 98.66                                                         |          |

Note: Regarding percentage of transaction amount to total operating revenues or total assets, it is computed based on period-end balance of transaction to total assets for balance sheet accounts and based on accumulated transaction amount for the period to total operating revenues for income statement accounts.

Table 5

TCI CO., LTD. and subsidiaries  
 Receivables from related parties reaching NT\$100 million or 20% of paid-in capital or more  
 Year ended December 31, 2025

Expressed in thousands of NTD  
 (Except as otherwise indicated)

| Creditor             | Counterparty                          | Relationship<br>with the counterparty |                     | Balance as at December 31, 2025 | Turnover rate times | Overdue receivables |                                               | Amount collected<br>subsequent to the<br>balance sheet date | Allowance for<br>doubtful accounts |
|----------------------|---------------------------------------|---------------------------------------|---------------------|---------------------------------|---------------------|---------------------|-----------------------------------------------|-------------------------------------------------------------|------------------------------------|
|                      |                                       |                                       |                     |                                 |                     | Amount              | Action taken                                  |                                                             |                                    |
| TCI CO., LTD.        | TCI BIOTECH<br>NETHERLANDS B.V.       | Subsidiary                            | Accounts receivable | \$ 249,576                      | 1.28                | \$ 147,640          | Repay according to<br>the mutual<br>agreement | \$ -                                                        | -                                  |
| TCI CO., LTD.        | TCI BIOTECH USA LLC                   | Subsidiary                            | Other receivables   | 724,245                         | 0.08                | -                   |                                               | -                                                           | -                                  |
| MAXIGEN BIOTECH INC. | Maxigen Biotech Shanghai Co.,<br>Ltd. | Subsidiary                            | Accounts receivable | 111,628                         | 0.55                | 111,628             | Repay according to<br>the mutual<br>agreement | -                                                           | -                                  |

TCI CO., LTD. and subsidiaries  
Significant inter-company transactions during the reporting periods  
Year ended December 31, 2025

Table 6

Expressed in thousands of NTD  
(Except as otherwise indicated)

| Number<br>(Note 1) | Company name                       | Counterparty                       | Relationship<br>(Note 2) | Transaction            |            |                                                                             | Percentage of consolidated total operating<br>revenues or total assets (Note 3) |
|--------------------|------------------------------------|------------------------------------|--------------------------|------------------------|------------|-----------------------------------------------------------------------------|---------------------------------------------------------------------------------|
|                    |                                    |                                    |                          | General ledger account | Amount     | Transaction terms                                                           |                                                                                 |
| 0                  | TCI CO., LTD.                      | TCI BIOTECH CO., LTD               | 1                        | Sales of goods         | \$ 387,165 | The prices and terms of sales and purchases are available to third parties. | 5.54                                                                            |
| 0                  | TCI CO., LTD.                      | TCI BIOTECH NETHERLANDS B.V.       | 1                        | Sales of goods         | 281,557    | The prices and terms of sales and purchases are available to third parties. | 4.03                                                                            |
| 0                  | TCI CO., LTD.                      | TCI BIOTECH NETHERLANDS B.V.       | 1                        | Accounts receivable    | 249,576    | The prices and terms of sales and purchases are available to third parties. | 1.69                                                                            |
| 0                  | TCI CO., LTD.                      | TCI BIOTECH LLC                    | 1                        | Sales of goods         | 683,810    | The prices and terms of sales and purchases are available to third parties. | 9.78                                                                            |
| 0                  | TCI CO., LTD.                      | TCI BIOTECH USA LLC                | 1                        | Other receivables      | 724,245    | According to the mutually agreed terms and conditions of the loan.          | 4.90                                                                            |
| 1                  | TCI BIOTECH USA LLC                | TCI BIOTECH LLC                    | 2                        | Sales of goods         | 340,675    | The prices and terms of sales and purchases are available to third parties. | 4.87                                                                            |
| 2                  | TCI BIOTECH CO., LTD               | TCI BIOTECH USA LLC                | 3                        | Other receivables      | 550,760    | According to the mutually agreed terms and conditions of the loan.          | 3.73                                                                            |
| 3                  | TCI International Trading Co., Ltd | TCI CO., LTD.                      | 2                        | Sales of goods         | 134,161    | The prices and terms of sales and purchases are available to third parties. | 1.92                                                                            |
| 4                  | MAXIGEN BIOTECH INC.               | Maxigen Biotech Shanghai Co., Ltd. | 3                        | Accounts receivable    | 111,628    | According to the mutually agreed terms and conditions of the loan.          | 0.75                                                                            |
| 4                  | MAXIGEN BIOTECH INC.               | Maxigen Biotech Shanghai Co., Ltd. | 3                        | Sales of goods         | 54,007     | According to the mutually agreed terms and conditions of the loan.          | 0.77                                                                            |

Note 1: The numbers filled in for the transaction company in respect of inter-company transactions are as follows:

- (1) Parent company is '0'.
- (2) The subsidiaries are numbered in order starting from '1'.

Note 2: Relationship between transaction company and counterparty is classified into the following three categories :

- (1) Parent company to subsidiary.
- (2) Subsidiary to parent company.
- (3) Subsidiary to subsidiary.

Note 3: Regarding percentage of transaction amount to total operating revenues or total assets, it is computed based on period-end balance of transaction to total assets for balance sheet accounts and based on accumulated transaction amount for the period to total operating revenues for income statement accounts.

TCI CO., LTD.and subsidiaries  
Information on investees  
Year ended December 31, 2025

Table 7

Expressed in thousands of NTD  
(Except as otherwise indicated)

| Investment                   |                                   |             |                                                                                         |                                 |                                 |                                     |               |              |                                                                        |                                                                              |          |
|------------------------------|-----------------------------------|-------------|-----------------------------------------------------------------------------------------|---------------------------------|---------------------------------|-------------------------------------|---------------|--------------|------------------------------------------------------------------------|------------------------------------------------------------------------------|----------|
| Investor                     | Investee                          | Location    | Main business activities                                                                | Initial investment amount       |                                 | Shares held as at December 31, 2025 |               |              | Net profit (loss) of the investee for the year ended December 31, 2025 | income (loss) recognized by the Company for the year ended December 31, 2025 | Footnote |
|                              |                                   |             |                                                                                         | Balance as at December 31, 2025 | Balance as at December 31, 2024 | Number of shares                    | Ownership (%) | Book value   |                                                                        |                                                                              |          |
| TCI CO., LTD.                | TCI FIRSTEK CORP.                 | Taiwan      | Wholesale and retail of health foods and cosmetics                                      | \$ 43,685                       | \$ 43,685                       | 214,885,489                         | 100.00        | \$ 2,973,160 | \$ 55,217                                                              | \$ 49,614                                                                    | Note 4   |
| TCI CO., LTD.                | GENE & NEXT INC.                  | Taiwan      | Research and development of biotechnology and genetics                                  | 37,079                          | 37,079                          | 11,173,692                          | 42.23         | 142,150      | 41,404                                                                 | 3,254                                                                        | None     |
| TCI CO., LTD.                | TCI HK LIMITED                    | Hong Kong   | Trading health foods and cosmetics                                                      | 21,046                          | 21,046                          | -                                   | 100.00        | 23,733       | 1,011                                                                  | 1,011                                                                        | None     |
| TCI CO., LTD.                | TCI BIOTECH LLC                   | U.S.A.      | Trading health foods and cosmetics                                                      | 8,778                           | 8,778                           | 300                                 | 3.85          | 7,851        | 136,422                                                                | 5,247                                                                        | None     |
| TCI CO., LTD.                | BIOSOME CO., LTD.                 | Taiwan      | Trading health foods and cosmetics                                                      | 5,000                           | 5,000                           | 500,000                             | 100.00        | 5,112        | 36                                                                     | 36                                                                           | None     |
| TCI CO., LTD.                | TCI JAPAN CO., LTD.               | JAPAN       | Trading health foods and cosmetics                                                      | 15,626                          | 15,626                          | 5,500                               | 100.00        | ( 875)       | ( 244)                                                                 | ( 244)                                                                       | None     |
| TCI CO., LTD.                | PT TCI BIOTEK INDO                | Indonesia   | Trading health foods and cosmetics                                                      | 17,635                          | 17,635                          | 89,000                              | 100.00        | 13,056       | ( 2,189)                                                               | ( 2,189)                                                                     | None     |
| TCI CO., LTD.                | TCI BIOTECH NETHERLANDS B.V.      | Netherlands | Trading health foods and cosmetics                                                      | 210,955                         | 210,955                         | 6,592,950                           | 100.00        | 131,270      | 137,877                                                                | 137,877                                                                      | None     |
| TCI CO., LTD.                | SMY INTERENT OF PACKAGE CO., LTD. | Taiwan      | Producing, manufacturing and selling of packaging containers                            | 1,900                           | 1,900                           | 190,000                             | 15.39         | 3,677        | ( 2,215)                                                               | ( 341)                                                                       | None     |
| TCI CO., LTD.                | QUANTUM BIOLOGY INC.              | Taiwan      | Research and development of biotechnology                                               | 30,000                          | 30,000                          | 3,000,000                           | 100.00        | 6,418        | ( 666)                                                                 | ( 416)                                                                       | Note 4   |
| TCI CO., LTD.                | MAXIGEN BIOTECH INC.              | Taiwan      | Wholesale of cosmetics and research and development, producing and sales of biologicals | 744,965                         | 591,156                         | 26,174,762                          | 29.19         | 750,754      | 260,361                                                                | 54,394                                                                       | None     |
| TCI CO., LTD.                | VEGAN JOY GLOBAL COMPANY LIMITED  | Taiwan      | Wholesale and retail of food, grocery and beverage                                      | 3,800                           | 3,800                           | 380,000                             | 19.00         | -            | ( 10,894)                                                              | -                                                                            | None     |
| TCI CO., LTD.                | WAN LIN LLC                       | Taiwan      | Wholesale and retail of food, grocery and beverage                                      | -                               | 1,140                           | -                                   | -             | -            | ( 124)                                                                 | ( 24)                                                                        | None     |
| TCI CO., LTD.                | AYURGA INDIA PRIVATE LIMITED      | India       | Trading health foods and cosmetics                                                      | 9,209                           | -                               | 26,000,000                          | 100.00        | 8,957        | ( 144)                                                                 | ( 144)                                                                       | Note 3   |
| TCI BIOTECH NETHERLANDS B.V. | TCI BIOTECH LLC                   | U.S.A       | Trading health foods and cosmetics                                                      | 207,588                         | 207,588                         | 7,500                               | 96.15         | 196,280      | 136,422                                                                | 131,175                                                                      | None     |
| TCI BIOTECH NETHERLANDS B.V. | Corpowell B.V.                    | Belgium     | Trading health foods and cosmetics                                                      | 5,207                           | 5,207                           | 25                                  | 25.00         | 20,927       | ( 111)                                                                 | ( 28)                                                                        | None     |
| TCI BIOTECH LLC              | TCI BIOTECH USA LLC               | U.S.A       | Producing and manufacturing health foods and cosmetics                                  | 207,588                         | 207,588                         | 7,500                               | 100.00        | 203,138      | ( 152,737)                                                             | ( 152,737)                                                                   | None     |

TCI CO., LTD.and subsidiaries  
Information on investees  
Year ended December 31, 2025

Table 7

Expressed in thousands of NTD  
(Except as otherwise indicated)

| Investor             | Investee                    | Location  | Main business activities                             | Initial investment amount       |                                 | Shares held as at December 31, 2025 |               |            | Net profit (loss) of the investee for the year ended December 31, 2025 | Investment income (loss) recognized by the Company for the year ended December 31, 2025 | Footnote |
|----------------------|-----------------------------|-----------|------------------------------------------------------|---------------------------------|---------------------------------|-------------------------------------|---------------|------------|------------------------------------------------------------------------|-----------------------------------------------------------------------------------------|----------|
|                      |                             |           |                                                      | Balance as at December 31, 2025 | Balance as at December 31, 2024 | Number of shares                    | Ownership (%) | Book value |                                                                        |                                                                                         |          |
| GENE & NEXT INC.     | GLUX HK LIMITED             | Hong Kong | Trading health foods and cosmetics                   | \$ -                            | \$ 29,542                       | -                                   | 0.00          | \$ -       | \$ -                                                                   | -                                                                                       | None     |
| GENE & NEXT INC.     | TCI LIVING CO., LTD.        | Taiwan    | Trading health foods and cosmetics                   | 43,175                          | 43,175                          | 4,463,254                           | 79.31         | 86,361 (   | 7,181) (                                                               | 5,695)                                                                                  | None     |
| GENE & NEXT INC.     | ASIA PATHOGENOMIC CO., LTD. | Taiwan    | Wholesale of chemical industrial and medical devices | 49,050                          | 34,200                          | 2,740,000                           | 16.75         | 20,484 (   | 43,010) (                                                              | 7,282)                                                                                  | None     |
| TCI LIVING CO., LTD. | TCI LIVING (HK) LIMITED     | Hong Kong | Trading health foods and cosmetics                   | 5,847                           | 5,847                           | -                                   | 100.00        | 3,092 (    | 5) (                                                                   | 5)                                                                                      | None     |

Note 1: If a public company is equipped with an overseas holding company and takes consolidated financial report as the main financial report according to the local law rules, it can only disclose the information of the overseas holding company about the disclosure of related overseas investee information.

Note 2: If situation does not belong to Note 1, fill in the columns according to the following regulations:

- (1)The columns of 'Investee', 'Location', 'Main business activities', 'Initial investment amount' and 'Shares held as at December 31, 2025' should fill orderly in the Company's (public company's) information on investees and every directly or indirectly controlled investee's investment information, and note the relationship between the Company (public company) and its investee each (ex. direct subsidiary or indirect subsidiary) in the 'footnote' column.
- (2)The 'Net profit (loss) of the investee for the year ended December 31, 2025' column should fill in amount of net profit (loss) of the investee for this period.
- (3)The 'Investment income (loss) recognized by the Company for the year ended December 31, 2025' column should fill in the Company (public company) recognized investment income (loss) of its direct subsidiary and recognized investment income (loss) of its investee accounted for under the equity method for this period. When filling in recognized investment income (loss) of its direct subsidiary, the Company (public company) should confirm that direct subsidiary's net profit (loss) for this period has included its investment income (loss) which shall be recognized by regulations.

Note 3: The company injected capital of \$9,209 on June 1, 2025.

Note 4:The company excludes both prior period patent transactions and current period patent amortization expenses from its calculation of investment gains/losses for this subsidiary.

TCI CO., LTD. and subsidiaries  
Information on investments in Mainland China  
Year ended December 31, 2025

Table 8

Expressed in thousands of NTD  
(Except as otherwise indicated)

| Investee in Mainland China            | Main business activities                                                               | Paid-in capital | Investment method | Amount remitted from Taiwan to                                                       |                                                                                        |                         |                                                                                        |                                                       |                                                    |                                                                                         |                                                                     |              | Accumulated amount of investment income remitted back to Taiwan as of December 31, 2025 | Footnote |
|---------------------------------------|----------------------------------------------------------------------------------------|-----------------|-------------------|--------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|-------------------------|----------------------------------------------------------------------------------------|-------------------------------------------------------|----------------------------------------------------|-----------------------------------------------------------------------------------------|---------------------------------------------------------------------|--------------|-----------------------------------------------------------------------------------------|----------|
|                                       |                                                                                        |                 |                   | Accumulated amount of remittance from Taiwan to Mainland China as of January 1, 2025 | Mainland China/<br>Amount remitted back to Taiwan for the year ended December 31, 2025 |                         | Accumulated amount of remittance from Taiwan to Mainland China as of December 31, 2025 | Net income (loss) of investee as of December 31, 2025 | Ownership held by the Company (direct or indirect) | Investment income (loss) recognized by the Company for the year ended December 31, 2025 | Book value of investments in Mainland China as of December 31, 2025 |              |                                                                                         |          |
|                                       |                                                                                        |                 |                   |                                                                                      | Remitted to Mainland China                                                             | Remitted back to Taiwan |                                                                                        |                                                       |                                                    |                                                                                         |                                                                     |              |                                                                                         |          |
| TCI International Trading Co., Ltd    | Wholesale of health foods, cosmetics and chemical productions; cosmetic manufacturing  | \$ 14,117       | Note 3            | \$ 15,440                                                                            | \$ -                                                                                   | \$ -                    | \$ 15,440                                                                              | \$ 55,207                                             | 100.00                                             | \$ 55,207                                                                               | \$ 3,023,711                                                        | \$ 1,383,547 | Note 4<br>Note 5                                                                        |          |
| SHANGHAI BIOSCIENCE CO., LTD.         | Wholesale of health foods, cosmetics and chemical productions; cosmetics manufacturing | 26,064          | Note 2            | -                                                                                    | -                                                                                      | -                       | -                                                                                      | 55,693                                                | 100.00                                             | 55,693                                                                                  | 2,638,992                                                           | -            | Note 4<br>Note 5                                                                        |          |
| SHANGHAI BIOCOSME CO., LTD.           | Producing cosmetics                                                                    | 143,352         | Note 2            | -                                                                                    | -                                                                                      | -                       | -                                                                                      | 59,483                                                | 100.00                                             | 59,483                                                                                  | 212,854                                                             | -            | Note 4<br>Note 5                                                                        |          |
| TCI BIOTECH CO., LTD                  | Producing health foods                                                                 | 1,131,425       | Note 1            | 438,307                                                                              | -                                                                                      | -                       | 438,307                                                                                | 64,881                                                | 100.00                                             | 65,196                                                                                  | 2,550,057                                                           | 942,055      | Note 4<br>Note 5                                                                        |          |
| TCI LIVING SHANGHAI CO., LTD.         | Trading health foods and cosmetics                                                     | 8,916           | Note 3            | 8,916                                                                                | -                                                                                      | -                       | 8,916                                                                                  | ( 101)                                                | 79.31                                              | ( 80)                                                                                   | 1,281                                                               | -            | Note 7<br>Note 4<br>Note 5                                                              |          |
| Maxigen Biotech Shanghai Co., Ltd.    | Sales of medical machinery and comestics                                               | US\$1,800       | Note 3            | 58,193                                                                               | -                                                                                      | -                       | 58,193                                                                                 | ( 12,086)                                             | 100.00                                             | ( 12,086)                                                                               | ( 75,653)                                                           | -            | Note 4<br>Note 5                                                                        |          |
| Shanghai Kaiaosi Technology Co., Ltd. | Sales of health food and cosmetics                                                     | 10,061          | Note 2            | -                                                                                    | -                                                                                      | -                       | -                                                                                      | ( 2,340)                                              | 18.40                                              | ( 430)                                                                                  | 1,801                                                               | -            | Note 4<br>Note 5                                                                        |          |

Note 1 : Reinvestments in a company in Mainland China through parent company in Taiwan and SHANGHAI BIOSCIENCE CO., LTD. (USD\$14,400 and RMB\$168,700)

Note 2 : Reinvestments in a company in Mainland China through TCI International Trading Co., Ltd.

Note 3 : Reinvestments in a company in Mainland China through domestic subsidiary company.

Note 4 : The amount recognized was based on the financial statements that were audited by R.O.C. parent company's CPA firm.

| Company name         | Accumulated amount of remittance from Taiwan to Mainland China as of December 31, 2025 | Investment amount approved by the Investment Commission of the Ministry of Economic Affairs (MOEA) | Ceiling on investments in Mainland China imposed by the Investment Commission of MOEA(Note 6) |
|----------------------|----------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------|
|                      |                                                                                        |                                                                                                    |                                                                                               |
| TCI CO., LTD.        | \$ 438,307                                                                             | \$ 692,000                                                                                         | \$ 5,494,072                                                                                  |
| TCI FIRSTEK CORP.    | 15,440                                                                                 | 15,440                                                                                             | 1,817,478                                                                                     |
| MAXIGEN BIOTECH INC. | 58,193                                                                                 | 58,193                                                                                             | 919,589                                                                                       |
| TCI LIVING CO., LTD. | 8,916                                                                                  | 31,484                                                                                             | 64,224                                                                                        |

Note 5 : The numbers in this table are expressed in New Taiwan dollars, except for: assets and liabilities presented at RMB\$1 : NTD\$4.4960, USD\$1 : NTD\$31.4300 ; income presented at RMB\$1 : NTD\$4.3287, USD\$1 : NTD\$31.1315;

Note 6 : The amount is the higher of limits on accumulated investment amounts or 60% of consolidated net assets was based on Investment Commission, MOEA Regulation No. 09704604680 announced on August 29, 2008.

Note 7 : The Company's investment income from the subsidiary excludes depreciation expenses on intercompany machinery and equipment transactions from prior and current periods.

TCI CO., LTD. and subsidiaries  
Significant transactions , either directly or indirectly through a third area, with investee companies in the Mainland Area  
Year ended December 31, 2025

Table 9

Expressed in thousands of NTD  
(Except as otherwise indicated)

| Investee in Mainland<br>China            | Sale (purchase) |      | Property transaction |   | Accounts receivable (payable)   |       | Provision of endorsements/guarantees<br>or collaterals |         | Maximum balance during<br>the year ended<br>December 31, 2025 | Financing                       |               | Interest during<br>the year ended<br>December 31, 2025 | Others |
|------------------------------------------|-----------------|------|----------------------|---|---------------------------------|-------|--------------------------------------------------------|---------|---------------------------------------------------------------|---------------------------------|---------------|--------------------------------------------------------|--------|
|                                          | Amount          | %    | Amount               | % | Balance at<br>December 31, 2025 | %     | Balance at<br>December 31, 2025                        | Purpose |                                                               | Balance at<br>December 31, 2025 | Interest rate |                                                        |        |
| TCI BIOTECH CO.,<br>LTD                  | \$ 387,165      | 8.77 | -                    | - | \$ -                            | -     | -                                                      | -       | -                                                             | -                               | -             | -                                                      | -      |
| Maxigen Biotech<br>Shanghai Co.,<br>Ltd. | 54,007          | 0.07 | -                    | - | 111,628                         | 45.82 | -                                                      | -       | -                                                             | -                               | -             | -                                                      | -      |

Note: Regarding percentage of transaction amount to total operating revenues or total assets, it is computed based on period-end balance of transaction to total assets for balance sheet accounts and based on accumulated transaction amount for the period to consolidated total operating revenues for income statement accounts.